|
Telix Pharmaceuticals Limited is a commercial-stage radiopharmaceutical company focused on targeted theranostics for cancer. The company develops diagnostic imaging agents and therapeutic radioconjugates to treat prostate, kidney, and brain cancers. Its commercial products include Illuccix and Gozellix for prostate cancer imaging, and Pixclara for glioma imaging. The pipeline includes late-stage therapeutic candidates TLX591-Tx for prostate cancer, TLX250-Tx for kidney cancer, and TLX101-Tx for glioblastoma. Telix operates a vertically integrated manufacturing and distribution network through Telix Manufacturing Solutions (TMS) and RLS Radiopharmacies. The company serves markets in the United States, Europe, and Asia-Pacific, and has entered a strategic collaboration with Regeneron Pharmaceuticals to co-develop next-generation radiopharmaceutical therapies. Summarised from the company's own disclosures, fiscal year ended Jun 2026 |
Industry Pharmaceuticals, Biotechnology & Life Sciences | Homepage telixpharma.com |
| Sector Healthcare | IR page ir.telixpharma.com | |
|
Tags
radiopharmaceuticals, theranostics, prostate cancer, kidney cancer, glioblastoma, pet imaging, radioconjugates, precision medicine, Illuccix, Gozellix, Pixclara, Zircaix, TLX591-Tx, TLX250-Tx, TLX101-Tx, TLX591-Px, TLX007-Px, TLX101-Px, TLX250-Px, BiPASS, Telix Manufacturing Solutions, RLS Radiopharmacies, Regeneron Pharmaceuticals
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | A$ 4.663B |
| Market cap (USD) | $ 3.14B |
| P/E | -55.77 |
| PEG | — |
| P/BV | — |
| P/S | 24.14 |
| P/OCF | -189.40 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -51.5% |
| ROI | -17.4% |
| ROIC | -9.0% |
| Profit margin | -73.2% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | 105.9% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -56.3% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Podcast Mentions
Announcements lodged with ASX, newest first, routine forms (director and substantial-holding notices, daily buy-back and quotation notices) included. The link opens the announcement on ASX. Material events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
Telix Pharmaceuticals Limited
ACN 616 620 369
55 Flemington Road
North Melbourne
Victoria, 3051
Australia
ASX ANNOUNCEMENT
Page 1
Telix Notice of General Meeting
Melbourne (Australia) – October 30, 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a General Meeting of shareholders to be held at The Events Centre, Level 5, Tower 2/727 Collins Street, Melbourne, VIC 3008 and online via meetings.openbriefing.com/TLXMeeting2026 on Tuesday, December 1, 2026 at 10:00 a.m. (Melbourne time). The shareholder pack, comprising the Notice of Meeting, Proxy Form and Online Guide, is attached. Authorized for lodgement by:
Marcin Firek Company Secretary
About Telix Pharmaceuticals Limited
Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) is a commercial-stage global
radiopharmaceutical company, advancing targeted theranostics to improve outcomes for people with
cancer across the patient journey. Theranostics pairs a precision diagnostic with a targeted therapy
to both diagnose and treat disease.
Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin
America and Asia-Pacific. For more information, visit www.telixpharma.com or follow Telix on
LinkedIn, X and Facebook.
Investor Relations Annie Kasparian [email protected]
Charlene Jaw
[email protected]
This announcement has been authorized for release by the Telix Pharmaceuticals Limited Company Secretary.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
Telix Pharmaceuticals
Notice of General Meeting
Invitation from the Chair Dear Shareholder On behalf of the Board of Directors, I am pleased to invite you to attend a General Meeting (Meeting) of Telix Pharmaceuticals Limited (Telix), relating to the proposed transaction of Telix and ITM Isotope Technologies Munich SE (ITM), a global leader in radioisotope production and radiopharmaceutical development. As announced on September 21, 2026, Telix has entered into a strategic agreement (the Transaction) to acquire 100% of the shares in ITM for total upfront consideration valued at US$1.65 billion on a cash-free/debt-free basis (as further described in the Explanatory Notes below) and additional contingent consideration of up to US$700 million upon achievement of future regulatory approvals and commercial sales milestones for ITM-11, ITM’s lead therapy candidate for the treatment of neuroendocrine tumors. The Transaction has been unanimously approved by Telix’s Board of Directors and, as of the date of this letter, has been agreed to by shareholders holding over 93% of ITM’s shares 1 . The Meeting is being held to seek Shareholder approval for certain matters related to the Transaction and will be convened at 10:00 a.m. (Melbourne time) on Tuesday, December 1, 2026 at The Events Centre, Level 5, Tower 2/727 Collins Street, Melbourne, Victoria 3008 (Venue) and via Telix’s share registry’s Virtual Meeting Online Platform at meetings.openbriefing.com/ TLXMeeting2026. The Board believes this Transaction is a defining step in Telix's evolution. It brings together two established leaders in radiopharmaceuticals with deep scientific expertise, a pipeline of novel candidates and the scale and infrastructure to compete and lead over the long term. The Transaction builds on many years of partnership between Telix and ITM, giving us a strong understanding of ITM's capabilities, operations and culture, and providing a solid foundation for integration and future value creation. The terms of the proposed Transaction are set out in the Explanatory Notes attached to this Notice of Meeting and further detailed in the investor presentation included as Appendix A (Investor Presentation). 2 This Notice of Meeting should be read in its entirety in conjunction with the accompanying Explanatory Notes and Investor Presentation. A Glossary of defined terms used in this Notice of Meeting is included after the Explanatory Notes. Strategic rationale Against a backdrop of rapid industry growth and consolidation, the Board believes that the next generation of radiopharmaceutical leaders will require integrated capabilities across discovery and development of both diagnostic and therapeutic agents, isotope production, manufacturing, supply chain and commercialization. This Transaction is designed to position Telix at the forefront of this industry evolution by bringing together three highly complementary growth engines: •A leading commercial precision medicine business with global reach and proven scale; •One of the industry's most extensive late-stage therapeutic radiopharmaceutical pipelines; and •A world-class radioisotope manufacturing and supply platform. The Transaction will further strengthen Telix’s leadership as a vertically integrated radiopharmaceutical company with the capabilities required to develop and deliver innovative treatments to patients globally. The addition of ITM’s commercially validated isotope production and distribution business adds a diversified revenue stream underpinned by strong historic growth and positive outlook, while securing supply chain control and infrastructure to support future therapeutic launches using a variety of isotopes. ITM’s late-stage compound, ITM-11 ( 177 Lu-edotreotide), is complementary to Telix and has the potential to accelerate Telix’s entry into the commercial therapeutic market for neuroendocrine tumors, a commercially validated and clinically significant market for targeted radionuclide therapy. ITM-11, which is a differentiated somatostatin receptor (SSTR)- targeted treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), has completed a successful Phase 3 trial (COMPETE, NCT03049189) and fully enrolled a second indication expansion Phase 3 study (COMPOSE, NCT04919226). The combined organization is expected to generate unaudited pro forma revenue and other income exceeding US$1.3 billion in 2026, based on management estimates. ITM's profitable, cash-generative isotope manufacturing business is expected to contribute continued growth. Along with cost savings already underway and targeted post-closing synergies, ITM is expected to contribute positively to Group EBITDA 3 from 2027 onwards. The Board has considered the integration, execution, regulatory, commercial and operational risks described in the Investor Presentation, which investors should read in its entirety before voting. This includes the realization of anticipated NOTICE OF GENERAL MEETING 2 1 Represents ITM shareholders that have signed the Share Purchase Agreement directly or via joinder agreement. No additional ITM shareholder approval is required for Closing. 2 The Investor Presentation was lodged with the ASX on September 21, 2026. The summary financial information previously contained in pages 27-29 of the Investor Presentation has been replaced and updated (in pages 27-28) of the attached Investor Presentation to reflect certain updated ITM financial information and Transaction adjustments. No other updates have been made to the Investor Presentation. Shareholders are advised that the summary financial information is unaudited and subject to change. 3 Earnings before interest, tax, depreciation and amortization.
synergies, regulatory outcomes for ITM-11 and the integration of two growing organizations. The deal structure includes protections to mitigate against certain transaction risks, which include closing conditions, financial adjustment and indemnity holdbacks, representation and warranty insurance, staggered escrow (lockup) of consideration shares of up to 15 months and retention agreements with key ITM employees. In summary, the Board believes the Transaction can create value through manufacturing growth, stronger supply chain control, operational efficiencies, targeted synergies, disciplined portfolio prioritization and the future commercialization potential of ITM-11. Accordingly, the items of business are set out below. Items of business The Notice of Meeting details the formal business to be dealt with at the Meeting, a necessary step to complete the Transaction. This will be to: 1.Approve the issue of Maximum Upfront Consideration Shares 2.Approve the issue of Regulatory Milestone Consideration Shares 3.Approve the issue of Future Sales Milestone Consideration Shares 4.Elect new Directors a.Elect Dr. Andrew Cavey, with effect from Closing b.Elect Dr. Barbara Weber, with effect from Closing 5.Approve the grant of share rights to the New Non-Executive Directors under the Equity Incentive Plan A Glossary of defined terms used in this Notice of Meeting is included after the Explanatory Notes. How to participate We invite shareholders to join the Board in supporting this defining step in Telix’s evolution. Details of how to participate in the Meeting are available on page 29 of this Notice of Meeting, a summary of which is provided below. Physical attendance Shareholders attending the Meeting can register from 9:15 a.m. (Melbourne time) on Tuesday, December 1, 2026 at the Venue. Shareholders are reminded to please bring your proxy form to assist with your registration at the Meeting. Shareholders will have an opportunity to meet with Directors and senior executives at the conclusion of the Meeting. Light refreshments will be provided. Online attendance Shareholders attending the Meeting online via Telix’s share registry’s Virtual Meeting Online Platform at meetings.openbriefing.com/TLXMeeting2026 will be able to hear and view the Meeting on their own devices, vote on the Resolutions and ask questions, and will be treated as if they were present at the physical location of the Meeting. Voting and questions Shareholders are encouraged to lodge their votes online ahead of the Meeting by logging in to their portfolio or shareholding at the share registry's Investor Centre website at au.investorcentre.mpms.mufg.com. If you are lodging your votes via Single Holding Login you will need your holder identifier (SRN or HIN) and postcode. Alternatively, you may lodge your completed proxy form by post or fax to the number on the form. If you wish to submit a question in advance of the Meeting, you can lodge your questions online at au.investorcentre.mpms.mufg.com. Upon login, click on 'Voting' and select the ‘Ask Question’ option under ‘Action’. Questions for the Company should be received by no later than 10:00 a.m. (Melbourne time) on Sunday, November 29, 2026. We will endeavor to respond to as many of the more frequently asked questions as possible at the Meeting. You may also ask questions at the Meeting. NOTICE OF GENERAL MEETING 3
Directors’ recommendation and voting statement The Directors unanimously recommend that Shareholders vote in favor of all Items of Business to be considered at the Meeting, and each of the Directors confirms that they will vote, or cause to be voted, any Shares that they own or otherwise control at the date of the Meeting in favor of Items 1 to 4. As the Directors are eligible to participate in the EIP, they are excluded from voting in favor of Item 5 notwithstanding that Item 5 relates only to the proposed issue of Share Rights to the New Non-Executive Directors. This Transaction represents a compelling strategic opportunity, creating a company with unmatched breadth and depth across the radiopharmaceutical value chain, supported by deep expertise and talent. We look forward to your attendance at the General Meeting. Yours faithfully, David N. Gill Chair of the Board NOTICE OF GENERAL MEETING 4
Notice of General Meeting Telix Pharmaceuticals Limited ACN 616 620 369 Notice is given that the General Meeting of the Shareholders of Telix Pharmaceuticals Limited ACN 616 620 369 will be convened as a hybrid meeting as follows: Time:10:00 a.m. (Melbourne time) Date:Tuesday, December 1, 2026 Physical location:The Events Centre, Level 5, Tower 2/727 Collins Street, Melbourne, Victoria 3008 Attend online: meetings.openbriefing.com/TLXMeeting2026 Under Rule 7.5 of Telix’s Constitution, Shareholders attending the Meeting online will be able to hear and view the Meeting on their own devices, vote on the Resolutions, ask questions and will otherwise be treated as if they were present at the Meeting. Details of how to attend the Meeting online can be found in the Virtual Meeting Online Guide lodged with ASX. The business to be considered at the Meeting is set out below. This Notice of Meeting should be read in its entirety in conjunction with the accompanying Explanatory Notes and Investor Presentation. If you are in any doubt as to how you should vote on the Resolutions, you should consult your financial, legal or other professional advisor. BACKGROUND As announced by Telix on September 21, 2026, Telix has signed a strategic agreement to acquire 100% of the shares in ITM, a global leader in radioisotope production and radiopharmaceutical development. The Transaction will further strengthen Telix’s leadership as a vertically integrated radiopharmaceutical company with the capabilities required to develop, manufacture and deliver innovative treatments to patients globally. The combined organization will be uniquely positioned as a radiopharmaceutical industry leader, differentiated by a world-class scaled isotope manufacturing business with a validated global distribution network, a market-leading commercial precision medicine platform and one of the industry’s most extensive therapeutic radiopharmaceutical pipeline. Further details of the Transaction are included in the Explanatory Notes to this Notice of Meeting and the Investor Presentation attached as Appendix A. This Notice of Meeting should be read in its entirety in conjunction with the accompanying Explanatory Notes and Investor Presentation. If you are in any doubt as to how you should vote on the Resolutions, you should consult your financial, legal, or other professional advisor. ITEMS OF BUSINESS
- Approve the issue of Maximum Upfront Consideration Shares To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That, for the purposes of Listing Rule 7.1 and for all other purposes, the issue of Maximum Upfront Consideration Shares, details of which are set out in the Explanatory Notes, is approved. A voting exclusion applies to this Resolution.
- Approve the issue of Regulatory Milestone Consideration Shares To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That, for the purposes of Listing Rule 7.1 and for all other purposes, the issue of the Regulatory Milestone Consideration Shares, details of which are set out in the Explanatory Notes, is approved. A voting exclusion applies to this Resolution.
- Approve the issue of Future Sales Milestone Consideration Shares To consider and, if thought fit, to pass the following resolution as an ordinary resolution: That, for the purposes of Listing Rule 7.1 and for all other purposes, the issue of Future Sales Milestone Consideration Shares, details of which are set out in the Explanatory Notes, is approved. A voting exclusion applies to this Resolution. NOTICE OF GENERAL MEETING 5
4.Elect new Directors To consider and, if thought fit, to pass the following resolutions as separate ordinary resolutions: a.That Dr. Andrew Cavey, being eligible, be elected as a Director of the Company, with effect from Closing. b.That Dr. Barbara Weber, being eligible, be elected as a Director of the Company, with effect from Closing. 5.Approve the grant of share rights to the New Non-Executive Directors under the Equity Incentive Plan To consider and, if thought fit, to pass the following resolutions as separate ordinary resolutions: a.That for the purposes of Listing Rule 10.14 and for all other purposes, the issue of share rights to Dr. Andrew Cavey (or nominee), details of which are set out in the Explanatory Notes, is approved by Shareholders. b.That for the purposes of Listing Rule 10.14 and for all other purposes, the issue of share rights to Dr. Barbara Weber (or nominee), details of which are set out in the Explanatory Notes, is approved by Shareholders. Voting exclusions apply to these Resolutions. NOTICE OF GENERAL MEETING 6
Voting exclusions Telix will disregard votes cast on the Resolutions by or on behalf of the persons, and in the manner, set out in the table below. The Chair of the Meeting intends to vote all available proxies in favor of each item of business requiring Shareholder Resolution (subject to the voting exclusions below and section 250BD of the Corporations Act). Item 1 – Approve the issue of Maximum Upfront Consideration Shares Telix will disregard votes cast by or on behalf of any person to whom Upfront Consideration Shares will be issued pursuant to the Share Purchase Agreement and any other person who will obtain a material benefit as a result of the issue of Upfront Consideration Shares (except a benefit solely by reason of being a holder of Shares) or an associate of that person (or those persons). However, votes will not be disregarded if they are cast: •as proxy or attorney for a person entitled to vote on the resolution in accordance with a direction given to the proxy or attorney to vote on the resolution in that way; •as proxy for a person entitled to vote on the item by the Chair of the Meeting in accordance with a direction given to the Chair of the Meeting to vote on the resolution as the Chair of the Meeting decides; or •by a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary, providing the following conditions are met: ◦the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting on the resolution; and ◦the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way. Items 2 – Approve the issue of Regulatory Milestone Consideration Shares Telix will disregard votes cast by or on behalf of any person to whom Regulatory Milestone Consideration Shares may be issued pursuant to the Share Purchase Agreement and any other person who will obtain a material benefit as a result of the issue of Regulatory Milestone Consideration Shares (except a benefit solely by reason of being a holder of Shares) or an associate of that person (or those persons). However, votes will not be disregarded if they are cast: •as proxy or attorney for a person entitled to vote on the resolution in accordance with a direction given to the proxy or attorney to vote on the resolution in that way; •as proxy for a person entitled to vote on the item by the Chair of the Meeting in accordance with a direction given to the Chair of the Meeting to vote on the resolution as the Chair of the Meeting decides; or •by a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary, providing the following conditions are met: ◦the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting on the resolution; and ◦the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that way. Item of business Voting exclusion and authorized voting NOTICE OF GENERAL MEETING 7
Item 3 –
Approve the
issue of Future
Sales Milestone
Consideration
Shares
Telix will disregard votes cast by or on behalf of any person to whom Future Sales Milestone Consideration
Shares may be issued pursuant to the Share Purchase Agreement and any other person who will obtain a
material benefit as a result of the issue of Future Sales Milestone Consideration Shares (except a benefit solely
by reason of being a holder of Shares) or an associate of that person (or those persons).
However, votes will not be disregarded if they are cast:
•as proxy or attorney for a person entitled to vote on the resolution in accordance with a direction
given to the proxy or attorney to vote on the resolution in that way;
•as proxy for a person entitled to vote on the item by the Chair of the Meeting in accordance with a
direction given to the Chair of the Meeting to vote on the resolution as the Chair of the Meeting
decides; or
•by a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a
beneficiary, providing the following conditions are met:
◦the beneficiary provides written confirmation to the holder that the beneficiary is not
excluded from voting, and is not an associate of a person excluded from voting on the
resolution; and
◦the holder votes on the resolution in accordance with directions given by the beneficiary to
the holder to vote in that way.
Item 5 -
Approve the
grant of share
rights to the
New Non-
Executive
Directors under
the Equity
Incentive Plan
Telix will disregard any votes cast in favor of Item 5 by or on behalf of:
•a person referred to in Listing Rule 10.14.1, 10.14.2, or 10.14.3 who is eligible to participate in the
Equity Incentive Plan; or
•an associate of any person referred to in the paragraph above.
However, votes will not be disregarded if they are cast:
•as proxy or attorney for a person entitled to vote on the resolution in accordance with a direction
given to the proxy or attorney to vote on the resolution in that way;
•by the Chair of the Meeting as proxy or attorney for a person entitled to vote on the resolution in
accordance with a direction given to the Chair of the Meeting to vote on the resolution as the Chair of
the Meeting decides; or
•by a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a
beneficiary, providing the following conditions are met:
◦the beneficiary provides written confirmation to the holder that the beneficiary is not
excluded from voting, and is not an associate of a person excluded from voting on the
resolution; and
◦the holder votes on the resolution in accordance with directions given by the beneficiary to
the holder to vote in that way.
In accordance with section 250BD of the Corporations Act, a person appointed as proxy must not vote on
Item 5 on the basis of that appointment if the proxy appointment does not specify the way in which the proxy
is to vote on Item 5 and the proxy is a member of the KMP (including the Directors) or a Closely Related Party
of a member of the KMP (such as close family members and any companies controlled by those persons),
unless:
•the proxy is the Chair of the Meeting; and
•the appointment expressly authorizes the Chair of the Meeting to exercise the proxy even though
Item 5 is connected directly or indirectly with the remuneration of a member of the KMP.
Item of
business
Voting exclusion and authorized voting
Dated October 29, 2026
By order of the Board
Marcin Firek
Company Secretary
NOTICE OF GENERAL MEETING
8
Explanatory Notes These Explanatory Notes have been prepared to provide Shareholders with important information regarding the items of business proposed for the Meeting. They form part of the Notice of Meeting and should be read in conjunction with it. Item 1 - Approve the issue of Maximum Upfront Consideration Shares Summary of the Transaction The key terms of the agreement pursuant to which Telix will acquire 100% of ITM (Share Purchase Agreement) are summarized in the table below: BuyerTelix Pharmaceuticals Limited SellersThe shareholders of ITM Isotope Technologies Munich SE party to the Share Purchase Agreement or acceding to the Share Purchase Agreement via joinders Date of Share Purchase Agreement September 20, 2026 Upfront Consideration and Issue of Upfront Consideration Shares Under the terms of the Share Purchase Agreement, and subject to Shareholder approval, Telix will acquire 100% of the shares in ITM held by the Sellers for US$1.65 billion upfront on a cash-free/debt-free basis expected as follows (the Upfront Consideration): •US$1.25 billion will be paid to the Sellers in the form of approximately 105.8 million Shares at the Issue Price 1 , which Shares will be released to the Sellers as Nasdaq- listed ADSs at the end of their respective escrow periods (see ‘Escrow arrangements’ below); •US$301.8 million of net debt will be assumed by Telix at Closing (assuming zero cash at Closing); and •US$96.0 million of management equity rollover and transaction expenses payable by the Sellers 2 , in each case subject to adjustments at Closing to account for cash on hand, variations in net working capital, increase or decrease in debt or transaction expenses, and other similar items measured as of Closing, along with any additional amounts to acquire the remaining ITM shares held by the shareholders of ITM that have not signed the Share Purchase Agreement. Such adjustments may mean that the final number of Shares issued as part of the Upfront Consideration (the Upfront Consideration Shares) is more or less than 105.8 million Shares. In accordance with the ASX Waiver, the Upfront Consideration Shares, other than any Shares issued on the release of a Holdback Amount, must be issued within 12 months of the date of the Meeting. * TermDescription NOTICE OF GENERAL MEETING 9 * 1 Priced at the 30-day trailing VWAP as of signing of US$11.84. The final number of Upfront Consideration Shares that will be issued will depend on certain Closing adjustments, including amounts held back from payment at Closing and potential indemnity claims under the Share Purchase Agreement. The maximum number of Upfront Consideration Shares for which Shareholder approval is being sought in Item 1 is 114.2 million. 2 Sellers may allocate and sell on the ASX through a single designated seller and a bank mutually agreed between Telix and such designated seller some of the Shares deducted from their Share consideration to settle a portion of these Seller transaction expenses.
Calculation of
Maximum Upfront
Consideration Shares
Shareholders are being asked to approve a total of 114.2 million Shares as the maximum
number of Shares to be issued at Closing, inclusive of the Holdback Amounts discussed
below (the Maximum Upfront Consideration Shares). The Maximum Upfront Consideration
Shares is calculated as follows:
•105.8 million Shares to be paid to the Sellers;
•up to 4.1 million Shares to account for any upward adjustments to the portion of
the Upfront Consideration payable in Shares, for example due to increase in cash
or net working capital or decrease in debt at Closing; and
•up to 4.3 million Shares that may be issued to a designated Seller or Seller
appointee and sold through a bank mutually agreed by Telix and the designated
Seller, to allow the Sellers to pay certain of their transaction expenses after
Closing.
The 8.4 million Shares do not increase the total consideration of US$1.65 billion being paid
for 100% of the shares in ITM on a cash-free/debt-free basis at Closing; but rather, allow
for the settlement of certain Closing adjustments and transaction expenses through Shares
that would otherwise be issuable to the Sellers as Upfront Consideration. Table 1 below
shows the total potential dilution from the issue of the Maximum Upfront Consideration
Shares.
Holdback AmountsAs described above, the Upfront Consideration paid at Closing is subject to financial
adjustments at Closing. US$10.0 million of the Upfront Consideration will be held back by
Telix against downward financial adjustments to be calculated following Closing (generally
within 90 days after Closing or, if later, 15 days after all Seller transaction expenses have
been paid) (Adjustments Holdback). Telix will also hold back from the Upfront
Consideration paid at Closing a general indemnity holdback of US$4.1 million (Indemnity
Holdback), and a special indemnity holdback of up to US$9.0 million in relation to specific
indemnities provided by the Sellers (Special Indemnity Holdback). The Adjustments
Holdback, the Indemnity Holdback and the Special Indemnity Holdback (collectively, the
“Holdback Amounts”) are a deduction from the Upfront Consideration Shares paid at
Closing. The 1.95 million Telix Shares (Holdback Shares) that represent the Holdback
Amounts will not be issued until the end of the applicable holdback periods assuming Telix
has no off-setting closing adjustments or indemnity claims. Table 1 below shows the total
potential dilution if all Holdback Shares are issued or forfeited. In accordance with the ASX
Waiver, any Upfront Consideration Shares issued as a consequence of the release of the
Holdback Amounts must be issued no later than 6 months after Closing in the case of the
Adjustments Holdback and 18 months after Closing in the case of the Indemnity Holdback
and the Special Indemnity Holdback. The Share Purchase Agreement provides that up to
US$3.0 million of the Special Indemnity Holdback may be released 3 years after Closing. As
that holdback release would fall outside the period permitted by the ASX Waiver, Telix will
seek further Shareholder approval or an ASX waiver required to issue Shares in respect of
that release, or satisfy that release in cash.
Issue PriceUS$11.84, being the 30-day volume weighted average price (VWAP) of Shares quoted on
ASX for the period ending on September 18, 2026, the last trading day prior to signing the
Share Purchase Agreement. The VWAP was A$16.65, converted at an AUD/USD exchange
rate of 0.71.
TermDescription
NOTICE OF GENERAL MEETING
10
Future Milestone Consideration 1* Telix has an obligation to make further payments of up to US$700 million to the Sellers subject to the achievement of specified regulatory approvals and sales milestones for ITM’s lead therapeutic asset (ITM-11) as set out below (Milestone Payments): •Up to US$250 million upon United States Food and Drug Administration (FDA) approval of ITM-11 across 3 different indications (together, the Regulatory Milestones): ◦US$100 million upon FDA approval for expected first indication in G1-G2 somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs) of pancreatic or gastroenteric origin no later than December 31, 2027 (Regulatory Milestone 1); ◦US$100 million upon FDA approval for indication in G2-G3 SSTR+-NETs of pancreatic or gastroenteric origin no later than December 31, 2030 (Regulatory Milestone 2); and ◦US$50 million upon FDA approval for lung and thymic SSTR+ tumor indication no later than December 31, 2031 (Regulatory Milestone 3). •up to US$450 million based on ITM-11 net global sales in excess of US$150 million in the calendar year ended December 31, 2030, based upon a payment of US$3.00 for each US$1.00 of net global sales above US$150 million capped at a maximum payment of US$450 million (Future Sales Milestone). Any Milestone Payment may be satisfied at the election of Telix by the payment of cash, the issue of Shares at a 30-day VWAP 3 of Shares quoted on ASX for the period ending on, and including the last trading day prior to the date on which such Milestone Event has become publicly known or, if earlier, the date on which such Milestone Event is finally determined to have been achieved, or a combination of both cash and Shares. All Milestone Payments settled in Shares will be issued to the Sellers as Nasdaq ADSs. Approval for the issue of Regulatory Milestone Consideration Shares is being sought in Item 2 and approval for the issue of Future Sales Milestone Consideration Shares is being sought in Item 3. Conditions precedentClosing is subject to various conditions precedent, including: •Telix’s shareholders approving the issue of the Maximum Upfront Consideration Shares; •certain scheduled regulatory approvals being obtained, including clearance or non- objection to the Transaction from the applicable regulatory bodies in Germany and other specified jurisdictions; •the representations and warranties of the parties remaining accurate (subject to applicable materiality standards) and performance of covenants in all material respects; •the re-submission by ITM to the FDA of a new drug application for ITM-11 or agreement by Telix in its reasonable discretion to proceed following receipt of final minutes from a Type A meeting between ITM and the FDA in relation to ITM-11; •neither Telix nor ITM having experienced certain material adverse events (subject to certain exceptions); •Telix having received the executed amendment to ITM’s financing agreement and other Closing deliverables; and •no restraints preventing or otherwise impeding Closing being issued by a court or other government body. TermDescription NOTICE OF GENERAL MEETING 11 * 1 The A$ VWAP will be converted to a US$ issue price at the applicable currency exchange rate at such time.
Escrow arrangementsThe Sellers are required to enter into escrow arrangements with effect from Closing in relation to their Upfront Consideration Shares, including those issued after Closing and within the relevant escrow period, and any Milestone Consideration Shares issued within the relevant escrow period. The escrow period for certain specified Sellers (including entities affiliated with ITM’s founders) is the earlier of 15 months after Closing and 3 months after the achievement of Regulatory Milestone 1. This currently represents approximately 26% of the Telix Shares being issued at Closing. The escrow period for all other Sellers is the earlier of 12 months after Closing and the date on which Regulatory Milestone 1 has been achieved. This currently represents approximately 74% of the Telix Shares being issued at Closing. The escrow arrangements are subject to customary exceptions and Telix will release from escrow a limited number of Shares to allow Sellers to pay certain tax liabilities that have arisen from the Transaction. TerminationThe Share Purchase Agreement may be terminated prior to Closing for reasons including: •mutual written consent of both parties; •if Closing has not taken place on or before 5:00 p.m. (U.S. Eastern time) on January 1, 2027 (the End Date), subject to an automatic three month extension where all conditions precedent have been satisfied or waived, other than the required regulatory approvals; •failure to obtain Shareholder approval for the issue of the Maximum Upfront Consideration Shares; or •by Telix or ITM, respectively, where representations and warranties or covenants of the other party have been breached such that the relevant condition to Closing would not be satisfied, provided that, if the breach is curable through reasonable efforts, termination may not occur until the earlier of 15 business days after notice of the breach and the End Date. Shareholder vote failure fee If Shareholders do not approve the issue of the Maximum Upfront Consideration Shares when the resolution is voted upon at the Meeting or any subsequent meeting if the Meeting is postponed or adjourned and the Share Purchase Agreement is validly terminated as a result, Telix must pay US$5 million in cash to ITM. OtherThe Share Purchase Agreement contains additional pre-Closing obligations, as well as representations and warranties which are customary for a transaction of this nature. TermDescription The table below (Table 1) illustrates the potential effects of the issue of Upfront Consideration Shares to the relative ownership of existing Telix shareholders and Sellers receiving Shares at Closing.
Notes to Table (1)Based on 340,330,385 Shares on issue as of the date of this Notice of Meeting, assuming no other share issues prior to Closing. (2)Reflects the issue of 105.8 million Shares issued at Closing inclusive of the issue of 1.95 million Holdback Shares. (3)Reflects the issue of 114.2 million Shares issued at Closing inclusive of the issue of 1.95 million Holdback Shares. 4.3 million (3.8%) of the Maximum Upfront Consideration Shares included in the Sellers Ownership would be sold to cover transaction expenses. (4)Reflects the issue of 112.3 million Shares at Closing and the forfeiture of all 1.95 million Holdback Shares. 4.3 million (3.8%) of the Maximum Upfront Consideration Shares included in the Sellers Ownership would be sold to cover transaction expenses. NOTICE OF GENERAL MEETING 12 Total Shares on Issue 1 Existing Telix Shareholder Ownership Sellers Ownership Estimated Upfront Consideration Shares 2 446,090,520 76.3 % 23.7 % Maximum Upfront Consideration Shares 3 454,568,899 74.9 % 25.1 % Forfeiture of Holdback Shares 4 452,615,774 75.2 % 24.8 %
Further detail about the Transaction is contained in the Investor Presentation, including detail in relation to known and unknown risks associated with the Transaction. Proposed timetable and acquisition of remaining ITM shares Telix expects that the Transaction should complete by the End Date. However, Closing remains subject to the terms of the Share Purchase Agreement and the conditions to Closing. As at the date of this Notice of Meeting, ITM shareholders holding over 93% of ITM’s shares have signed on to the Share Purchase Agreement either directly or via joinder agreements. Under the Share Purchase Agreement, ITM is required to use commercially reasonable efforts to obtain joinder agreements from its remaining shareholders before Closing. It is a condition to Telix’s obligation to complete the Transaction that ITM shareholders holding at least 92.5% of ITM’s shares immediately prior to Closing have signed the Share Purchase Agreement or a joinder agreement, which condition has been fulfilled. Therefore, no further approval is needed from ITM’s shareholders in order to proceed with the Transaction, and accordingly, Telix may hold less than 100% of ITM’s shares at Closing. If Telix does not hold 100% of ITM’s shares following Closing, Telix intends to acquire the remaining ITM shares under the compulsory acquisition procedures available under German law. In this instance, the minority ITM shareholders would receive cash compensation, which is determined based on a valuation of ITM and reviewed by a court-appointed auditor and may be challenged by the minority shareholders. The compulsory acquisition does not require the issue of Shares. A voting exclusion applies to Item 1 and is set out on page 7 of the Notice of Meeting. Listing Rule 7.1 Listing Rule 7.1 limits the number of equity securities that a listed company can issue without the approval of its shareholders over any 12 month period to 15% of the fully paid ordinary securities it had on issue at the start of that 12 month period (15% Placement Capacity) subject to specified exceptions. Shareholder approval in accordance with Listing Rule 7.1 is required for the issue of the Maximum Upfront Consideration Shares as those Shares represent more than 15% of the Shares on issue and no exception to the 15% Placement Capacity limit applies. If Item 1 is passed, Telix will be able to proceed with the issue of the Upfront Consideration Shares and that condition precedent to the Transaction will be satisfied. In addition, the issue of the Shares up to Maximum Upfront Consideration Shares will be excluded from the calculation of the number of equity securities that Telix can issue without Shareholder approval under Listing Rule 7.1. If Item 1 is not passed, Telix will not be able to proceed with the issue of the Upfront Consideration Shares and that condition precedent to Closing will not be satisfied. Therefore, the Transaction will not proceed. If Shareholders do not approve Item 1 and the Share Purchase Agreement is validly terminated as a result, Telix must also pay a shareholder vote failure fee of US$5 million in cash to ITM. Waiver from Listing Rule 7.3.4 Listing Rule 7.3 sets out the requirements for shareholder approval under Listing Rule 7.1. In particular, Listing Rule 7.3.4 provides that the notice of meeting must state the date by which the entity will issue the securities, which date must be no later than 3 months after the date of the shareholder meeting. The issue of the Upfront Consideration Shares is contingent on the satisfaction or waiver of the conditions precedent to the Share Purchase Agreement, including certain regulatory approvals being obtained, which may cause the issue to occur more than 3 months after the date of the Meeting. The issue of the Milestone Consideration Shares (see the Explanatory Notes to Items 2 and 3) are subject to conditions which mean that if those Shares are issued, those issues will be more than 3 months after the Meeting. Telix applied for, and ASX has granted, waivers from Listing Rule 7.3.4 to permit Telix to issue the Upfront Consideration Shares and the Milestone Consideration Shares on a date that is more than 3 months after the date of the Meeting (ASX Waiver). The ASX Waiver was disclosed by Telix by an ASX announcement on September 22, 2026. The ASX Waiver has been granted on the following conditions: •the Upfront Consideration Shares are, except as noted below, to be issued upon achievement or waiver of the applicable conditions to Closing, and in any event, no later than 12 months from the receipt of shareholder approval for the issue of the Upfront Consideration Shares; •any Upfront Consideration Shares that are not issued at Closing pending the determination of any release of the Adjustments Holdback or release of the Indemnity Holdbacks, may be issued no later than 6 months after Closing in the case of the Adjustments Holdback and no later than 18 months after Closing in the case of the Indemnity Holdbacks and Special Indemnity Holdback; NOTICE OF GENERAL MEETING 13
•any shares issued as Regulatory Milestone Consideration Shares are to be issued no later than 3 months after the
achievement of such milestone;
•any shares issued as Future Sales Milestone Consideration Shares are to be issued no later than 4 months after
the issue of Telix’s 2030 financial statements;
•the material terms of the Upfront Consideration Shares must not be varied, and the material terms of the Upfront
Consideration Shares and the Milestone Consideration Shares (including the conditions and milestones for their
issue) are fully and clearly set out in this Notice of Meeting;
•details regarding the potential dilutive effect of the Upfront Consideration Shares and the Milestone Consideration
Shares on Telix’s capital structure is included in this Notice of Meeting to ASX’s satisfaction;
•the terms of the ASX Waiver are clearly disclosed in this Notice of Meeting to ASX’s satisfaction;
•if any of the conditions to the issue of the Upfront Consideration Shares are achieved or waived, the achievement
or waiver of that condition and the basis on which Telix determined that the condition has been achieved or
waived is announced to the market, along with the number of Upfront Consideration Shares issued;
•if any of the milestone conditions to the issue of the Milestone Consideration Shares are achieved, the
achievement of that milestone and the basis on which Telix determined that the milestone has been achieved is
announced to the market, along with the number of Milestone Consideration Shares issued;
•for any annual reporting period during which any Upfront Consideration Shares or Milestone Consideration Shares
have been issued or any of them remain to be issued, Telix’s annual report sets out the number of Upfront
Consideration Shares and Milestone Consideration Shares issued in that annual reporting period, the number of
Upfront Consideration Shares and Milestone Consideration Shares that remain to be issued and the basis on
which the Upfront Consideration Shares and Milestone Consideration Shares may be issued; and
•Telix releases an announcement to the market that discloses the nature and effect of the ASX Waiver and Telix’s
reasons for seeking the waivers. The announcement must be released no later than the next business day after
ASX communicates to Telix that the waiver has been granted.
Information required by Listing Rule 7.3
The following information in relation to the issue of the Maximum Upfront Consideration Shares is provided to
Shareholders for the purposes of Listing Rule 7.3:
1.Shares in an amount up to the Maximum Upfront Consideration Shares will be issued to the Sellers (and/or the
Sellers' nominees), none of whom is currently a related party, Key Management Personnel, substantial shareholder
or advisor of Telix or an associate of those persons;
2.The maximum number of Upfront Consideration Shares to be issued is 114.2 million.
3.All Upfront Consideration Shares will be fully paid ordinary shares which rank equally with all other Shares on
issue;
4.Subject to the terms of the ASX Waiver, the Upfront Consideration Shares (in an amount up to the Maximum
Upfront Consideration Shares) will be issued no later than 12 months following the date of the Meeting. Any
Upfront Consideration Shares held back as part of the Holdback Amounts may be issued up to 6 months after
Closing for the Adjustments Holdback and up to 18 months after Closing for the Indemnity Holdback and the
Special Indemnity Holdback. See also, “Holdback Amounts” above in the description of the key terms of the Share
Purchase Agreement in relation to the portion of the Special Indemnity Holdback that may be released 3 years
after Closing;
5.The Upfront Consideration Shares will have an issue price of US$11.84 per Share, being the Issue Price;
6.The purpose of the issue of the Upfront Consideration Shares is part-consideration for the Transaction.
Accordingly, no funds will be raised from the issue;
7.The Upfront Consideration Shares will be issued under the Share Purchase Agreement. A summary of the material
terms of the Share Purchase Agreement is contained above;
8.The Upfront Consideration Shares are not being issued under, or to fund, a reverse takeover; and
A voting exclusion statement is included in the Notice of Meeting for Item 1.
Board recommendation
The Directors unanimously recommend that Shareholders vote in favor of Item 1.
NOTICE OF GENERAL MEETING
14
Item 2 – Approve the issue of Regulatory Milestone Consideration
Shares
Background
As outlined above, in addition to the Upfront Consideration, there is potential for Milestone Payments to be paid by Telix
upon the achievement of agreed milestones in relation to ITM-11. Refer to Item 1 above for a summary of the Transaction
and the Milestone Payments.
Any Milestone Payment may be satisfied at the election of Telix by the payment of cash, the issue of Shares at a 30-day
VWAP
1
of Shares quoted on ASX for the period ending on, and including the last trading day prior to the date on which
such Milestone Event has become publicly known or, if earlier, the date on which such Milestone Event is finally
determined to have been achieved, or a combination of both cash and Shares.
Item 2 seeks Shareholder approval for a maximum number of Regulatory Milestone Consideration Shares to be issued at
the Issue Price, being US$11.84. The Issue Price is being used as a floor price (Floor Price) for the purpose of determining
the maximum number of Shares that may be issued as Regulatory Milestone Consideration Shares and approved by
Shareholders. However, the actual issue price of any Regulatory Milestone Consideration Shares that are issued may be
higher or lower than the Floor Price.
If Item 2 is passed and the future VWAP used to determine the number of Regulatory Milestone Consideration Shares to be
issued on the achievement of a Regulatory Milestone is higher than the Floor Price, then if Telix elects to issue Shares the
number of Shares that will need to be issued for the relevant Regulatory Milestone will be less than the maximum number
of Shares approved for that Regulatory Milestone pursuant to Item 2.
If Item 2 is passed and the future VWAP used to determine the number of Regulatory Milestone Consideration Shares to be
issued on the achievement of a Regulatory Milestone is lower than the Floor Price, then Telix will be able to issue the
maximum number of Shares approved pursuant to Item 2 for that Regulatory Milestone and will be required to pay a further
amount in cash to ensure that the Sellers receive the full Milestone Payment.
The maximum number of Regulatory Milestone Consideration Shares to be issued as payment for the achievement of each
Regulatory Milestone, based on the Floor Price, is as follows:
•Subject to Regulatory Milestone 1 being achieved by December 31, 2027, 8,445,946 shares (Regulatory Milestone
1 Maximum Shares).
•Subject to Regulatory Milestone 2 being achieved by December 31, 2030, 8,445,946 shares (Regulatory Milestone
2 Maximum Shares).
•Subject to Regulatory Milestone 3 being achieved by December 31, 2031, 4,222,973 shares (Regulatory Milestone
3 Maximum Shares).
If any Regulatory Milestone is not achieved by its specified deadline, no Regulatory Milestone Consideration Shares will be
issuable by Telix for that milestone.
Waiver from Listing Rule 7.3.4
Refer to Item 1 for a summary of Listing Rule 7.3.4 and a description of the ASX Waiver which allows the Regulatory
Milestone Shares to be issued more than 3 months after the Meeting.
The payment of each Milestone Payment is contingent on the achievement of the relevant milestone as described in the
Explanatory Notes to Item 1 in the key terms of the Share Purchase Agreement, each of which will only be able to be
determined on a date that is more than 3 months after the date of the Meeting. The ASX Waiver permits Telix to issue
Regulatory Milestone Consideration Shares on dates that are more than 3 months after the date of the Meeting. Refer to
Item 1 for the conditions of the ASX Waiver.
Voting exclusions apply to Item 2 and are set out on page 7 of the Notice of Meeting.
As described in the Explanatory Notes to Item 1 in the key terms of the Share Purchase Agreement, Telix will be required to
pay a Milestone Payment under the Share Purchase Agreement if a Regulatory Milestone is achieved. Each Milestone
Payment may be satisfied at the election of Telix by the payment of cash, the issue of Shares at a 30-day VWAP of Shares
quoted on ASX for the period ending on, and including the last trading day prior to the date on which such Milestone Event
has become publicly known or, if earlier, the date on which such Milestone Event is finally determined to have been
achieved, or a combination of both cash and Shares.
NOTICE OF GENERAL MEETING
15
1
The A$ VWAP will be converted to a US$ issue price at the applicable currency exchange rate at such time.
Item 2 seeks Shareholder approval in accordance with Listing Rule 7.1 for the issue of the Regulatory Milestone Consideration Shares. Listing Rule 7.1 Refer to Item 1 for a summary of Listing Rule 7.1. If Item 2 is passed, the issue of the Regulatory Milestone Consideration Shares will be excluded from the calculation of the number of equity securities that Telix can issue without Shareholder approval under Listing Rule 7.1. If Item 2 is not passed, the future issue of the Regulatory Milestone Consideration Shares will be included in calculating Telix’s 15% Placement Capacity, effectively decreasing the number of equity securities Telix can issue without obtaining Shareholder approval over the 12 month period following the date of the Share Purchase Agreement. Failure to pass Item 2 would potentially materially limit the flexibility of Telix during that 12 month period to pursue future near term strategic transactions which involve the issue, or agreement to issue, Shares. However, if Item 2 is not passed that will not prevent Telix from being able to issue the full amount of Regulatory Milestone Consideration Shares. Information required by Listing Rule 7.3 The following information in relation to the Regulatory Milestone Consideration Shares is provided to Shareholders for the purposes of Listing Rule 7.3: 1.The Regulatory Milestone Consideration Shares will be issued to the Sellers (and/or the Sellers' nominees), none of whom is currently a related party, Key Management Personnel, substantial shareholder or advisor of Telix or an associate of those persons; 2.The maximum number of Regulatory Milestone Consideration Shares to be issued is 21,114,865, which is calculated by dividing the aggregate amount of Regulatory Milestone Payments, being US$250 million, by the Floor Price of US$11.84. The maximum number of Regulatory Milestone Consideration Shares that may be issued for each Regulatory Milestone is: a.8,445,946 for Regulatory Milestone 1; b.8,445,946 for Regulatory Milestone 2; and c.4,222,973 for Regulatory Milestone 3. 3.The table below provides an example of the number of Regulatory Milestone Consideration Shares that may be issued if Shareholders approve Item 2 (although, as noted above, Telix has sufficient placement capacity to issue the Regulatory Milestone Consideration Shares even if Item 2 is not passed). The table uses: a.the Issue Price (which operates as a Floor Price to calculate the maximum number of Shares approved by Shareholders); b.an issue price that is 20% lower than the Floor Price, reflecting a 20% decreased VWAP at the time of issue of the Regulatory Milestone Consideration Shares, which would mean that an additional cash payment is required to pay the full Milestone Payment; and c.an issue price that is 20% higher than the Floor Price, reflecting a 20% increased VWAP at the time of issue of the Regulatory Milestone Consideration Shares, which would mean that less than the maximum number of Shares approved by Shareholders will need to be issued. The table shows the number of Regulatory Milestone Consideration Shares that may be issued for each Regulatory Milestone, and assumes that such Regulatory Milestone is achieved by the applicable deadline date. Regulatory Milestone 18,445,9468,445,946 1 7,037,298 Regulatory Milestone 28,445,9468,445,946 1 7,037,298 Regulatory Milestone 34,222,9734,222,973 2 3,518,649 Number of Regulatory Milestone Consideration Shares US$11.84 (Floor Price) US$9.47 (20% below Floor Price) US$14.21 (20% above Floor Price) Notes to Table (1)Telix would be required to pay an additional approximately US$20 million in cash to satisfy its Milestone Payment obligations. (2)Telix would be required to pay an additional approximately US$10 million in cash to satisfy its Milestone Payment obligations. NOTICE OF GENERAL MEETING 16
4.The Regulatory Milestone Consideration Shares will be fully paid ordinary shares which rank equally with all other
Shares on issue;
5.In accordance with the ASX Waiver, and assuming each Regulatory Milestone is achieved:
a.the Regulatory Milestone 1 Consideration Shares will be issued no later than March 31, 2028;
b.the Regulatory Milestone 2 Consideration Shares will be issued no later than March 31, 2031; and
c.the Regulatory Milestone 3 Consideration Shares will be issued no later than March 31, 2032;
6.The actual issue price of each tranche of Regulatory Milestone Consideration Shares will be calculated using the
30-day VWAP
1
of Shares quoted on ASX for the period ending on, and including, the last trading day prior to the
date on which such Milestone Event has become publicly known or, if earlier, the date on which such Milestone
Event is finally determined to have been achieved.
Set out below is an example of the potential dilution of the issue of Regulatory Milestone Consideration Shares.
Table showing potential dilutive effects:
US$11.84
(Floor Price)
Regulatory Milestone 11.86%
Regulatory Milestone 21.86%
Regulatory Milestone 30.93%
All Regulatory Milestones Achieved 4.65%
US$14.21
(20% above Floor Price)
Regulatory Milestone 1 1.55%
Regulatory Milestone 2 1.55%
Regulatory Milestone 3 0.77%
All Regulatory Milestones Achieved3.87%
US$9.47
(20% below Floor Price)
Regulatory Milestone 1 1.86%
Regulatory Milestone 2 1.86%
Regulatory Milestone 3 0.93%
All Regulatory Milestones Achieved (2)4.65%
Issue PriceMilestoneDilution Factor (1)
Notes to Table:
(1) Based on 454,568,899 Shares on issue immediately following Closing, assuming the issue of approximately 114.2
million new Shares at Closing and no further Shares being issued before the issue of all the Regulatory Milestone
Consideration Shares in this scenario.
(2) An aggregate of an additional approximately US$50 million would also be payable in cash in this scenario if all
Regulatory Milestones are achieved, in addition to the issue of 21,114,865 Regulatory Milestone Consideration Shares.
7.The purpose of the issue of the Regulatory Milestone Consideration Shares is to satisfy the relevant Milestone
Payments, assuming such Regulatory Milestone is achieved by the deadline date. Accordingly, no funds will be
raised from the issue;
8.The Regulatory Milestone Consideration Shares will be issued under the Share Purchase Agreement. A summary
of the material terms of the Share Purchase Agreement is contained above;
9.The Regulatory Milestone Consideration Shares are not being issued under, or to fund, a reverse takeover; and
A voting exclusion statement is included in the Notice of Meeting for Item 2.
Board recommendation
The Directors unanimously recommend that Shareholders vote in favor of Item 2.
NOTICE OF GENERAL MEETING
17
1
The A$ VWAP will be converted to a US$ issue price at the applicable currency exchange rate at such time.
Item 3 – Approve the issue of Future Sales Milestone
Consideration Shares
Background
As outlined above, in addition to the Upfront Consideration, there is potential for Milestone Payments to be paid by Telix
upon the achievement of agreed commercial milestones in relation to ITM-11 net global sales. Refer to Item 1 above for a
summary of the Transaction and the Milestone Payments.
Any Milestone Payment may be satisfied at the election of Telix by the payment of cash, the issue of Shares at a 30-day
VWAP
1
of Shares quoted on ASX for the period ending on, and including the last trading day prior to the date on which
such Milestone Event has become publicly known or, if earlier, the date on which such Milestone Event is finally
determined to have been achieved, or a combination of both cash and Shares.
Item 3 seeks Shareholder approval for a maximum number of Future Sales Milestone Consideration Shares to be issued to
the Sellers (and/or the Sellers' nominees) at the Issue Price of US$11.84. As with Item 2, the Issue Price is being used as a
Floor Price for the purpose of determining the maximum number of Shares that may be issued as Future Sales Milestone
Consideration Shares and approved by Shareholders. However, the actual issue price of any Future Sales Milestone
Consideration Shares that are issued may be higher or lower than the Floor Price.
If Item 3 is passed and the future VWAP used to determine the number of Future Sales Milestone Consideration Shares to
be issued on the achievement of the Future Sales Milestone is higher than the Floor Price, then if Telix elects to issue
Shares the number of Shares that will need to be issued will be less than the maximum number of Shares approved
pursuant to Item 3.
If Item 3 is passed and the future VWAP used to determine the number of Future Sales Milestone Consideration Shares to
be issued on the achievement of the Future Sales Milestone is lower than the Floor Price, then Telix will be able to issue
the maximum number of Shares approved pursuant to Item 3 and will be required to pay a further amount in cash to ensure
that the Sellers receive the full Milestone Payment.
The number of actual Future Sales Milestone Consideration Shares (as defined below) to be issued will be determined
based on net global sales of ITM-11 in the calendar year 2030, and will only be paid to the extent such sales exceed
US$150 million (the Minimum Sales Threshold). For every US$1.00 above the Minimum Sales Threshold, Telix will pay
US$3.00 in Milestone Payments up to a maximum payment of US$450 million, assuming achievement of US$300 million in
2030 net global sales for ITM-11. Therefore, the number of Future Sales Milestone Consideration Shares actually issued
will vary based on both issue price at the time of achievement and future sales performance of ITM-11.
Subject to 100% of the Future Sales Milestone being achieved, the maximum number of Shares to be issued as payment
for the achievement of the Future Sales Milestone will be 38,006,757 (Future Sales Milestone Consideration Shares). See
table below for potential Share issues based on different issue price and sales performance scenarios.
Waiver from Listing Rule 7.3.4
Refer to Item 1 for a summary of Listing Rule 7.3.4 and a description of the ASX Waiver which allows for the Future Sales
Milestone Consideration Shares to be issued more than 3 months after the Meeting.
The payment of each Milestone Payment is contingent on the achievement of the relevant milestone as described in the
Explanatory Notes to Item 1 in the key terms of the Share Purchase Agreement, each of which will only be able to be
determined on a date that is more than 3 months after the date of the Meeting. The ASX Waiver permits Telix to issue
Future Sales Milestone Consideration Shares on a date that is more than 3 months after the date of the Meeting. Refer to
Item 1 for the conditions of the ASX Waiver.
A voting exclusion applies to Item 3 and is set out on page 8 of the Notice of Meeting.
Listing Rule 7.1
Refer to Item 1 for a summary of Listing Rule 7.1.
If Item 3 is passed, Telix will be able to proceed with the issue of the Future Sales Milestone Consideration Shares in
satisfaction of the Future Sales Milestone Payment (assuming the Future Sales Milestone is achieved). In addition, the
Future Sales Milestone Consideration Shares will be excluded from the calculation of the number of equity securities that
Telix can issue without Shareholder approval under Listing Rule 7.1.
If Item 3 is not passed, Telix will not be able to proceed with the issue of the Future Sales Milestone Consideration Shares
in satisfaction of the Future Sales Milestone Payment (assuming the Future Sales Milestone is achieved). Telix may need to
seek this Shareholder approval at a future meeting of Shareholders (before the date on which the Future Sales Milestone
NOTICE OF GENERAL MEETING
18
1
The A$ VWAP will be converted to a US$ issue price at the applicable currency exchange rate at such time.
Consideration Shares must be issued), otherwise Telix will be required to pay any Future Sales Milestone Payment for the
achievement of the Future Sales Milestone in cash.
Information required by Listing Rule 7.3
The following information in relation to the Future Sales Milestone Consideration Shares is provided to Shareholders for the
purposes of Listing Rule 7.3:
1.The Future Sales Milestone Consideration Shares will be issued to the Sellers (and/or the Sellers' nominees), none
of whom is currently a related party, KMP, substantial shareholder or advisor of Telix or an associate of those
persons;
2.The maximum number of Future Sales Milestone Consideration Shares to be issued is 38,006,757, which is
calculated by dividing US$450 million by the Floor Price which assumes 100% achievement of the Future Sales
Milestone;
3.The table below provides examples of the number of Future Sales Milestone Consideration Shares that may be
issued if Shareholders approve Item 3. The table uses:
a.the Issue Price (which operates as a Floor Price to calculate the maximum number of Shares approved by
Shareholders);
b.an issue price that is 20% lower than the Floor Price, reflecting a 20% decreased VWAP at the time of
issue of the Future Sales Milestone Consideration Shares, which means that an additional cash payment is
required to pay the full Milestone Payment; and
c.an issue price that is 20% higher than the Floor Price, reflecting a 20% increased VWAP at the time of
issue of the Future Sales Milestone Consideration Shares, which means that less than the maximum
number of Shares approved by Shareholders will need to be issued even upon full milestone performance.
The table also provides examples of different performance levels for this milestone: net global sales in 2030 less
than or equal to US$150 million, US$200 million, and US$300 million (full performance).
</= US$150 million000
US$200 million 12,668,91915,839,49310,555,947
US$300 million 38,006,75738,006,757
(1)
31,667,840
Number of Future Sales Milestone Consideration Shares
Net Global Sales in 2030US$11.84
(Floor Price)
US$9.47
(20% below Floor Price)
US$14.21
(20% above Floor Price)
(1)Telix would be required to pay an additional US$90 million in cash to satisfy its Milestone Payment obligations.
4.The Future Sales Milestone Consideration Shares will be fully paid ordinary shares which rank equally with all
other Shares on issue;
5.In accordance with the ASX Waiver, the Future Sales Milestone Consideration Shares will be issued no later than
four months after the issue of Telix’s 2030 financial statements. If the Sellers dispute the sales milestone such that
the process to determine the amount of any Future Sales Milestone payment extends beyond the four months,
Telix may no longer be able to rely on this Shareholder approval to issue Future Sales Milestone Consideration
Shares and may instead seek further Shareholder approval or an ASX waiver or make the payment in cash;
6.The issue price of Future Sales Milestone Consideration Shares will be calculated using the 30-day VWAP of
Shares quoted on ASX for the period ending on, and including, the last trading day prior to the date on which such
Milestone Event has become publicly known or, if earlier, the date on which such Milestone Event is finally
determined to have been achieved;
7.Set out below is an example of the potential dilution of the issue of the Future Sales Milestone Consideration
Shares.
NOTICE OF GENERAL MEETING
19
Potential dilution effect:
</= US$150 million000
US$200 million 2.69% (2)3.36% (3)2.24% (4)
US$300 million 8.06% (5)8.06% (5) (6)6.72% (7)
Dilutive Effect of Future Sales Milestone Consideration Shares (1)
Net Global Sales in 2030US$11.84
(Floor Price)
US$9.47
(20% below Floor Price)
US$14.21
(20% above Floor Price)
Notes to Table:
(1) Based on 471,460,791 Shares on issue immediately following Closing, assuming the issue of 114.2 million new Shares at
Closing and that the maximum numbers of Regulatory Milestone Consideration Shares (excluding Regulatory Milestone 3
Consideration Shares, which may not be issuable until 2031) are issued and no further Shares being issued before the issue of
the Future Sales Milestone Consideration Shares.
(2) Would result in 12,668,919 Shares being issued, and approximately 484,129,710 total Shares on Issue.
(3) Would result in 15,839,493 Shares being issued, and approximately 487,300,284 total Shares on Issue.
(4) Would result in 10,555,947 Shares being issued, and approximately 482,016,738 total Shares on Issue.
(5) Would result in 38,006,757 Shares being issued, and approximately 509,467,548 total Shares on Issue.
(6) Telix would also be required to pay an additional US$90 million in cash to satisfy its Milestone Payment obligations.
(7) Would result in 31,667,840 Shares being issued, and approximately 503,128,631 total Shares on Issue.
8.The purpose of the issue of the Future Sales Milestone Consideration Shares is to satisfy the relevant Milestone
Payment under the Share Purchase Agreement (assuming the Future Sales Milestone is achieved). Accordingly, no
funds will be raised from the issue;
9.The Future Sales Milestone Consideration Shares will be issued under the Share Purchase Agreement. A summary
of the material terms of the Share Purchase Agreement is contained above in Item 1;
10.The Future Sales Milestone Consideration Shares are not being issued under, or to fund, a reverse takeover; and
A voting exclusion statement is included in the Notice of Meeting for Item 3.
Board recommendation
The Directors unanimously recommend that Shareholders vote in favor of Item 3.
NOTICE OF GENERAL MEETING
20
Item 4 – Elect new Directors Background Under the Share Purchase Agreement, Telix has agreed to seek Shareholder approval for the election of Dr. Andrew Cavey and Dr. Barbara Weber to the Board, effective immediately following Closing for a 3-year term, and the Board has agreed to recommend that Shareholders approve their election. The Board considers that each of Dr. Cavey and Dr. Weber has the relevant qualifications, experience and skills to contribute positively to Board deliberations of the combined entity and to complement the current skills of the Board as a whole. Each has deep knowledge of ITM, its business and the markets in which it operates. Details of their skills and experience are set out below. The contribution of each Director is and continues to be important to Telix’s long term success as a vertically integrated radiopharmaceutical company with the capabilities required to develop and deliver innovative treatments to patients globally. The Board considers that as a whole it has an appropriate mix of skills, backgrounds, knowledge, experience and diversity to operate effectively. The current seven member Telix Board is comprised of six independent non-executive directors and the MD & CEO Dr. Christian Behrenbruch. Subject to Closing, Dr. Weber will join the Board as an independent non-executive director and Dr. Cavey, given his tenure as previous CEO of ITM, will not be considered to be independent although he will cease his role as CEO and join the Board as a Non-Executive Director while providing Telix with advice to support integration of the combined operations. Dr. Weber and Dr. Cavey have confirmed that they have the time available to discharge effectively their responsibilities as a Telix Board member. Item 4(a) – Elect Dr. Andrew Cavey as a Director Dr. Andrew Cavey BM BCh, MA, MPH, MRCP (UK) Appointment Following Closing Career summary Dr. Andrew Cavey has served as Chief Executive Officer of ITM since September 2024. Dr. Cavey is a physician and an experienced healthcare executive, with expertise and a successful track record in radiopharmaceutical drug development and commercialization across leading global biopharmaceutical organizations. Before joining ITM, Dr. Cavey was SVP, Head of Global Program Leaders, Hematology, Oncology, Cell Therapy at Bristol Myers Squibb. Over the course of his career, he has also held a number of corporate strategy, commercial and drug development leadership roles at Novartis culminating in his role as Global Program Head, Prostate Cancer, in which he co-led the company’s Radiopharmaceutical Therapy strategy and led teams overseeing the clinical development and regulatory approvals of radiopharmaceuticals in the U.S. and Europe. In his early career, he practiced medicine as a physician in the UK’s NHS, and worked as a humanitarian aid worker for various non-governmental organizations in sub-Saharan Africa and South Asia. Dr. Cavey holds physiological sciences and medical degrees from Oxford University, and a Master’s in Public Health from Harvard University. He gained membership to the UK Royal College of Physicians and is a member of the board of ReBio Pharma. Board recommendation The Directors unanimously recommend that Shareholders vote in favor of item 4(a). NOTICE OF GENERAL MEETING 21
Item 4(b) – Elect Dr. Barbara Weber as a Director Dr. Barbara Weber B.A. Chemistry; M.D. (University of Washington) Appointment Following Closing Career summary Dr. Barbara Weber is a physician, biotechnology executive and director with more than 25 years' experience spanning pharmaceutical research and development, biotechnology leadership and venture capital. She has served on the Supervisory Board of ITM since April 2025. Dr. Weber is the founder and former CEO and Chair of Tango Therapeutics (NASDAQ: TNGX), a clinical-stage precision oncology company, with a lead asset in Phase 3 clinical development. Earlier in her career, Dr. Weber held senior oncology research and translational medicine leadership positions with Novartis (SWX: NOVN) and GlaxoSmithKline (LON:GSK), including serving as Senior Vice President and Global Head of Oncology Translational Medicine at Novartis. Before entering the biopharmaceutical industry, she was Professor of Medicine and Genetics at the University of Pennsylvania, where she led research in cancer genetics. Dr. Weber is an elected member of the American Association of Physicians and the American Society for Clinical Investigation, of which she served as president in 2005. She has also served on the board of directors of both ASCO and AACR. Dr. Weber received her medical degree from the University of Washington, completed her residency in Internal Medicine at Yale University and undertook fellowship training in Medical Oncology at the Dana- Farber Cancer Institute. Dr. Weber currently serves on the board of directors of Parabilis Medicines (NASDAQ:PMBS) and privately-held Sesame Therapeutics. Board recommendation The Directors unanimously recommend that Shareholders vote in favor of item 4(b). NOTICE OF GENERAL MEETING 22
Item 5 – Approve the grant of share rights to the New Non- Executive Directors under the Equity Incentive Plan Background The Board has agreed, subject to Closing and the election of Dr. Cavey and Dr. Weber and obtaining Shareholder approval, to grant Share Rights (SRs) to: • Dr. Andrew Cavey (Item 5(a)); • Dr. Barbara Weber (Item 5(b)); (together, the New NEDs) The grants will be made pursuant to the EIP on the terms and conditions set out in in these Explanatory Notes to Item 5. The Board considers that the proposed one-off grants of SRs to each New NED is appropriate and reasonable remuneration for the New NEDs and encourages and attracts high-caliber professional Non-Executive Directors (NEDs), with the skills, expertise and experience identified by the Board as adding value, to join the Company as Directors. Both of the New NEDs have agreed to join the Board as part of the Transaction. Governance oversight of the global nature of the Company’s structure and operations necessitates the appointment of appropriately qualified specialist overseas directors, and the Board considers it appropriate for the Company’s remuneration structures to reflect global remuneration philosophies. As disclosed in the 2025 Annual Report, Telix partnered with Mercer to undertake market benchmarking of global NED remuneration. The proposed SR grants are consistent with market practice in jurisdictions in which Telix operates. The proposed grants of SRs to the New NEDs are equivalent in value to the one-off share appreciation rights (SARs) granted to Marie McDonald, David Gill, William Jellison and Dr. Maria Rivas following Shareholder approval at the 2026 Annual General Meeting. Accordingly, each incoming NED will receive SRs equal to a value of US$115,000, continuing Telix’s practice of granting one-off equity awards to NED on commencement. The Board has determined to grant SRs rather than SARs. SRs track the Telix share price in both directions, so NEDs share in the downside as well as the upside, to the same extent as Shareholders. Like the SARs, the SRs are not subject to performance conditions. This is consistent with equity granted to NEDs, creating alignment without impacting independence. The SRs will remunerate the New NEDs for their contribution to the Company. The New NED SRs have a 3-year vesting schedule, which is aligned with Shareholder interests. Listing Rule 10.14.1 provides that a listed company must not permit a director of the Company to acquire equity securities under an employee incentive share scheme unless it obtains shareholder approval. Accordingly, Shareholder approval is sought for the issue of SRs to the New NEDs, for the purposes of Listing Rule 10.14 and for all other purposes. If Item 5(a) and Item 5(b) are passed, the Company will be permitted to proceed with the grant of SRs to Dr. Andrew Cavey (or nominee) and to Dr. Barbara Weber (or nominee) and the issue of Shares on the exercise of any vested SRs. If the above items are not passed, Telix will not be able to proceed with the issue of SRs to the applicable New NED(s) and no alternative remuneration will be provided. Further details of the proposed grant of SRs to New Non-Executive Directors Instrument New NEDs will be invited to apply for SRs, which are a form of Rights that may be issued under the EIP as described at section 2 of the EIP (a copy of which is available on the Company’s website and is summarized in Appendix B). SRs have been selected because they create alignment between NEDs and Shareholder experience, without compromising the independence of NEDs. Each SR is an entitlement to receive one fully paid ordinary share in Telix (or one ADS, in the case of ADS-backed SRs), subject to satisfaction of the applicable vesting conditions. No amount is payable by the New NED(s) for the grant of the SRs, and there is no exercise price. Because each SR represents the value of one underlying Share, the value of the SRs will rise and fall with the Telix share price. Unlike SARs, SRs do not provide leverage to share price growth. The SRs are not subject to performance conditions. SRs do not carry dividend or voting rights unless and until they vest and Shares are allocated. The Board retains discretion to settle vested SRs by a cash equivalent payment in lieu of an allocation of Shares. NOTICE OF GENERAL MEETING 23
Vesting conditions All SRs will vest on the date that is the third year anniversary of the grant date, subject to the continued tenure of the New NED until the end of the vesting period (subject to the cessation of employment provisions outlined below). Term Telix intends to grant the SRs shortly after the appointments of the New NEDs to the Board (i.e. after Closing), and in any event, the SRs will be granted within 12 months of the appointments. Cost of Rights and allocation price No amount is payable by the New NEDs for the SRs, either in respect of their grant, or their vesting. The SRs have no exercise price. On vesting, each SR will entitle the New NED to one Share (or one ADS, in the case of ADS-backed SRs) for no further consideration. The number of SRs to be granted to each New NED will be calculated by dividing the dollar value of their grant by the allocation price. The allocation price is the five-day VWAP of Shares traded on ASX (for ASX-backed SRs), or of ADSs traded on Nasdaq (for ADS-backed SRs), for the five trading days up to and including the trading day prior to the grant date. The Board considers that the allocation price appropriately reflects the fair market value of the Shares or ADSs underlying the SRs, while reducing the impact of short-term share price volatility on the number of SRs granted. Number of SRs and calculation methodology The Board has determined that the New NEDs will each be granted a dollar value worth of SRs as outlined below. DirectorDollar valueSecurity backing Dr. Andrew CaveyA$170,000ASX-backed share Dr. Barbara WeberUS$115,000ADS-backed share The number of SRs proposed to be granted to each New NED will be calculated by dividing the dollar value of the grant, by the five-day VWAP of Shares traded on ASX (for ASX-backed SRs), or of ADSs traded on Nasdaq (for ADS-backed SRs), for the five trading days up to and including the trading day prior to the grant date. Examples of number of SRs that may be granted Outlined below are examples of the number of SRs that would be granted to each of the New NEDs at each of the respective VWAP, underlying share prices and number of SRs granted. DirectorDollar valueAssumed 5 day VWAP at grant Assumed SR valuation at grant Number of SRs to be granted Dr. Andrew CaveyA$170,000A$13.50A$13.50 12,593 Dr. Barbara WeberUS$115,000US$9.50US$9.50 12,105 Dr. Andrew CaveyA$170,000A$14.50A$14.50 11,724 Dr. Barbara WeberUS$115,000US$10.50US$10.50 10,952 Dr. Andrew CaveyA$170,000A$16.00A$16.00 10,625 Dr. Barbara WeberUS$115,000US$11.50US$11.50 10,000 In summary, at the: •lowest assumed VWAP and underlying share price (of A$13.50 and US$9.50), a total of 24,698 SRs would be granted; and •highest assumed VWAP and underlying share price (of A$16.00 and US$11.50), a total of 20,625 SRs would be granted. however in no circumstances will the dollar value of the grants exceed the amounts specified above. NOTICE OF GENERAL MEETING 24
Automatic exercise of vested SRs Subject to applicable law, the EIP Rules and the terms of the relevant Offer, vested SRs will be automatically exercised on the applicable vesting date (Vesting Date)without the New NED being required to submit an Exercise Notice. If the automatic exercise and/or settlement of vested SRs cannot occur on the Vesting Date, due to applicable law, Telix’s Securities Dealing Policy, or other applicable dealing restrictions, the timing and/or manner of exercise or settlement may be adjusted in accordance with the EIP Rules, applicable law and the terms of the relevant Offer. On exercise, each vested SR will entitle the New NED to receive one Share or, in the case of an ADS-backed SR, one ADS, for no further consideration. The Board intends to settle vested SRs by issuing or transferring Shares, or by delivering ADSs, as applicable. The Board retains discretion, subject to the EIP Rules, applicable law and the terms of the relevant Offer, to settle some or all vested SRs by making a cash equivalent payment instead. Any cash equivalent payment will be calculated by multiplying the number of vested SRs settled in cash by the applicable Current Market Price, determined in accordance with the EIP Rules and the terms of the relevant Offer. The Company may issue new Shares or acquire Shares on-market to satisfy the exercise of vested SRs. Shares issued or transferred on exercise of vested SRs will rank equally with existing fully paid ordinary Shares. Shares and ADSs delivered on exercise will be subject to Telix’s Securities Dealing Policy, applicable law and any other applicable dealing restrictions. The detailed exercise, settlement, withholding and dealing restriction arrangements applicable to each New NED will be set out in the relevant Offer, in accordance with the EIP Rules and applicable law in the relevant jurisdictions. Other terms applicable to the SRs This section sets out other key terms applicable to the grant of SRs to the New NEDs. Dealing and disposal restrictions SRs may not be sold, transferred, mortgaged, charged or otherwise dealt with or encumbered, except by force of law. Change of control In the event of a change of control of the Company, the Board may determine that all or a specified number of SRs will vest in accordance with the Company’s EIP Rules. The Board also has discretion to determine the treatment of vested SRs where a change of control occurs. Malus and clawback Under the EIP Rules, the Board has broad powers to determine that unvested or unexercised SRs lapse, any shares allocated on vesting are forfeited, or that cash amounts are to be repaid in certain circumstances (such as dishonesty, fraud, gross misconduct, or breach of duties or obligations to Telix). Corporate actions Under the EIP Rules, the Board may grant additional SRs or make any adjustments to the terms of a SR it considers appropriate to minimize or eliminate any material advantage or disadvantage to a participant resulting from a corporate action such as a return of capital or capital reconstruction. Treatment on retirement as a Director Unvested SRs will generally be forfeited if the New NED retires as a Director prior to the Vesting Date, unless otherwise determined by the Board. The Board has discretion to determine a different treatment, including that some or all of the unvested SRs stay on foot (to vest in the ordinary course) or vest on retirement, subject to Part 2D.2 Division 2 of the Corporations Act (including the restrictions on termination benefits in section 200B). Information provided in accordance with Listing Rule 10.15 The following information is provided in relation to the proposed issue of the SRs in accordance with the requirements of Listing Rule 10.15: NOTICE OF GENERAL MEETING 25
•the SRs are proposed to be granted to Dr. Andrew Cavey and Dr. Barbara Weber (or their respective nominees). Neither of the New NEDs is a Director at the time of this Notice. Each New NED has agreed to join the Board on Closing and, as a proposed Director, falls within Listing Rule 10.14.3 at the date of this Notice. The SRs will only be granted after each New NED has been appointed as a Director, at which time they will fall within Listing Rule 10.14.1. Any nominee would fall within Listing Rule 10.14.2; •the SRs are share rights, each being an entitlement to receive one fully paid ordinary share (or one ADS, in the case of ADS-backed SRs) on vesting. The number of SRs to be granted to each New NED will be calculated by dividing A$170,000 for ASX-backed SRs or US$115,000 for ADS-backed SRs by the 5-day VWAP of Shares, as described under "Cost of Rights and allocation price" above. Worked examples of the number of SRs that may be granted are set out under "Examples of number of SRs that may be granted" above. In any event, the number of SRs granted to each New NED will not exceed a total value of A$170,000 or US$115,000 (as applicable). •details (including the amount) of the New NEDs' current total remuneration package, being the remuneration that will apply from their appointment as a Director including under Telix’s current NED remuneration schedule for Board and committee membership, are set out in the table below 1 : New Non-Executive DirectorNED annual fees in cash Value of SRs grant Integration services feeTotal Remuneration Package Dr. Andrew CaveyA$234,000A$170,000A$870,000 2 A$1,274,000 Dr. Barbara WeberUS$237,500 3 US$115,000 — US$352,500 •Dr. Andrew Cavey has entered into an agreement with Telix and ITM to provide services to assist with the integration of the businesses of Telix and ITM during the 12 month period after Closing. Dr. Andrew Cavey has also agreed not to perform any activity competing with Telix or ITM during that period. Under the agreement Dr. Andrew Cavey will be paid CHF500,000; •Dr. Andrew Cavey is expected to receive from the Sellers a transaction incentive payment of EUR5,950,000 4
pursuant to a Management Transaction Incentive Program established by the Sellers for the purposes of the Sellers making payments to selected management of ITM in connection with the Transaction. Such payment can be made in cash, Shares or a combination of cash and Shares as determined by the Sellers; •neither of the proposed New NEDs has been issued equity securities by Telix prior to the date of this Notice; •the terms of the issue of the SRs are described in the Explanatory Notes to this Item 5 and the key terms of the EIP are set out in Appendix B of this Notice of Meeting; •the SRs will be granted for nil consideration, and no amount is payable on vesting; •there is no loan associated with the grant or exercise of the SRs; •details of any securities issued under the EIP will be published in the Company’s annual report relating to the period in which they were issued, along with a statement that approval for the issue was obtained under Listing Rule 10.14; •any additional persons covered by Listing Rule 10.14 who become entitled to participate in an issue of securities under the EIP after the Resolution is approved and who were not named in this Notice will not participate until approval is obtained under Listing Rule 10.14 unless an exception under Listing Rule 10.16 applies; and Voting exclusions apply to Items 5(a) and 5(b) and are set out on page 8 of the Notice of Meeting. The Board considered the above matters, including extensive experience and reputation of the New NEDs, the current market price of Shares, the implied value of the SRs, current market practices for companies listed in Australia and the United States and the quantum and value of prior grants of SARs to NEDs when determining the number and terms of NED SRs to be issued under this Resolution. Board recommendation The Directors unanimously recommend that Shareholders vote in favor of Items 5(a) and 5(b). NOTICE OF GENERAL MEETING 26 1 The New NEDs will be compensated in line with the approved NED remuneration schedule applicable at the time of their appointments, and will be eligible for any subsequent changes to the NED remuneration schedule for Board and committee membership (as determined by the Board). 2 This amount represents CHF500,000 which is the total fee payable to Dr. Cavey under his agreement to provide integration services converted to A$ at 1 CHF equals approximately A$1.74. 3 Assumes the fee associated with one committee membership. 4 Approximately A$9,520,000 converted to A$ at 1 EUR equals approximately A$1.60.
Glossary
15% Placement CapacityAs described in the Explanatory Notes to Item 1.
Adjustments HoldbackAs described in the Explanatory Notes to Item 1.
ADSsAmerican Depositary Shares represent ownership in Telix's stock traded on Nasdaq. Each ADS
represents one Share in Telix.
ASXASX Limited or the securities exchange it operates (as the context requires).
ASX WaiverThe waiver granted by ASX from Listing Rule 7.3.4 as described in the Explanatory Notes to
Item 1.
BoardThe Board of Directors of Telix.
BuyerTelix Pharmaceuticals Limited ACN 616 620 369.
Closely Related PartiesA closely related party of a member of the KMP means: (a) a spouse or child of the member;
(b) a child of the member's spouse; (c) a dependent of the member or a member's spouse; (d)
anyone else who is one of the member's family and may be expected to influence the member,
or be influenced by the member, in the member's dealings with the Company; (e) a company
the member controls; or (f) a person prescribed by the Corporations Regulations 2001 (Cth).
ClosingThe completion of the Transaction in accordance with the Share Purchase Agreement.
Consideration SharesThe Upfront Consideration Shares and the Milestone Considerations Shares, collectively.
Corporations ActThe Corporations Act 2001 (Cth).
DirectorA director of Telix.
Equity Incentive Plan /
EIP
The Equity Incentive Plan of Telix.
Explanatory NotesThe explanatory notes to the Notice of Meeting.
FDAUnited States Food and Drug Administration.
Future Milestone
Consideration
As described in the Explanatory Notes to Item 1.
Future Sales MilestoneAs described in the Explanatory Notes to Item 1.
Future Sales Milestone
Consideration Shares
Up to 38,006,757 Shares being the maximum number of Shares that may be issued as
payment for the achievement of the Future Sales Milestone.
General Meeting /
Meeting
The general meeting of Shareholders, as convened by the Notice of Meeting.
Holdback AmountsAs described in the Explanatory Notes to Item 1.
Indemnity HoldbackAs described in the Explanatory Notes to Item 1.
Investor PresentationThe investor presentation released to ASX on September 21, 2026, as updated on October 29,
2026, which is included in Appendix A to this Notice of Meeting.
Issue PriceUS$11.84, being the 30-day VWAP of Shares quoted on ASX for the period ending on
September 18, 2026, the last trading day prior to signing the Share Purchase Agreement.
ITMITM Isotope Technologies Munich SE.
Key Management
Personnel / KMP
As defined in the Listing Rules.
Listing RulesThe Listing Rules of ASX.
Maximum Upfront
Consideration Shares
The maximum number of Upfront Consideration Shares that may be issued by Telix, being
114.2 million Shares, for which Shareholder approval is being sought in Item 1.
Milestone Consideration
Shares
The Future Sales Milestone Consideration Shares and the Regulatory Milestone Consideration
Shares
Milestone EventEach of the Future Sales Milestone and the Regulatory Milestones.
Milestone PaymentsPayments to the Sellers subject to the achievement of certain regulatory and commercial
milestones for ITM-11.
NasdaqNasdaq Global Select Market.
New Non-Executive
Director / New NED
As described in the Explanatory Notes to Item 5.
Non-Executive
Director / NED
A non-executive director of Telix.
TermMeaning
NOTICE OF GENERAL MEETING
27
Notice of MeetingThis Notice of Meeting convening the Meeting, which includes (as the context requires) the Chair’s Letter, the Explanatory Notes, this Glossary, Appendix A and the proxy form. Regulatory MilestonesRegulatory Milestone 1, Regulatory Milestone 2 and Regulatory Milestone 3. Regulatory Milestone Consideration Shares The Regulatory Milestone 1 Consideration Shares, Regulatory Milestone 2 Consideration Shares and Regulatory Milestone 3 Consideration Shares. Regulatory Milestone 1As described in the Explanatory Notes to Item 1. Regulatory Milestone 1 Consideration Shares 8,445,946 Shares, being the maximum number of Shares to be issued as payment for the achievement of Regulatory Milestone 1. Regulatory Milestone 2As described in the Explanatory Notes to Item 1. Regulatory Milestone 2 Consideration Shares 8,445,946 Shares, being the maximum number of Shares to be issued as payment for the achievement of Regulatory Milestone 2. Regulatory Milestone 3As described in the Explanatory Notes to Item 1. Regulatory Milestone 3 Consideration Shares 4,222,973 Shares, being the maximum number of Shares to be issued as payment for the achievement of Regulatory Milestone 3. ResolutionsThe resolutions contained in the Notice of Meeting. SellersThe shareholders of ITM Isotope Technologies Munich SE party to the Share Purchase Agreement (including via joinders). ShareUnless stated otherwise, a fully paid ordinary share in Telix. ShareholderA holder of Telix ordinary shares listed on ASX or Telix American Depositary Shares listed on Nasdaq. Share Purchase Agreement The agreement pursuant to which Telix will acquire 100% of ITM dated September 20, 2026. Special Indemnity Holdback As described in the Explanatory Notes to Item 1. TelixTelix Pharmaceuticals Limited ACN 616 620 369 (and, when the context requires, its wholly- owned direct and indirect subsidiaries). TransactionThe acquisition of 100% of the shares in ITM by Telix for total upfront consideration valued at US$1.65 billion on a cash-free/debt-free basis and additional contingent consideration of up to US$700 million upon achievement of future regulatory approvals and commercial sales milestones for ITM-11, pursuant to the Share Purchase Agreement. Upfront ConsiderationAs described in the Explanatory Notes to Item 1. Upfront Consideration Shares The Shares issued as part of the Upfront Consideration. U.S.United States of America. VenueThe venue of the Meeting, being The Events Centre, Level 5, Tower 2/727 Collins Street, Melbourne, Victoria 3008 Vesting DateAs described in the Explanatory Notes to Item 5. VWAPVolume weighted average price. TermMeaning NOTICE OF GENERAL MEETING 28
Information for Shareholders By hosting a hybrid Meeting, the Company will enable Shareholders to attend in person or online. Details of how to attend and participate online can be found in the Virtual Meeting Online Guide, released to ASX and also accessible at ir.telixpharma.com. Eligibility Shareholders Shareholders will be eligible to vote and ask questions at the Meeting if they are registered holders of ordinary Shares in the Company as at 10:00 a.m. (Melbourne time) on Sunday, November 29, 2026. Shareholders attending the Meeting can register from 9:15 a.m. (Melbourne time) at the Venue. Please bring your proxy form to assist with your registration at the Meeting. If you have any questions in relation to your Shareholding(s), please contact our share registry at +61 1300 554 474 or email [email protected]. Proxies A Shareholder entitled to be present and vote at the Meeting is entitled to appoint a proxy. A proxy need not be a Shareholder of the Company. The appointment of one or more proxies will not preclude a Shareholder from being present, voting and asking questions. A Shareholder entitled to cast more than one vote on a Resolution may appoint two proxies, in which case the Shareholder should specify the proportion or number of votes that each proxy is appointed to exercise. If no proportions or numbers are specified, each proxy may exercise half of the Shareholder’s votes. Shareholders are encouraged to direct their proxies how to vote on each Resolution by selecting the ‘for’, ‘against’ or ‘abstain’ box for each item on the proxy form. If a proxy chooses to vote, then he/she must vote in accordance with the directions set out in the proxy appointment form. If the Chair of the Meeting is appointed, or taken to be appointed, as a proxy but the appointment does not direct the proxy how to vote on a Resolution, then the Chair of the Meeting intends to exercise the relevant Shareholder’s votes in favor of the relevant Resolution (subject to the other provisions of these notes, including any voting exclusions set out in this Notice of Meeting). In order for the proxy appointment to be valid, completed proxy forms (together with any authority under which the proxy was signed or a certified copy of the authority) must be returned before 10:00 a.m. (Melbourne time) on Sunday, November 29, 2026 in one of the following ways: By mailTelix Pharmaceuticals Limited C/- MUFG Corporate Markets (AU) Limited Locked Bag A14 Sydney South NSW 1235 Australia Onlineau.investorcentre.mpms.mufg.com By mobile deviceUsing the QR code in the proxy form, or enter the voting link au.investorcentre.mpms.mufg.com into your mobile device By fax+61 2 9287 0309 By handMUFG Corporate Markets (AU) Limited Parramatta Square Level 22, Tower 6 10 Darcy Street Parramatta NSW 2150 (during business hours - Monday to Friday, 9:00 a.m. – 5:00 p.m.) Attorneys A Shareholder may appoint an attorney to participate in the Meeting, including to vote, on his or her behalf. For an appointment to be effective for the Meeting, the instrument effecting the appointment (or a certified copy of it) must be received by our share registry by no later than 10:00 a.m. (Melbourne time) on Sunday, November 29, 2026. Corporate representatives A body corporate which is a Shareholder, or which has been appointed as a proxy, may appoint an individual to act as its representative at the Meeting in accordance with section 250D of the Corporations Act. If you wish to appoint a body corporate as your proxy, you must specify on the proxy form: •the full name of the body corporate appointed as proxy; and •the full name or title of the individual representative of the body corporate who will be present in person or virtually at the Meeting. NOTICE OF GENERAL MEETING 29
Representatives should provide satisfactory evidence of their appointment including any authority under which that
appointment is signed (unless previously given to the Company).
If a representative of the corporation is to attend the Meeting virtually the appropriate “Certificate of Appointment of
Corporate Representative” must be received at [email protected] prior to admission in accordance with this
Notice of Meeting. A form of the certificate may be obtained from our share registry or online at www.mpms.mufg.com.
How to vote
Shareholders can vote:
•by attending the Meeting and voting in person or by attorney or, in the case of body corporate Shareholders, by
corporate representative;
•by attending the Meeting and voting via the Virtual Meeting Online Platform, in person or by attorney or, in the
case of body corporate Shareholders, by corporate representative; or
•by appointing a proxy to attend and vote at the Meeting on their behalf. A proxy does not need to be a
Shareholder of the Company.
How to ask questions prior to the Meeting
Shareholders’ questions are welcome at the Meeting. In the interests of all present, Shareholders are asked to confine
questions to matters before the Meeting that are relevant to Shareholders as a whole.
Shareholders are strongly encouraged to submit questions before the Meeting so that the Company can consider and
address relevant questions as part of the Meeting presentation. Questions can be submitted by Shareholders before the
Meeting by logging into your portfolio or holding at au.investorcentre.mpms.mufg.com, select 'Voting' and then ‘Ask a
Question’ under the 'Action' column.
Submitting questions in advance of the Meeting will facilitate a considered reply of relevant questions, but will not stop
any Shareholder, proxy, attorney or corporate representative from asking questions at the Meeting should they wish to do
so.
Questions for the Company should be received no later than 10:00 a.m. (Melbourne time) on Sunday, November 29, 2026.
Telix will respond to as many of the more frequently asked questions as possible at the Meeting. Please note that
individual responses will not be sent.
How to be present, vote and ask questions virtually (online)
Shareholders who would prefer to participate online will have the opportunity to be present and will be able to vote and
ask questions electronically in real time via the share registry's online platform.
The online platform can be accessed at meetings.openbriefing.com/TLXMeeting2026. To vote or ask a question,
Shareholders will need their holder identifier (SRN, HIN or employee identification) and postcode. Proxies will need to
enter the proxy number that the share registry will send via email 24 hours before the Meeting.
Voting will open at commencement of registration.
More information regarding online participation at the Meeting, including how to vote and ask questions through the
online platform is available in the Virtual Meeting Online Guide. The Guide is available on Telix’s website and has been
lodged with ASX.
Poll
The Chair of the Meeting intends to call a poll on each of the Resolutions set out in this Notice of Meeting.
Technical difficulties
In the event that technical issues arise during the course of the Meeting, the Company will have regard to the impact of
the technical issues on Shareholders participating and casting direct votes online.
The Chair of the Meeting may, in exercising his powers as the Chair of the Meeting, issue any instructions for resolving
the issue and may continue the Meeting if it is appropriate to do so.
NOTICE OF GENERAL MEETING
30
A radiopharmaceutical powerhouse with enhanced capabilities across the value chain Telix + ITM Telix Pharmaceuticals ASX: TLX | NASDAQ: TLX Updated October 27, 2026 Appendix A: Investor Presentation
2 Disclaimer and forward-looking statements Notices: This presentation should be read together with TelixPharmaceuticals Limited’s (Telix) risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. This presentation is for informational purposes only and does not constitute an offer to sell, or the solicitation of any offer to buy any securities ofTelix or ITM Isotope Technologies Munich SE (ITM) in any jurisdiction, including the United States, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The American Depositary Shares to be issued by Telix as consideration in the transaction have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (Securities Act), and are being issued in reliance on exemptions from registration, including Rule 802 under the Securities Act (and Regulation S and/or Regulation D, as applicable). Such securities may not be offered or sold in the United States absent registration under, or an applicable exemption from, the registration requirements of the Securities Act. Forward-looking statements: The information and opinions contained in this presentation aresubject to change without notification.To the maximum extent permitted by law,Telixand ITM disclaim any obligation or undertaking to update or revise any information or opinions contained in this presentation, including any forward-looking statements (as referred to below), whetheras a result ofnew information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in this presentation. This presentation may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identifiedby the use ofwords such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may causeTelixor ITM’s actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based onTelix’sand, as applicable, ITM’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affectTelixor ITM’s respective businesses and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context ofTelixand ITM’s respective businesses, forward- looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results ofpreclinical and clinical trials, andresearch and development programs;ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals forproduct candidates, including the planned NDA resubmission for ITM-11 and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization ofproduct candidates, if or when they have been approved;the parties’ability to obtain an adequate supply of raw materials at reasonable costs for products and product candidates; estimates ofexpenses, future revenues and capital requirements;the parties’financial performance; developments relating tothe parties’ respective competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions onthe parties’ respective businesses, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement ofthe parties’product candidates, if and after they have been approved.Telixor ITM’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. This presentation also contains estimates and other statistical data made by independent parties and byTelixand ITM relating to market size and other data about their industry. This data involvesa number ofassumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates ofthe parties’future performance and the future performance of the markets in which they operate are necessarily subject to a high degree of uncertainty and risk. Use of Non-IFRS Measures.Telix’sresults are reported under International Financial Reporting Standards (IFRS). ITM’s results are reported under IFRS as adopted by the European Union. This announcement includes various non-IFRS financial information to reflectunderlying performance, whichhasnot been subject to audit or review.Thesenon-IFRS measures include Adjusted EBITDA, whichfor Telix, representsnet earningsattributable to the Telix Group excluding financecosts, income tax expense, depreciation and amortization, remeasurement of provisions, and net gains / losses.As required by SEC rules, Telix has provided reconciliationsofits non-IFRS financial measuresto the most directly comparable IFRS measures, which for Adjusted EBITDA, is Profit/(loss) before income tax. Telix believes that thesenon-IFRS measures, which are not considered to be a substitute for or superior to IFRS measures, provide stakeholders withadditionaluseful information on the underlying trends, performance and position of the Telix Group and are consistent with how business performance is measured internally. Thenon-IFRSmeasures are not defined by IFRS and therefore may not be directly comparable with other companies’ alternative performance measures. Regulatory: Telix’sfirst generation PSMA-PET imaging product, gallium-68 (68Ga)gozetotideinjection (also known as68Ga PSMA-11 and marketed under the brand nameIlluccix®), has been approved in multiple markets globally.Gozellix® (kit for the preparation of gallium-68 (68Ga)gozetotideinjection) has been approved by the U.S. Food and Drug Administration (FDA). Telix’s glioma imaging agent, floretyrosine F 18, marketed under the brand name Pixclara®, is also approved by the FDA. Telix’sosteomyelitis (bone infection) imaging agent, technetium-99m (99mTc)besilesomab(marketed under the brand nameScintimun®) is approved in 32 European countries and Mexico.Telix’sminiaturized surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, is registered with the FDA for use in the U.S. and has attained aConformité Européenne(CE) Mark for use in the EEA. ITM’s Lutetium (177Lu) chloride solution marketed under the brand name EndolucinBeta® has been approved by the European Medicines Agency and is approved in multiple EU member states. Registrations vary country to country. Refer to your local approved label or regulatory authority status for full information. No otherTelixdrug or device has received marketing authorization in any jurisdiction. ITM’s drug candidate ITM-11 has not received marketing authorization in any jurisdiction. Any otherTelix or ITMdrug or device that is discussed in this presentation, includingZircaix, is investigational or under development and not approved by any regulatory authority. The efficacy or safety profile of any unapproved drug or device has not been determined by any regulatory authority.In addition,the Zircaixbrand name and launch is subject to final regulatory approval. Trademarks: All trademarks and trade names referenced in this presentation are the property ofTelixPharmaceuticals Limited (Telix) or, where applicable, the property of ITM or their respective owners. For convenience, trademarks and trade names may appear without the ® or symbols. Such omissions are not intended to indicate any waiver of rights byTelix, ITMor the respective owners. Trademark registration status may vary from country to country.Telix and ITMdo not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties. ©2026TelixPharmaceuticals Limited and ITM Isotope Technologies Munich SE. All rights reserved.
Contents 1 2 3 4 3 Transaction overview Value creation and synergies ITM manufacturing platform Therapeutic opportunity Key Terms and Financial Statements (updates as of Oct. 27, 2026) Key Risks 5 6
Telix + ITM creates a differentiated and scaled global platform 4 1 Best-in-class radioisotope manufacturing and supply ITM’s commercial-scale production of lutetium-177 ( 177 Lu) secures supply and enhances group EBITDA; ongoing expansion into actinium-225 ( 225 Ac) and, subsequently, terbium-161 ( 161 Tb) has potential to provide further long- term growth 2 Industry’s most advanced therapeutic pipeline Late-stage assets in prostate, brain, neuroendocrine (NET) and renal cancers. Addition of ITM-11 potentially accelerates entry into commercial therapeutic market 3 Scaled commercial precision medicine Market-leading commercial precision medicine business. ITM early-stage pipeline and global footprint provides platform for market expansion Merger creates a differentiated, vertically integrated radiopharmaceutical company with commercial scale, enhanced supply chain and a promising late-stage theranostic pipeline Positioned for long-term leadership in a rapidly growing industry
A strategically compelling transaction with clear value creation
1.Earnings before interest, tax, depreciation and amortization.
2.Share price as converted from A$16.65, based on 30-day trailing volume weighted average price (VWAP) from signing. Exact number of Telix Shares subject to closing adjustments for cash, expenses, NWC and debt.
3.Telix will seek Shareholder approval for the future issue of milestone Shares based on Telix’s share price at signing; Share settlement is based on 30-day VWAP price at time of milestone achievement.
4.Further detail of the escrow arrangements is included on slide 26.
Transaction
Highlights
•Enhances efficiencies as a vertically integrated radiopharmaceutical company
•Adds profitable manufacturing business, enhancing supply chain control and strengthening EBITDA
1
•Provides an entry point into commercial therapeutic market upon regulatory approval of ITM-11
•ITM expected to be EBITDA positive from FY 2027 onward
Consideration
•US$1.65B upfront on a cash-free/debt-free basis. After adjustments, ITM Shareholders are expected to be paid
approximately US$1.25B in Telix Shares at US$11.84
2
per share, released as Nasdaq ADRs after escrow period
Milestones
•Up to US$700M of deferred consideration contingent on ITM-11 regulatory approvals through FY 2031 and
FY 2030 ITM-11 net sales target, fundable in cash or Telix Shares at Telix’s election
3
Structure
•Telix to acquire all outstanding issued equity securities of ITM, with ITM Shareholders to own 23.7% of
Telix’s Shares on issue at close, subject to escrow restrictions of up to 15 months
4
Expected
closing
•Closing expected by end of FY 2026, subject to Telix Shareholder approval, with a Shareholder vote
expected to be held in November 2026, and other closing conditions
Deal Terms (further details on slide 25)
5
Transaction summary
ITMhas built a leading position of innovation in the radiopharmaceutical market Differentiated radioisotope manufacturing platform •World's largest supplier of 177 Lu, underpinned by long-term contracts including Novartis since 2018 •Expanding into 225 Ac via joint venture Actineer, with 161 Tb planned •Integrated across the full value chain, from raw materials and irradiation to quality control release and logistics •Distribution reach spanning 65 countries and >400 destinations weekly US$273M revenue (2025 audited) | 2x GMP 4 manufacturing sites | ~ 850 employees 6 Robust radiopharmaceutical pipeline •ITM-11 is a novel therapeutic that has completed Phase 3 for initial indication of Grade 1-Grade 2 GEP-NETs 1 •Phase 3 COMPOSE trial 2 for Grade 2-Grade 3 GEP-NETs, completed enrollment •Phase 3 LEVEL trial 3 for lung NETs, ~90% enrolled •Pipeline includes novel targets and isotopes, and is complementary to Telix’s pipeline 1.Gastroenteropancreatic neuroendocrine tumors. 2.ClinicalTrials.gov ID:NCT04919226. 3.ClinicalTrials.gov ID:NCT05918302. 4.Good Manufacturing Practice.
ITM’s proven growth platform is well positioned to capture expanding radioisotope demand Historical ITM revenue growth 1 Demand for radioisotopes is forecast to grow $70 M $273 M $- $50 $100 $150 $200 $250 $300 20212025 177 Lu total market (US$B) 2 Growth to $2.1B risk adjusted by 2035 Strong track record of revenue growth at ~40% CAGR from 2021–2025 Radioisotope markets forecast to compound at ~30% p.a. through 2035 2 225 Ac total market (US$B) 2 Growth to $1.4B risk adjusted by 2035 7 US$M 177 Lu: Industry snapshot Two commercial-stage therapies, and an additional 41 assets in development 3 225 Ac: Industry snapshot Second most used isotope in trials behind 177 Lu, with 34 assets in development 3 1.Revenue figures from ITM audited financial statements; Values converted using an EUR / USD spot rate of 1.14. 2.Advancy research & analysis, Commercial Vendor Due Diligence | February 2026. 3.William Blair Equity Research 2026. $0.5 B $2.1 B $0.0 $0.5 $1.0 $1.5 $2.0 $2.5 20252035 $0.1 B $1.4 B 20252035 45% CAGR 23% CAGR 40% CAGR US$B
Transaction reinforces Telix’s growth strategy High value therapeutics pipeline Vertically integrated manufacturing / supply chain Specialist commercial organization R&D platform for new molecular entities Precision Medicine portfolio Accelerates entry into established NET market Enhanced development capabilities Novel product and life-cycle management opportunities Adds commercial depth and expertise Value creation from therapeutic radioisotopes leadership ✓✓✓✓✓ The combination of Telix + ITM enhances our ability to compete 8
9 ITM’s differentiated radioisotope manufacturing platform
Reliable and proven model for scaled radioisotope production n.c.a. 1
177 Lu Proprietary Production Processes Scaled GMP Production Commercial & Sales Distribution & Logistics Secure Raw Material Supply Superior Irradiation Capacity 10 Producing 177 Lu at commercial scale with best-in-class end-to-end capabilities Very large stockpile of non- restricted ytterbium-176 ( 176 Yb) starting material, with exclusive supply agreements Specialist infrastructure and logistics address short half-life constraints in >65 countries Specialist commercial and customer- service teams Unrivaled irradiation flexibility exclusive 24/7/365 Isogen agreement, leveraging Bruce Power reactors Proprietary production methods, including high-purity n.c.a. 177 Lu and recycling for cost-efficiency In-house and partner GMP manufacturing sites provide capacity to meet global demand 1.Non carrier added. ITM is uniquely positioned in a highly regulated and growing market
ITM’s experience in
177
Lu creates a platform for next
generation radioisotopes
Combined supply chain covers a wide range of therapeutic and diagnostic radioisotopes
177
Lu
Lutetium (n.c.a.)
World-leading GMP supply
Commercially scaled, validated global supply and distribution network for
177
Lu
•By revenue, the largest supplier of commercial and clinical
177
Lu globally
•Primary external supplier of
177
Lu for Pluvicto
1
•Key supplier to other customers under long-term contracts
•Secures supply for ITM-11 and Telix’s late-stage assets (TLX591-Tx, TLX597-Tx, TLX250-Tx)
225
Ac
Actinium
Next-generation radioisotope
Positioned to be one of the first commercial suppliers of GMP-grade
225
Ac, the most
clinically advanced alpha-emitting radioisotope
•Exclusive, long-term access to radium-226 (
226
Ra) precursor material
2
•Actineer joint venture for scalable manufacturing and purification
161
Tb
Terbium
Future growth opportunity
Leveraging proven manufacturing to produce next-generation radioisotope,
161
Tb
•Pre-clinical data and industry programs highlight interest in
161
Tb as a next-generation
radioisotope for prostate cancer and other indications
11
1.ITM supplies
177
Lu for Pluvicto, and other commercially available
177
Lu–based radioligand therapies (RLTs).
2.Via agreement with Canadian Nuclear Laboratories (CNL).
68
Ga
Gallium-68
89
Zr
Zirconium-89
211
At
Astatine-211
153
Sm
Samarium-153
212
Pb
Lead-212
18
F
Fluorine-18
Global network enables just-in-time delivery at commercial scale
Opens new market opportunities for Telix’s products
12
JV
TMS
Sacramento
Telix planned
cyclotron installation
at RLS locations
3x manufacturing
sites & 2x
cyclotrons in BE
Global HQ & 2x
manufacturing
sites in DE
TMS Yokohama
Cyclotron facility
Just-in-time delivery:
24-48hr within EU/US and 72hr
across 65 countries worldwide
Exclusive, long-standing
distributor partnerships in key
markets
>99%
Order fulfillment rate (2025A)
>400
1
Destinations supplied weekly
JV
US HQ
US HQ
Global HQ &
TMS North
Melbourne
Partnered reactor network
spanning Europe, Africa, North
America, and Australia
Network covering
>85% of the U.S.
market
1.Includes direct customer sites, customer sites managed by distributors and B2B customer sites. >1,000 end-market customer sites reached.
Therapeutic opportunity Artist’s impression showing SSTR receptors on the surface of GEP-NETs and SSTR+ tumors: Source ITM.
Abbreviations: SSTR: Somatostatin Receptor; CAXII: Carbonic Anhydrase XII, IIT: Investigator Initiated Trial
1.ClinicalTrials.gov ID:NCT03049189.
2.ClinicalTrials.gov ID:NCT04919226.
3.ClinicalTrials.gov ID:NCT05918302.
4.ClinicalTrials.gov ID:NCT06441331.
Complementary therapeutic franchise with multiple pathways for
growth
ProgramTargetIndicationIsotopePreclinicalPhase
1
Phase
2
Phase
3
FiledClinical
PoC
ITM-31CAXII
Glioblas-
toma
177
Lu
ITM-63
SSTR
antagonist
SSTR+
tumors
161
Tb
ITM-64
68
Ga
TherapeuticDiagnostic
Late-Stage Therapeutics (ITM-11)Complementary Early-Stage Pipeline
COMPOSE
LEVEL (ISS)
COMPETE FDA Fast Track granted
(October 2022)
ProgramTargetIndicationIsotopePreclinicalPhase
1
Phase
2
Phase
3
FiledClinical
PoC
ITM-11
SSTR
(agonist)
GEP-NETs
(G1/G2)
177
Lu
GEP-NETs
(G2/G3)
177
Lu
Lung NET
177
Lu
SSTR+
tumors
(pediatric)
177
Lu
COMPOSE
2
LEVEL
3
(IIT)
COMPETE
1
FDA Fast Track granted
(October 2022)
14
IIT
Theranostic
pair
IIT
Strong clinical data supporting potential for multiple
indications
Select early-stage assets to be prioritized under combined
Telix + ITM ownership
KinLET
4
ITM-11 is a novel, next-generation therapeutic candidate Targets a significant commercial opportunity in GEP-NETs U.S. addressable market 2 US$1.7B Grade 1 5
~5,000 Grade 3 5 ~1,100 •ITM-11 is a novel SSTR-targeted radiopharmaceutical incorporating edotreotide and n.c.a. 177 Lu for the treatment of GEP-NETs •Positive Phase 3 data in the Grade 1-2 setting (COMPETE), demonstrating PFS and ORR benefit head-to-head vs. everolimus •COMPETE is the first and only Phase 3 trial head-to-head against everolimus, and included harder-to-treat pancreatic NETpatients as well as first-line patients •Flexibility to use a monotherapy or in combination with an SSA (somatostatin analog) •Ongoing Phase 3 trial (COMPOSE) could expand ITM-11 into first- or second-line treatment of aggressive Grade 2-3 SSTR- positive GEP-NETs •Commercially validated category with global annual sales of US$800M for approved SSTR-targeted radioligand therapies 1 15 1.Dollar ($) value is management estimate based on $210k per patient, in line with current RLT treatment pricing in the U.S. 2.Drug treated Advanced & Metastatic Neuroendocrine-Tumors incidence, net sales of current approved products, Datamonitor patient-based forecast. 3.Fitzgerald PA. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) & Carcinoid Tumors, Current Medical Diagnosis & Treatment 2025. 4.Lawrence et al., The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors, Endocrinol Metab Clin North Am 40 (2011). 5.Maratta et al., A Comprehensive Analysis in the Era of Somatostatin Receptor PET Imaging, Cancers 17, 1937 (2025), doi:10.3390/cancers17121937. Unresectable (65%) 4 & SSTR-positive (90%) 5 COMPETE Phase 3 trial (completed) COMPOSE Phase 3 trial (enrollment completed) Drug Treated GI & Pancreatic NETs 2 ~25,400 patients Grade 2 5
~7,600
1.Derived from a two-sided test between the two groups. 2.Hazard ratio is expressed as ITM-11 / everolimus and estimated from the corresponding Cox model; Stratification factors are: 1) primary tumor origin GE-NETs and P-NETs, 2) prior medical therapy (1st line vs. 2nd line); data was presented at the 2025 ENETS Conference, March 2025. 3.Peptide Receptor Radionuclide Therapy. 4.Walter, T, et al. The Lancet, July 2, 2026. COMPETE Phase 3 trial met its primary endpoint of progression-free survival (PFS) Statistically significant improvement in median PFS for ITM-11: 23.9 versus 14.1 months for everolimus •309 G1-G2 patients across GI and pancreatic NETs, first and second line, high proportion of Grade 2 •Hazard ratio (stratified), ITM-11 / everolimus 0.673, 95% CI [0.477, 0.948] •Safety data demonstrated a lower incidence of Grade 3/4 treatment- related adverse events in patients receiving ITM-11 compared to everolimus (18% vs. 40%) •COMPETE is the first Phase 3, head- to-head PRRT 3 vs. standard-of-care evidence in GEP-NETs 4 (The Lancet, July 2026) Progression Free Survival Kaplan-Meier plot documented central review data Full Analysis Set Probability of Progression
Free Survival 16 ITM-11Everolimus N207102 Event (%)101 (48.8%)51 (50.0%) Median (95% CI)23.918 (18.727, 30.029)14.094 (9.166, 20.928) Unstratified Log-rank P-value 1 0.0178 Unstratified HR 2 0.664 (0.472, 0.934) Stratified Log-rank P-value 1 0.0223 Stratified HR 2 0.673 (0.477, 0.948)
ITM-11 U.S. regulatory status CRL received on August 7, 2026 is limited to CMC and third-party facility items and no clinical or nonclinical deficiencies were identified CRL scope FDA cited Chemistry, Manufacturing and Controls (CMC) and third-party commercial facility inspection- related items Clinical package No clinical safety or efficacy issues were identified, and no additional clinical or nonclinical data were requested RemediationITM is reviewing the feedback and coordinating with relevant external parties to address the cited items Resubmission ITM intends to resubmit the NDA to complete FDA review; timing remains subject to remediation and agency interaction. Resubmission or Telix/ITM agreement on path-forward is a closing condition US$250M in milestones dependent on ITM-11 regulatory approvals 1 17 1.For further details on milestones refer to slide 25.
18 •Phase 3 trial supporting indication expansion into G2/G3 GEP-NETs •1 st or 2 nd line of treatment •Enrollment completed in Q1 2025 (N = 250) •Comparator arm: Standard therapy with CAPTEM or everolimus or FOLFOX •Primary endpoint: PFS •Phase 3, investigator-initiated trial •Supports indication expansion into NETs of the lung or thymus origin –Lung NETs account for approximately 20%–30% of all NETs, treatment options are limited •Target enrollment 170 patients (~90% enrolled) •6 cycles of ITM-11 •Comparator arm: everolimus •Primary endpoint: PFS COMPOSE 1 Phase 3 Aggressive G2/G3 SSTR+ GEP-NETs LEVEL 2 Phase 3 Advanced SSTR+ Lung and Thymic NETs Next catalyst: Second interim analysis expected (H1 2027) Next catalyst: Interim analysis expected (H2 2027) Milestone payment: US$100M upon FDA approval 3
for G2-G3 GEP-NETs indication Milestone payment: US$50M upon FDA approval 3 for lung NETs indication ITM-11 Phase 3 expansion programs create meaningful upside Ongoing ITM-11 clinical trials 1.ClinicalTrials.gov ID:NCT04919226. 2.ClinicalTrials.gov ID:NCT05918302. 3.Milestone payments in cash or ADRs at Telix’s election, subject to Shareholder approval. Further detail on slide 25.
19 Value creation and synergies
$517 $804 >$1.0B 3 $198 $273 ~$300 2 $715 $1,077 ~$1,300 2024A2025A2026E TelixITM Combination enhances commercial scale with strong growth and diverse business mix 20 61% 14% 25% Product revenueTMS third-party revenueIsotopes Telix + ITM revenue by division 1 (1) US$M ITM is expected to positively contribute to Group EBITDA from 2027 onward Pro forma Telix + ITM revenue & other income 1 % H1 2026A 1.ITM and Telix historical revenue and other income from audited financial statements. ITM revenue translated at an EUR / USD spot rate of 1.14, 2026 estimate. 2.Unaudited ITM H1 2026 revenue annualized. 3.Telix 2026 revenue guidance (upper end US$970M plus US$40M reported other income).
21 ITM strong revenue growth outlook US$156M H1 2026 revenue 1 Driven by radioisotope manufacturing Gross margin (>40%) ITM enhances our EBITDA ITM manufacturing division expected to generate FY 2026 annualized EBITDA of US$106M 2 Continued revenue growth,cost savings and targeted synergies expected to positively contribute to Group EBITDA from FY 2027 Manufacturing growth ITM manufacturing revenue expected to deliver double-digit growth Combined entity has a robust balance sheet Pro forma cash US$325M 1 As of June 30, 2026 Combined pro forma market capitalization of US$5.3B based on deal size Therapeutic revenue If approved by FDA, ITM-11 expected to add high-margin commercial therapeutic revenues Enhancing EBITDA The combined group market cap provides flexibility and agility to manage the capital needs of the combined group 1.Unaudited. ITM figures translated at an EUR / USD spot rate of 1.14. 2.Unaudited ITM H1 2026 Manufacturing EBITDA annualized. 3.Excludes one-off integration costs. Cost savings and synergies 3
ITM cost saving program underway to reduce operating costs to FY 2025 levels. Telix targeted synergies expected to reduce costs by a further US$50M in first two years Attractive financial profile with revenue growth and positive EBITDA
Multiple levers to accelerate growth, improve efficiency and enhance value Telix expects to deliver US$50M targeted synergies in first two years in addition to ITM cost savings 22 •Enhanced vertical integration, supply chain control and an expanded global footprint •Manufacturing becomes a profit driver while supply chain security supports future growth in therapeutics •ITM-11 provides potential near-term pathway to commercial therapeutics, with acceleration of indication expansion through Telix’s development platform •Additional pipeline optimization and life-cycle management opportunities across early-stage assets •Combine complementary radiochemistry, clinical and regulatory capabilities to improve development speed and execution •Unite highly specialized scientific, manufacturing, and commercial teams within a global talent pool •Consolidate overlapping functions, systems and procurement to simplify operations and improve efficiency Supply chain Pipeline R&D productivity Talent Corporate efficiencies
Telix + ITM creates a differentiated and scaled global platform Scaled commercial precision medicine Industry’s most advanced therapeutic pipeline Best-in-class radioisotope manufacturing and supply •Potential near-term revenue contribution from ITM-11 with further upside from indication expansion •Expansion into commercially validated NET market •Synergies expected from disciplined capital allocation and optimizing in-house R&D capabilities •Commercially scaled high growth business •Near-term revenue diversification and growth potential through new products and label expansion •ITM’s complementary pipeline adds attractive lifecycle management opportunities •Global radioisotope demand for commercial and clinical use is increasing •ITM’s high growth, high- margin radioisotope manufacturing enhances cash generation •End-to-end integration of critical global supply chain derisks supply for future commercial products 23 Three complementary growth engines under one platform
Key terms and financial statements
Transaction summary 1.Share price as converted from A$16.65 and based on 30-day trailing VWAP from last full trading day on ASX prior to signing, and AUD/USD exchange rate of 0.71. 2.Subject to closing adjustments. Sellers may allocate and sell some of the Telix Shares deducted from closing consideration to settle a portion of these transaction expenses. 3.Telix will seek Shareholder approval for the issue of Shares for the milestone payments. 25 Transaction Overview Telix to acquire 100% of ITM Isotope Technologies Munich SE for US$1.65B (“Upfront Consideration”) on a cash-free/ debt-free basis. Up to a further US$700M dependent upon achievement of future regulatory milestones and sales targets (“Future Consideration”) Future Milestone Consideration •Telix to pay up to US$250M upon FDA approval of ITM-11 therapeutic product across different indications: •US$100M upon FDA approval for G1-G2 GEP-NETs indication by end of FY 2027 (Milestone #1) •US$100M upon FDA approval for G2-G3 GEP-NETs indication by end of FY 2030 (Milestone #2) •US$50M upon FDA approval for lung NETs indication by end of FY 2031 (Milestone #3) •Telix to pay up to US$450M based on ITM-11 net global sales in FY 2030 (Net Global Sales Milestone Payment) •Calculated as 3.0x ITM-11 global net sales in excess of US$150M (up to Milestone cap) •Future consideration payable in cash or Telix Shares at Telix’s election 3 Upfront Consideration •Telix to pay US$1.65B upfront on a cash-free/debt-free basis, expected as follows: •US$1.25Bpaid in Telix Shares at US$11.84 1 per share, released as Nasdaq ADRs after the escrow period •US$302M assumed net debt 2
•US$96M management equity rollover and transaction expenses payable by the sellers 2 •ITM Shareholders to own 23.7% of Telix shares on issue at close
Transaction summary (cont’d)
1.The transaction will not proceed if this Shareholder approval is not obtained. Failure to obtain this Shareholder approval may require Telix to pay a US$5M Shareholder vote failure fee.
2.Telix will be required to make Milestone Payments in cash if Shareholder approval is not obtained for these proposals.
26
Closing and
Extraordinary General
Meeting
•Transaction expected to close by end of 2026, subject to Telix Shareholder approval, regulatory approvals and
customary closing conditions
•Telix to convene an Extraordinary General Meeting (EGM) in November 2026 to seek Telix Shareholder approval of:
•The share issue comprising the Upfront Consideration
1
•Maximum share issues for each of the Milestone Payments
2
•The appointment of Dr. Andrew Cavey and Dr. Barbara Weber to the Telix Board of Directors (3-year term,
effective from closing)
Escrow
•Shares issued in relation to Upfront Consideration are subject to staggered escrow (lockup):
•Founders and key executives: earlier of 3 months after Milestone #1 and 15 months after closing;
•All other ITM Shareholders: earlier of Milestone #1 and 12 months after closing
Governance and
Board Representation
•Identified key employees to sign employment and retention agreements before closing
•One (1) director from ITM, along with ITM’s current CEO, will join the Telix Board of Directors upon closing, subject to
Telix Shareholder approval
Summary pro forma financial information (unaudited) Financial performance for the year ended December 31, 2025 and half year ended June 30, 2026 December 31, 2025 Full Year June 30, 2026 6 months US$MTelixITM 1 Transaction adjustments CombinedTelixITM 2 Transaction adjustments Combined Revenue804270-1,074477160-637 Gross profit426116-54226067-327 Research and development(171)(82)-(253)(124)(38)-(162) Operating expenses(237)(90)(18) 3 (345)(136)(73)19 4 (190) Other items12(3)-946(2)-44 Operating profit / (loss)30(59)(18)(47)46(46)1919 Net finance costs(35)1-(34)(17)-(19)(36) Share of loss of equity accounted investees-(7)-(7)-(2)-(2) Profit / (loss) before taxation(5)(65)(18)(88)29(48)-(19) Adjusted EBITDA39(45)-(6)52(36)1935 Of which: Precision Medicine216-- 216 132--132 Therapeutics(98)(102)- (200) (32)(59)-(91) Manufacturing(22)77- 55 (23)53-30 Other(57)(20)- (77) (25)(30)19(36) 27 1.ITM figures translated at an EUR / USD average rate of 1.13. 2.ITM figures translated at an EUR / USD average rate of 1.17. 3.Transaction costs incurred by Telix in H2 2026 related to the Merger. 4.Reclassification of one-off costs associated with loan reassignment incurred by ITM to Finance Costs 27 Updated
US$MTelixITM 1 Transaction adjustments Combined Cash25273-325 Trade and other receivables16440-204 Inventories39185-224 Other current assets3322-55 Total current assets488320-808 Intangible assets585461,9552,586 Property, plant, equipment72180-252 Right of use assets5756-113 Other non-current assets16012-172 Total non-current assets8742941,9553,123 Trade and other payables1696118248 Current taxes payable34--34 Derivative liabilities-43-43 Other current liabilities3920-59 Total current liabilities24212418384 Borrowings505157-662 Lease liabilities6057-117 Deferred tax liabilities43--43 Other non-current liabilities2415700739 Total non-current liabilities6322297001,561 Net assets4882611,2371,986 28 1.ITM figures translated at an EUR / USD closing rate of 1.14. 2.Preliminary purchase price adjustments allocated to Intangible Assets ($1,955M) and Contingent Consideration ($700M), and transaction costs incurred by Telix ($18M) Summary pro forma financial information (unaudited) Financial position at June 30, 2026 Updated
Key risks
Key risks
Transaction may not be
completedor may be delayed,
which could result in
additional costs or adversely
impact Telix's financial
performance and profitability
•Completion of the proposed acquisition of ITM by Telix (the Transaction) is conditional on certain matters taking place, some of which
are beyond Telix's control. There is a risk that the Transaction will not be completed, including if it is terminated prior to completion
pursuant to the terms of the SPA, e.g., for failure to satisfy one or more closing conditions (such as not obtaining required regulatory
approvals),a breach of continuing obligations under the Share Purchase Agreement (SPA) by either party, or if either party
experiences a Material Adverse Event (MAE, as defined in the SPA).
•Approval by Telix Shareholders for the issue of shares for the Upfront Consideration is a condition to completion. If Telix Shareholder
approval is not obtained for that matter, a Shareholder vote failure fee of US$5M would be payable by Telix to ITM, in addition to other
significant Transaction costs in relation to service providers and other parties that Telix will have incurred.
•Other conditions to Telix’s obligation to close include satisfactory rollover of ITM’s funded debt, FDA re-submission of ITM-11 (or
satisfactory path to re-submission as determined by Telix), performance of ITM pre-closing operational covenants, continuing accuracy
of ITM’s representations to Telix, and the absence of a MAE affecting ITM. There is no assurance that these conditions will be met by
the stated End Date (December 31, 2026) which can only be extended for three months for regulatory delays.
•If completion of the Transaction is delayed, Telix may incur additional costs and it may take longer than anticipated for Telix to realize
the benefits of the Transaction, including the targeted synergies described in this presentation. Any failure to complete, or delay in
completing, the Transaction may adversely impact Telix's financial performance and profitability.
30
This section includes some of the key risks associated with the proposed acquisition by Telix of ITM. Individually, or in combination, these risks may affect the future operating and financial
performance of Telix, its investment returns and the value of an investment in shares in Telix.
The risks included in this section are not exhaustive of the risks associated with an investment in Telix, either now or in the future, and this information should be considered in conjunction with all
other information in the presentation. Further, Telix continues to be, and the combined Telix and ITM group will be, subject to the risks to Telix’s existing business and operations disclosed in
Telix’s most recently filed reports with the ASX, the SEC, and Telix’s website, including in Telix’s Annual Report on Form 20-F and Telix’s 2026 Interim Report.Additional risks and uncertainties
thatTelixis unaware of, or that it currently considers to be immaterial, may also become important factors that may adversely affectTelix’soperating and financial performance.
Before investing in Telix or continuing to hold an investment in Telix you should consider whether that investment is suitable for you having regard to publicly available information (including this
presentation), your personal circumstances and following consultation with financial or other professional advisers. No recommendation is being made with respect to the securities of any
company in any jurisdiction, including the United States. Please see the notices and forward-looking statements disclaimer on page 2 of this presentation for further details and other important
considerations.
Key risks (cont'd)
Telix's due diligence of the
Transaction has
reliedsubstantiallyon
information provided by ITM,
which may prove to be
incomplete, inaccurate or
misleading. As a result, there
is a risk that not all material
issues have been identified
•Telix has undertaken a due diligence process in respect of the Transaction, which substantially relied on the review of financial
(including unaudited and other financial information), technical, operational, production, legal, IP, and other information provided by
ITM, its management and its current owners.
•Despite making reasonable efforts, Telix has not been able to verify the accuracy, reliability or completeness of all the information
which was provided to it or to which it has had access. If any of the information relied upon by Telix in its due diligence process and its
preparation of this presentation proves to be incomplete, inaccurate or misleading (for example, as a result of historical accounting
errors or incorrect application of accounting standards), there is a risk that the actual financial and operating position and performance
of ITM and the combined group may be materially different to those reflected in this presentation.
•There is a risk that the due diligence conducted has not identified all material issues and risks, and that issues identified as not material
are actually material. Unforeseen issues and risks may arise which could adversely affect the operations, financial performance,
reputation or position of the combined group. Telix has attempted to mitigate risks through indemnity structures, purchase price
holdbacks, contingent payments, and transaction insurance, however, these efforts may prove inadequate.
•The information reviewed by Telix included forward-looking information. While Telix has been able to review some of the foundations
for that information, forward-looking information is inherently unreliable and based on assumptions that may change in the future.
31
Inaccurate analysis of the
Transaction by Telix may
result in lower than expected
profitability, earnings or
targeted synergies for the
combined group
•Telix has undertaken financial, tax, business and other analyses of ITM in order to determine its attractiveness and whether to pursue
the Transaction. It is possible that such analyses, and the best estimate assumptions made by Telix, has resulted in conclusions and
forecasts that are inaccurate or which will not be realized in due course. These analyses include sales and market growth estimates for
ITM’s isotope business and the radioisotope sector generally, costs and availability of key materials, regulatory pathway and
commercial opportunity for ITM-11, competition in the sectors that ITM operates, and other similar areas.
•To the extent that the actual results achieved by ITM as part of the combined group differ from those forecast by Telix's analyses, there
is a risk that the profitability and future earnings of the combined group, or the targeted synergies, may be materially lower than
reflected in this presentation.
Key risks (cont'd) Recourse to sellers and under the Representations and Warranties (R&W) insurance policy may be limited or unavailable •The ability of Telix to achieve its stated objectives will depend on the performance by the parties of their obligations under the agreements for, and related to, the Transaction. If any party defaults, it may be necessary for Telix to approach a court to seek a legal remedy, which can be expensive and time consuming. •Telix has taken out R&W insurance in respect of certain claims it may make under the SPA. The policy may not respond on all matters and is subject to a maximum liability cap along with time and other limitations, as well as express carve-outs for certain matters. There is a risk the policy may not respond, the insurer may deny the claim, or funds may not be available to meet the claim in its entirety. There can also be no guarantee as to the ongoing financial capacity of the Shareholders of ITM. Any inability to recover amounts claimed could materially adversely affect the combined group's financial position and performance. The expected synergies of the Transactionmay not be realized on the anticipated timeline, or at all, and a failure to fully integrate ITM's business or a delay in the integration process could adversely affect the combined group's financial results and performance •The integration of ITM carries risk, including potential delays or additional costs in implementing necessary changes, and difficulties in integrating various operations and systems. The success of the Transaction, and the ability to realize the expected synergy benefits, will be dependent on the effective and timely integration of the ITM business alongside Telix's business following completion. •The synergy benefits remain Telix's estimate, and there is a risk that actual synergies may be less than expected or delayed, may not materialize at all, may cost more to achieve than originally expected, or that dis-synergies may arise. These risks include, among others, unforeseen costs relating to key employee retention and overall workforce integration, IT and infrastructure consolidation, pipeline optimization, and other similar initiatives. •A failure to fully integrate the operations of ITM, or a delay in the integration process, could impose unexpected costs that may adversely affect the financial performance and position of the combined group. 32 The combined group will be exposed to ITM's historical liabilities, for which insuranceor other recourse may not be adequate or available •Following completion, Telix will become directly or indirectly liable for any liabilities that ITM has incurred in the past, including liabilities not identified during due diligence or which are greater than expected, for which insurance may not be adequate or available, and for which Telix may not have post-completion recourse under the SPA or the R&W insurance. These could include liabilities relating to litigation or other proceedings, security breaches or cyber attacks, failure by ITM to hold required regulatory approvals, authorizations or licenses, regulatory actions, health and safety claims, warranty or performance claims, historical tax liabilities, IP infringement, and other liabilities. •Such liabilities and related historical activities of ITM may adversely affect the financial performance or position of the combined group and may also adversely affect Telix's reputation.
Key risks (cont'd) Loss of key personnel •Retention of key ITM personnel is a risk associated with the combined group's business performance. Certain management personnel of ITM have been identified by Telix as critical to the ongoing performance of the combined group, including due to their extensive industry experience and knowledge of ITM's business. •Failure to retain some or all of these individuals may materially adversely impact the combined group's operational and financial performance, the achievement of its growth strategy and integration plan, or result in the loss of important relationships with customers and suppliers. Transaction accounting may give rise to differences in financial information disclosed •Telix is required to undertake an assessment of the fair value of the tangible and intangible assets acquired as well as the actual and contingent liabilities of ITM at the date of the Transaction. Accounting Standards provide for up to twelve months from completion for this assessment to be finalized. •The outcome of this assessment could give rise to different values being applied than those used in the pro forma financial information contained in this presentation, and could impact the values of assets and liabilities reported in the consolidated financial position. There may also be differences in cost of goods sold, depreciation and amortization charges which may impact reported profit before tax and net profit after tax. Dilution of Telix shareholding •Subject to Telix Shareholder approval of the Upfront Consideration, the Transaction will be funded through the issue of new Telix shares to the ITM Shareholders. Existing Telix Shareholders will have their percentage shareholding (and therefore effective voting entitlement) diluted as a result of completion. •The Transaction provides for future payment of consideration to ITM’s Shareholders upon achievement of Regulatory Milestones and a Net Global Sales Milestone in relation to ITM-11. These payments may be made at Telix's election in cash or, subject to Telix Shareholder approval, Shares. •If milestones are achieved and Telix elects to issue Shares, such issues will dilute the holdings of then current Shareholders. If Telix elects to pay cash, this may result in that cash not being available for other opportunities. 33
Key risks (cont'd) ITM-11 milestones may not be achieved •There is a risk that all or some of the Milestone Events may not be achieved. If all or some of the Milestone Events are not achieved, there is a risk that the profitability and future earnings of the combined group may be materially lower than reflected in this presentation or expected by the market. Sell down by ITM Shareholders of Shares •As consideration for the Transaction, the ITM Shareholders will receive Shares which are subject to periods of escrow of up to 15 months from completion. Following expiration of these escrow periods, there is a risk that a significant sale or sales of Shares (or the perception that such a sale might occur) could affect the market price and liquidity of Shares and could result in increased share price volatility. Certain Shares may be sold following closing to cover the sellers’ taxes and transaction expenses. Loss of or significant changes to arrangements with key customers and suppliers •The ITM business relies on a limited number of key customer and supplier contracts and arrangements. There can be no assurance that these will continue, will be renewed on expiration, or that the terms of any renewal will be as favorable as current arrangements. •ITM’s isotope business is exposed to significant customer concentration risk, and the loss of a small number of customers, a significant reduction in sales from these customers, or a significant change in commercial terms could have a material adverse impact on the combined group's financial performance and prospects. 34 Supply chain and procurement risks •The combined group's operations depend on the reliable supply of specialized radioisotopes, precursor materials, and other critical inputs that are subject to significant sourcing constraints concentrated among a small number of suppliers under exclusive or long-term agreements. The radiopharmaceutical supply chain involves the cross-border transport of radioactive materials with extremely short half- lives, requiring specialist logistics infrastructure. •Geopolitical disruptions, trade restrictions, tariffs, sanctions, reactor outages, or other events affecting access to raw materials, irradiation capacity, or international transport routes could constrain the combined group's ability to manufacture and distribute products on a timely basis. •Input cost volatility – including changes in the pricing of enriched precursor materials, reactor access fees, and third-party manufacturing services – may adversely affect the combined group's cost structure and margins, and there can be no assurance that the combined group will be able to pass increased costs through to customers. •Changes in applicable laws, regulations, or government policies could impose additional obligations on the combined group's operations, increase costs, or require modifications to its products, manufacturing processes, or commercial practices.
Key risks (cont'd) Operational continuity risks •The combined group's manufacturing operations are concentrated in a limited number of facilities. Certain critical infrastructure, including hot cells and HVAC systems at its production facility, may require replacement, and any unplanned downtime at these sites could materially disrupt production and customer supply. •The combined group's operations may be adversely affected by events of force majeure, including natural disasters, extreme weather, pandemics or other public health emergencies, acts of war or terrorism, government actions, cyber attacks, or other events beyond its reasonable control. Given the short half-life of the combined group's principal radioisotope products, even temporary production interruptions may result in the loss of finished product inventory, missed customer deliveries, and the potential triggering of contractual force majeure, termination, price modification, or alternative-sourcing provisions by key counterparties. •There can be no assurance that the combined group's business continuity and disaster recovery plans will adequately address the full range of events that could disrupt operations, and any material disruption could adversely affect the combined group's revenue, relationships with customers and suppliers, and competitive position. 35 Infrastructure and technology risks •The combined group relies on information technology and operational technology systems to support manufacturing, quality control, supply chain logistics, and enterprise functions, including systems that manage automated data flows between production, laboratory, and enterprise environments. These environments may include legacy systems, and there is a risk that planned enhancements – including IT/OT network segmentation, centralized monitoring, and vulnerability management – may not be completed on the anticipated time or to the anticipated standard. •Any failure, disruption, or compromise of these systems – whether resulting from hardware or software malfunctions, human error, or malicious acts including ransomware attacks, unauthorized access, data breaches, or other cyber security incidents – could compromise the integrity of quality and regulatory data, delay product release, or result in the loss or unauthorized disclosure of proprietary, personal, or regulated information. •While the combined group maintains cyber security and incident response procedures, and carries cyber security specific insurance policies, there can be no assurance that these measures will be sufficient to prevent, detect, or mitigate all threats, and a significant incident or prolonged system outage could result in regulatory notification obligations, remediation costs, reputational harm, and potential legal or regulatory liability.
Appendix B: Key terms of the EIP The key terms of the Telix Equity Incentive Plan (Plan) are as set out below. The full Plan is available on the Company’s website: https://ir.telixpharma.com/governance/documents-charters EligibilityOffers may be made at the Board’s discretion to employees of a Group Company, Directors of a Group Company, a casual employee or a contractor. Types of securitiesThe Plan provides flexibility for the Company to grant one or more of the following securities as incentives, subject to the terms of individual offers: • Rights, which are an entitlement to receive Shares upon satisfaction of applicable conditions; • Options, which are an entitlement to receive Shares upon satisfaction of applicable conditions and payment of the applicable exercises; • Share Rights, which are an entitlement to the value of each Share Right either paid in cash, converted into Shares, or a combination of cash and Shares, as determined by the Board; and • Restricted Shares, which are Shares that are subject to dealing restrictions, vesting conditions or other restrictions or conditions. Offers under the Plan The Board may make offers at its discretion and any offer documents must contain the information required by the Plan. The Board has the discretion to set the terms and conditions on which it will offer Rights, Options, Share Rights and Restricted Shares in individual offer documents. Offers must be accepted by the employee and can be made on an opt-in or opt-out basis. VestingVesting of Rights, Options, Share Rights and Restricted Shares under the Plan is subject to any vesting or performance conditions determined by the Board and specified in the invitation. Options must be exercised by the employee before Shares are allocated. Subject to the Plan and the terms of the specific offer document, any Rights, Options, Share Rights or Restricted Shares will either lapse or be forfeited if the relevant vesting and performance conditions are not satisfied. Cessation of employment Under the Plan, all unvested Rights, Options, Share Rights or Restricted Shares will generally be forfeited on cessation of employment, unless otherwise determined by the Board. The Board has discretion to determine a different treatment, including that some or all of a participant’s unvested or vested Rights, Options, Share Rights or Restricted Shares stay on foot (to vest in the ordinary course), vest or lapse/be forfeited. Preventing inappropriate benefits The Plan provides the Board with broad powers to lapse or forfeit unvested Rights, Share Rights or Options, vested but unexercised Rights, Share Rights or Options, and Restricted Shares or Shares allocated under the Plan if, for example, the participant has acted fraudulently or dishonestly, engaged in gross misconduct or brought any Group Company into disrepute, breached their duties or obligations to the Group, or where there is a financial misstatement circumstance. The Board may also determine that a participant must pay or repay to the Company proceeds of the sale of Shares allocated under the EIP, any cash payments received in lieu of Shares, or any dividends received in respect of Shares allocated under the EIP. Change of controlThe Board may determine that all or a specified number of a participant’s Rights, Options, Share Rights or Restricted Shares will vest or cease to be subject to restrictions on a change of control event in accordance with the plan. Restrictions on dealing Prior to vesting, the Plan provides that participants must not sell, transfer, assign, encumber, hedge or otherwise deal with their incentives. After vesting, participants must deal with their incentives subject to the Company’s Securities Dealing Policy. Other termsThe Plan contains customary and usual terms of dealing with administration, variation, suspension and termination of the Plan. TermDescription NOTICE OF GENERAL MEETING
STEP 1 Please mark either A or B STEP 2 Proxies will only be valid and accepted by the Company if they are signed and received no later than 48 hours before the Meeting. Please read the voting instructions overleaf before marking any boxes with an T
- If you mark the Abstain box for a particular Item, you are directing your proxy not to vote on your behalf and your votes will not be counted in
computing the required majority. VOTING DIRECTIONS 1 Approve the issue of Maximum
Upfront Consideration Shares 2 Approve the issue of Regulatory Milestone Consideration Shares 3 Approve the issue of Future Sales Milestone Consideration Shares 5b Grant to Dr Barbara Weber 4a Elect new Director –
Dr. Andrew Cavey Resolutions 4b Elect new Director –
Dr. Barbara Weber 5a Grant to Dr Andrew Cavey ForForAgainstAgainstAbstainAbstain TLX PRX2603N TLX PRX2603N I/We being a member(s) of Telix Pharmaceuticals Limited and entitled to attend and vote hereby appoint: VOTING/PROXY FORM or failing the person or body corporate named, or if no person or body corporate is named, the Chairman of the Meeting, as my/our proxy to act on my/our behalf (including to vote in accordance with the following directions or, if no directions have been given and to the extent permitted by the law, as the proxy sees fit) at the General Meeting of the Company to be held at 10:00am (Melbourne time) on Tuesday, 1 December 2026 (the Meeting) and at any postponement or adjournment of the Meeting. The Meeting will be conducted as a hybrid event. You can participate by attending in person at The Events Centre, Level 5, Tower 2, 727 Collins Street, Melbourne VIC 3000 or logging in online at https://meetings. openbriefing.com/TLXMeeting2026 (refer to details in the Virtual General Meeting Online Guide). The Chairman of the Meeting intends to vote undirected proxies in favour of each item of business. the Chairman of the Meeting (mark box) elect to lodge my/our
vote(s) directly (mark box) OR if you are NOT appointing the Chairman of the Meeting as your proxy, please write the name and email of the person or body corporate you are appointing as your proxy VOTE DIREC TLY OR APPOINT A PROXY STEP 3 This form should be signed by the shareholder. If a joint holding, either shareholder may sign. If signed by the shareholder’s attorney, the power of attorney must have been previously noted by the registry or a certified copy attached to this form. If executed by a company, the form must be executed in accordance with the company’s constitution and the Corporations Act 2001 (Cth). Shareholder 1 (Individual)Joint Shareholder 2 (Individual)Joint Shareholder 3 (Individual) Sole Director and Sole Company Secretary Director/Company Secretary (Delete one)Director SIGNATURE OF SHAREHOLDERS – THIS MUST BE COMPLETED BA Name Email LODGE YOUR VOTE ONLINE https://au.investorcentre.mpms.mufg.com BY MAIL Telix Pharmaceuticals Limited C/- MUFG Corporate Markets (AU) Limited Locked Bag A14 Sydney South NSW 1235 Australia
BY FAX +61 2 9287 0309 BY HAND MUFG Corporate Markets (AU) Limited Parramatta Square, Level 22, Tower 6, 10 Darcy Street, Parramatta NSW 2150 ALL ENQUIRIES TO Telephone: 1300 554 474 Overseas: +61 1300 554 474 in relation to the General Meeting of the Company to be held at 10:00am (Melbourne time) on Tuesday, 1 December 2026, and at any adjournment or postponement of the Meeting. You should mark either “for” or “against” for each item. Do not mark the “abstain” box. ACN 616 620 369 X99999999999 X99999999999 SAMPLE
HOW TO COMPLETE THIS SHAREHOLDER VOTING/PROXY FORM
YOUR NAME AND ADDRESS
This is your name and address as it appears on the Company’s share register. If
this information is incorrect, please make the correction on the form. Shareholders
sponsored by a broker should advise their broker of any changes. Please note:
you cannot change ownership of your shares using this form.
VOTING UNDER BOX A
If you ticked the box under Box A you are indicating that you wish to vote directly.
Please only mark either “for” or “against” for each item. Do not mark the
“abstain” box. If you mark the “abstain” box for an item, your vote for that item
will be invalid.
If no direction is given on all of the items, or if you complete both Box A and Box B,
your vote may be passed to the Chairman of the Meeting as your proxy.
Custodians and nominees may, with the Share Registrar’s consent, identify on
the Voting/Proxy Form the total number of votes in each of the categories “for”
and “against” and their votes will be valid.
If you have lodged a direct vote, and then you attend the Meeting, your attendance
will cancel your direct vote.
The Chairman’s decision as to whether a direct vote is valid is conclusive.
VOTING UNDER BOX B – APPOINTMENT OF PROXY
If you wish to appoint the Chairman of the Meeting as your proxy, mark the box
in Step 1. If you wish to appoint someone other than the Chairman of the Meeting
as your proxy, please write the name and email of that individual or body corporate
in Step 1. A proxy need not be a shareholder of the Company.
DEFAULT TO CHAIRMAN OF THE MEETING
Any directed proxies that are not voted on a poll at the Meeting will default to the
Chairman of the Meeting, who is required to vote those proxies as directed. Any
undirected proxies that default to the Chairman of the Meeting will be voted
according to the instructions set out in this Voting/Proxy Form.
VOTES ON ITEMS OF BUSINESS – PROXY APPOINTMENT
You may direct your proxy how to vote by placing a mark in one of the boxes
opposite each item of business. All your shares will be voted in accordance with
such a direction unless you indicate only a portion of voting rights are to be voted
on any item by inserting the percentage or number of shares you wish to vote in
the appropriate box or boxes. If you do not mark any of the boxes on the items of
business, your proxy may vote as they choose. If you mark more than one box on
an item your vote on that item will be invalid.
APPOINTMENT OF A SECOND PROXY
You are entitled to appoint up to two persons as proxies to attend the Meeting and
vote on a poll. If you wish to appoint a second proxy, an additional Voting/Proxy
Form may be obtained by telephoning the Company’s share registry or you may
copy this form and return them both together.
To appoint a second proxy you must:
(a) on each of the first Voting/Proxy Form and the second Voting/Proxy Form state
the percentage of your voting rights or number of shares applicable to that
form. If the appointments do not specify the percentage or number of votes
that each proxy may exercise, each proxy may exercise half your votes.
Fractions of votes will be disregarded; and
(b) return both forms together.
SIGNING INSTRUCTIONS
You must sign this form as follows in the spaces provided:
Individual: where the holding is in one name, the holder must sign.
Joint Holding: where the holding is in more than one name, either shareholder
may sign.
Power of Attorney: to sign under Power of Attorney, you must lodge the Power
of Attorney with the registry. If you have not previously lodged this document for
notation, please attach a certified photocopy of the Power of Attorney to this form
when you return it.
Companies: where the company has a Sole Director who is also the Sole Company
Secretary, this form must be signed by that person. If the company (pursuant to
section 204A of the Corporations Act 2001) does not have a Company Secretary,
a Sole Director can also sign alone. Otherwise this form must be signed by a
Director jointly with either another Director or a Company Secretary. Please indicate
the office held by signing in the appropriate place.
CORPORATE REPRESENTATIVES
If a representative of the corporation is to attend the Meeting virtually the
appropriate “Certificate of Appointment of Corporate Representative” must be
received at [email protected] prior to admission in
accordance with the Notice of General Meeting. A form of the certificate may
be obtained from the Company’s share registry or online at www.
linkmarketservices.com.au.
LODGEMENT OF A VOTING/PROXY FORM
This Voting Form (and any Power of Attorney under which it is signed) must
be received at an address given below by 10:00am (Melbourne time) on
Sunday, 29 November 2026, being not later than 48 hours before the
commencement of the Meeting. Any Voting Form received after that time will
not be valid for the scheduled Meeting.
Voting/Proxy Forms may be lodged using the reply paid envelope or:
ONLINE
https://au.investorcentre.mpms.mufg.com
Login to the Investor Centre using the holding details as shown on the
Voting/Proxy Form. Select ‘Voting’ and follow the prompts to lodge
your vote. To use the online lodgement facility, shareholders will need
their “Holder Identifier” - Securityholder Reference Number (SRN) or
Holder Identification Number (HIN).
BY MOBILE DEVICE
Our voting website is designed specifically for
voting online. You can now lodge your vote by
scanning the QR code adjacent or enter the
voting link
https://au.investorcentre.mpms.mufg.com
into your mobile device. Log in using the Holder
Identifier and postcode for your shareholding.
QR Code
To scan the code you will need a QR code reader application which
can be downloaded for free on your mobile device.
BY MAIL
Telix Pharmaceuticals Limited
C/- MUFG Corporate Markets (AU) Limited
Locked Bag A14
Sydney South NSW 1235
Australia
BY FAX
+61 2 9287 0309
BY HAND
delivering it to MUFG Corporate Markets (AU) Limited*
Parramatta Square
Level 22, Tower 6
10 Darcy Street
Parramatta NSW 2150
- in business hours (Monday to Friday, 9:00am–5:00pm) SAMPLE
Before you begin Ensure your browser is compatible. Check your current browser by going to the website: whatismybrowser.com Supported browsers are: •Chrome – Version 44 & 45 and after • Edge – 92.0 and up To attend and vote you must have your shareholder number and postcode. Appointed Proxy: Your proxy number will be provided by MUFG before the meeting. Please make sure you have this information before proceeding. Online Meeting Guide Corporate Markets
2 • Online Meeting Guide
Online Meeting Guide
S
tep 1
Open your web browser and go to
https://meetings.openbriefing.com/TLXMeeting2026
Step 2
Log in to the portal using your full name,
mobile number and email address, and
participant type
Please read and accept the terms and conditions
before clicking on the ‘Register and Watch Meeting’
button.
•
On the left – a live webcast of the Meeting starts
automatically once the meeting has commenced.
If the webcast does not start automatically please
press the play button and ensure the audio on your
computer or device is turned on.
•
On the right – the presentation slides that will be
addressed during the Meeting
•At the bottom – buttons for ‘Get a Voting Card’,
‘Ask a Question’ and a list of company documents
to download
Note: If you close your browser, your session will
expire and you will need to re-register. If using the
same email address, you can request a link to be
emailed to you to log back in.
- Get a Voting Card
To register to vote – click on the
‘Get a Voting Card’ button.
This will bring up a box which looks like this.
If you are an individual or joint shareholder you
will need to register and provide validation by entering your shareholder number and postcode. If you are an appointed Proxy, please enter the Proxy Number issued by MUFG in the PROXY DETAILS section. Then click the ‘SUBMIT DETAILS AND VOTE’ button. Once you have registered, your voting card will appear with all of the resolutions to be voted on by shareholders at the Meeting (as set out in the Notice of Meeting). You may need to use the scroll bar on the right hand side of the voting card to view all resolutions. Shareholders and proxies can submit a either Full Vote or Partial Vote.
Online Meeting Guide • 3 Full Votes To submit a full vote on a resolution ensure you are in the ‘Full Vote’ tab. Place your vote by clicking on the ‘For’, ‘Against’, or ‘Abstain’ voting buttons. Partial Votes To submit a partial vote on a resolution ensure you are in the ‘Partial Vote’ tab. You can enter the number of votes (for any or all) resolution/s. The total amount of votes that you are entitled to vote for will be listed under each resolution. When you enter the number of votes it will automatically tally how many votes you have left. Note: If you are submitting a partial vote and do not use all of your entitled votes, the un-voted portion will be submitted as No Instruction and therefore will not be counted. Once you have finished voting on the resolutions scroll down to the bottom of the box and click on the ‘Submit Vote’ or ‘Submit Partial Vote’ button. Note: You can close your voting card without submitting your vote at any time while voting remains open. Any votes you have already made will be saved for the next time you open up the voting card. The voting card will appear on the bottom left corner of the webpage. The message ‘Not yet submitted’ will appear at the bottom of the page. You can edit your voting card at any point while voting is open by clicking on ‘Edit Card’. This will reopen the voting card with any previous votes made.
4 • Online Meeting Guide
2. How to ask a question
Note: Only verified Shareholders, Proxyholders and
Corporate Representatives are eligible to ask questions.
If you have yet to obtain a voting card, you
will be prompted to enter your shareholder
number and postcode or proxy details before
you can ask a question. To ask a question,
click on the ‘Ask a Question’ button either at
the top or bottom of the webpage.
2a. How to ask a written question
The ‘Ask a Question’ box will pop up and you have
the option to type in a written question of ask an audio
question over the phone line.
In the ‘Regarding’ section click on the drop down arrow
and select the category/resolution for your question.
Click in the ‘Question’ section and type your question
and click on ‘Submit’.
A ‘View Questions’ box will appear where you can
view your questions at any point. Only you can see
the questions you have asked.
If your question has been answered and you would
like to exercise your right of reply, you can submit
another question.
Note, the company will do their best to address
all questions.
2b. How to ask an audio question
Step 1
Click on ‘Go to Web Phone’
Step 2
Type in your name and hit the green call button.
You will then be in the meeting and able to listen
to proceedings.
Online Meeting Guide continued
Step 3 A box will pop up with a microphone test. Select ‘Start Call’ Step 4 You are now in the meeting (on mute) and will be able to listen to proceedings. When the Chair calls for questions or comments on each item of business, press *1 on the keypad on your screen for the item of business that your questions or comments relates to. if at any time you no longer wish to ask a question or make a comment, you can lower your hand by pressing *2 on the keypad. Step 5 When it is time to ask your question or make your comment, the moderator will introduce you to the meeting. Your line will be unmuted and you will be prompted to speak. If you have also joined the Meeting online, please mute your laptop, desktop, tablet or mobile device before you speak to avoid technical difficulties for you and other shareholders. Step 6 Your line will be muted once your question or comment has been asked / responded to Step 7 You can hang up and resume watching the meeting via the online platform. If you would like to ask a question on another item of business, you can repeat the process above. Please ensure you have muted the webcast audio. 3. Downloads View relevant documentation in the Downloads section. 4. Voting closing Voting will end 5 minutes after the close of the Meeting. At the conclusion of the Meeting a red bar with a countdown timer will appear at the top of the Webcast and Slide screens advising the remaining voting time. If you have not submitted your vote, you should do so now. Once voting has been closed all submitted voting cards cannot be changed.
September 22, 2026 ASX: TLX | NASDAQ: TLX R&D Day
Thispresentationshouldbereadtogetherwithourriskfactors,asdisclosedinourmostrecentlyfiledreportswiththeAustralianSecuritiesExchange(ASX),U.S.SecuritiesandExchangeCommission(SEC),includingourAnnualReporton Form20-FfiledwiththeSEC,oronourwebsite. Theinformationcontainedinthispresentationisnotintendedtobeanofferforsubscription,invitationorrecommendationwithrespecttosharesofTelixPharmaceuticalsLimited(Telix)inanyjurisdiction,includingtheUnitedStates.The informationandopinionscontainedinthispresentationaresubjecttochangewithoutnotification.Tothemaximumextentpermittedbylaw,Telixdisclaimsanyobligationorundertakingtoupdateorreviseanyinformationoropinionscontained inthispresentation,includinganyforward-lookingstatements(asreferredtobelow),whetherasaresultofnewinformation,futuredevelopments,achangeinexpectationsorassumptions,orotherwise.Norepresentationorwarranty,express orimplied,ismadeinrelationtotheaccuracyorcompletenessoftheinformationcontainedoropinionsexpressedinthispresentation. Thispresentationmaycontainforward-lookingstatements,includingwithinthemeaningoftheU.S.PrivateSecuritiesLitigationReformActof1995,thatrelatetoanticipatedfutureevents,financialperformance,plans,strategiesorbusiness developments.Forward-lookingstatementscangenerallybeidentifiedbytheuseofwordssuchas“may”,“expect”,“intend”,“plan”,“estimate”,“anticipate”,“believe”,“outlook”,“forecast”and“guidance”,orthenegativeofthesewordsorother similartermsorexpressions.Forward-lookingstatementsinvolveknownandunknownrisks,uncertaintiesandotherfactorsthatmaycauseTelix’sactualresults,levelsofactivity,performanceorachievementstodiffermateriallyfromanyfuture results,levelsofactivity,performanceorachievementsexpressedorimpliedbytheseforward-lookingstatements.Forward-lookingstatementsarebasedonTelix’sgood-faithassumptionsastothefinancial,market,regulatoryandotherrisks andconsiderationsthatexistandaffectTelix’sbusinessandoperationsinthefutureandtherecanbenoassurancethatanyoftheassumptionswillprovetobecorrect.InthecontextofTelix’sbusiness,forward-lookingstatementsmay include,butarenotlimitedto,statementsabout:theinitiation,timing,progress,completionandresultsofTelix’spreclinicalandclinicaltrials,andTelix’sresearchanddevelopmentprograms;Telix’sabilitytoadvanceproductcandidatesinto, enrollandsuccessfullycomplete,clinicalstudies,includingmulti-nationalclinicaltrials;thetimingorlikelihoodofregulatoryfilingsandapprovalsforTelix’sproductcandidates,manufacturingactivitiesandproductmarketing activities;Telix’ssales,marketinganddistributionandmanufacturingcapabilitiesandstrategies;thecommercializationofTelix’sproductcandidates,iforwhentheyhavebeenapproved;Telix’sabilitytoobtainanadequatesupplyofraw materialsatreasonablecostsforitsproductsandproductcandidates;estimatesofTelix’sexpenses,futurerevenuesandcapitalrequirements;Telix’sfinancialperformance;developmentsrelatingtoTelix’scompetitorsandindustry;the anticipatedimpactofU.S.andforeigntariffsandothermacroeconomicconditionsonTelix’sbusiness,includingasaresultofwarorothergeopoliticalconflicts;andthepricingandreimbursementofTelix’sproductcandidates,ifandafterthey havebeenapproved.Telix’sactualresults,performanceorachievementsmaybemateriallydifferentfromthosewhichmaybeexpressedorimpliedbysuchstatements,andthedifferencesmaybeadverse.Accordingly,youshouldnotplace unduerelianceontheseforward-lookingstatements. ThispresentationalsocontainsestimatesandotherstatisticaldatamadebyindependentpartiesandbyTelixrelatingtomarketsizeandotherdataaboutitsindustry.Thisdatainvolvesanumberofassumptionsandlimitations,andyouare cautionednottogiveundueweighttosuchdataandestimates.Inaddition,projections,assumptionsandestimatesofTelix’sfutureperformanceandthefutureperformanceofthemarketsinwhichitoperatesarenecessarilysubjecttoahigh degreeofuncertaintyandrisk. UseofNon-IFRSMeasures.Telix’sresultsarereportedunderInternationalFinancialReportingStandards(IFRS).Thisannouncementincludesvariousnon-IFRSfinancialinformationtoreflectitsunderlyingperformance,whichhavenotbeen subjecttoauditorreview.Thesenon-IFRSmeasuresincludeAdjustedEBITDA,whichrepresentsnetearningsattributabletotheGroupexcludingfinancecosts,incometaxexpense,depreciationandamortization,remeasurementof provisions,otherincomeandexpenses.AsrequiredbySECrules,wehaveprovidedreconciliationsofthesenon-IFRSfinancialmeasurestothemostdirectlycomparableIFRSmeasures,whichforAdjustedEBITDA,isProfit/(loss)before incometax.TheGroupbelievesthatthesenon-IFRSmeasures,whicharenotconsideredtobeasubstitutefororsuperiortoIFRSmeasures,providestakeholderswithadditionalusefulinformationontheunderlyingtrends,performanceand positionoftheGroupandareconsistentwithhowbusinessperformanceismeasuredinternally.Thenon-IFRSmeasuresarenotdefinedbyIFRSandthereforemaynotbedirectlycomparablewithothercompanies’alternativeperformance measures. Telix’sfirstgenerationPSMA-PETimagingproduct,gallium-68( 68 Ga)gozetotideinjection(alsoknownas 68 GaPSMA-11andmarketedunderthebrandnameIlluccix®),hasbeenapprovedinmultiplemarketsglobally.Gozellix®(kitforthe preparationofgallium-68( 68 Ga)gozetotideinjection)hasbeenapprovedbytheU.S.Food and Drug Administration (FDA). Telix’s glioma imaging agent, floretyrosine F 18, marketed under the brand name Pixclara ® , is also approved by the FDA. Telix’sosteomyelitis(boneinfection)imagingagent,technetium-99m( 99m Tc)besilesomab(marketedunderthebrandnameScintimun®)isapprovedin32EuropeancountriesandMexico.Telix’sminiaturizedsurgicalgammaprobe, SENSEI®,forminimallyinvasiveandrobotic-assistedsurgery,isregisteredwiththeFDAforuseintheU.S.andhasattainedaConformitéEuropéenne(CE)MarkforuseintheEEA.Registrationsvarycountrytocountry.Refertoyourlocal approvedlabelorregulatoryauthoritystatusforfullinformation. NootherTelixdrugordevicehasreceivedmarketingauthorizationinanyjurisdiction.AnyotherTelixdrugordevicethatisdiscussedinthispresentation,includingZircaix and Pixlumi,isinvestigationalorunderdevelopmentandnotapproved byanyregulatoryauthority.Theefficacyorsafetyprofileofanyunapproveddrugordevicehasnotbeendeterminedbyanyregulatoryauthority.Inaddition,ZircaixandPixlumibrandnamesandlauncharesubjecttofinalregulatoryapproval. AlltrademarksandtradenamesreferencedinthispresentationarethepropertyofTelixPharmaceuticalsLimited(Telix)or,whereapplicable,thepropertyoftheirrespectiveowners.Forconvenience,trademarksandtradenamesmayappear withoutthe®orsymbols.SuchomissionsarenotintendedtoindicateanywaiverofrightsbyTelixortherespectiveowners.Trademarkregistrationstatusmayvaryfromcountrytocountry.Telixdoesnotintendtheuseordisplayofany third-partytrademarksortradenamestoimplyanyaffiliationwith,endorsementby,orsponsorshipfromthosethirdparties. ©2026TelixPharmaceuticalsLimited.Allrightsreserved. 2 Forward looking statement
Today’s presenters – Telix management
Dr. Christian Behrenbruch
Managing Director and
Group CEO
Dr. David N. Cade, MD
Group Chief Medical Officer
Mr. Kevin Richardson
CEO, Precision Medicine
Mr. Richard Valeix
CEO, Therapeutics
Dr. Michael Wheatcroft
Vice President Discovery
Sciences
3
Key Opinion Leaders Dr. Alicia Morgans Associate Professor of Medicine Harvard Medical School, Director of Adult Survivorship Program, Dana-Farber Cancer Institute, Genitourinary Medical Oncologist Dr. Sumanta Pal Professor and Vice Chair of Academic Affairs, Department of Medical Oncology and Therapeutics Research, Co-director Kidney Cancer Program, City of Hope Dr. Arthur Braat Associate Professor Translational Nuclear Oncology and Nuclear Medicine Physician University Medical Center Utrecht 4 Presenters are independent experts not employed by Telix but have been paid fair market value for their time. Views expressed are speakers’ own. Any presenter’s response during Q&A has not been reviewed in advance by Telix. Dr. Varun Sundaram Surgical Urologist and Advanced Prostate Cancer Specialist with Urology Austin
Strategy & overview Dr. Christian Behrenbruch Managing Director and Group CEO
Five pillars defining our competitive leadership in radiopharma 6 High value therapeutics pipeline Vertically integrated manufacturing and supply chain Specialist commercial organization Integrated Theranostic Approach See It. Treat It. R&D platform for new molecular entities Precision Medicine portfolio
Three FDA approvals across prostate and glioma imaging •Launched in 22 countries 1 •17 countries 1 in Europe •NDA under review by NMPA in China 2 •Registration enabling study in Japan 3 •First FDA-approved FET- PET imaging drug for glioma 4 •Included in National Comprehensive Cancer Network (NCCN ® ) guidelines •Inclusion in International guidelines:EANM/EANO /RANO/SNMMI NDA = New Drug Application. NMPA = National Medical Products Administration.
- Telix ASX disclosure April 6, 2026. 2. Telix ASX disclosure January 20, 2026. 3. Japan Registry of Clinical Trials identifier: JRCT2031250473.
- Telix ASX disclosure September 14, 2026. 7
115 135 142 186 204 206 208 230 247 1Q242Q243Q244Q241Q252Q253Q254Q251Q262Q26 124 Revenue has more than doubled since 2024 REVENUE US$M ® Near-term growth drivers Note: Zircaix and BiPASS have not been evaluated, approved, or cleared by the FDA to diagnose, treat, cure, or prevent any disease. Brand names subject to regulatory approval. A proven track record of commercial execution 8
Creating a fully integrated global radiopharma leader 9 Marketing authorizations granted Ongoing clinical trials Building on U.S. success to drive global growth Sale allowed under special exemption (South Korea and New Zealand)
Opens new market opportunities for Telix’s products
Global network enables just-in-time delivery at commercial scale
10
JV
TMS
Sacramento
Telix planned
cyclotron installation
at RLS locations
3x manufacturing
sites & 2x
cyclotrons in BE
Global HQ & 2x
manufacturing
sites in DE
TMS Yokohama
Cyclotron facility
Just-in-time delivery:
24-48hr within EU/US and 72hr
across 65 countries worldwide
Exclusive, long-standing
distributor partnerships in key
markets
>99%
Order fulfillment rate (2025A)
>400
2
Destinations supplied weekly
JV
US HQ
US HQ
Global HQ &
TMS North
Melbourne
Partnered reactor network
spanning Europe, Africa, North
America, and Australia
Network covering
>85% of the U.S.
market
1.The transaction with ITM is expected to close in FY2026 subject to Telix Shareholder approval, regulatory approvals, and other customary closing conditions.
2.Includes direct customer sites, customer sites managed by distributors and B2B customer sites. >1,000 end-market customer sites reached.
1
Strategic investments and partnerships for long-term growth 11 2025 2026 2024 2023 Commercialization Development Discovery Research Capabilities across manufacturing & supply, R&D and isotope production 1 1.The transaction with ITM is expected to close in FY2026 subject to Telix Shareholder approval, regulatory approvals, and other customary closing conditions.
Telix + ITM creates a differentiated and scaled global platform Scaled commercial precision medicine Industry’s most advanced therapeutic pipeline Best-in-class radioisotope manufacturing and supply •Potential near-term revenue contribution from ITM-11 with further upside from indication expansion •Expansion into commercially validated NET market •Synergies expected from disciplined capital allocation and optimizing in-house R&D capabilities •Commercially scaled high growth business •Near-term revenue diversification and growth potential through new products and label expansion •ITM’s complementary pipeline adds attractive lifecycle management opportunities •Global radioisotope demand for commercial and clinical use is increasing •ITM’s high growth, high- margin radioisotope manufacturing enhances cash generation •End-to-end integration of critical global supply chain derisks supply for future commercial products Three complementary growth engines under one platform 12 1 1.The transaction with ITM is expected to close in FY2026 subject to Telix Shareholder approval, regulatory approvals, and other customary closing conditions.
Transaction reinforces Telix’s growth strategy High value therapeutics pipeline Vertically integrated manufacturing / supply chain Specialist commercial organization R&D platform for new molecular entities Precision Medicine portfolio Accelerates entry into established NET market Enhanced development capabilities Novel product and life-cycle management opportunities Adds commercial depth and expertise Value creation from therapeutic radioisotopes leadership ✓✓✓✓✓ The combination of ITM + Telix enhances our ability to compete 13 1 1.The transaction with ITM is expected to close in FY2026 subject to Telix Shareholder approval, regulatory approvals, and other customary closing conditions.
Dr. Michael Wheatcroft VP, Discovery Sciences R&D Strategy
Target selection: Unlocking the advantages of targeted radiation Our approach to target selection •Tumor-specific antigens that enable a favorable therapeutic window •High target prevalence in the selected indication •High expression to maximizeefficient radiation delivery •Internalizing targets supporting sustained intracellular radiation exposure •Validated target biology to inform clinical development •Stable, durable target expression supporting reliable tumor targeting Established targets in late-stage development (PSMA, CAIX, LAT1); novel targets in early-stage research 15
Optimized targeting agents drive next-generation candidates
- Wu et al. Methods. 2014; PK: Pharmacokinetics. 2. Monoclonal antibody.
- Telix ASX disclosure January 31, 2025. Telix acquired a proprietary novel biologics technology platform from ImaginAb, Inc. Format trade-offs Small molecule/peptideEngineered mAb 2 Full length mAb (IgG) Time to max. tumor uptake Blood clearance Tumor retention Internalization Fast Fast Low Less likely Slow Slow High Highly likely Small molecule/ peptide NanobodyscFvDiabodyscFv-FcMinibodyIgG△CH2IgG 1.6 kDa15285580100130150 kDa Mainly cleared via kidneyMainly cleared via liver Different formats offer different features; trade-offs for delivery to and interaction with the cancer cell Accessing adiversity of formats with different propertiessupports a range ofradioisotopes with differing clinical utilities A modality agnostic approach enables the right candidate for the right clinical need 16
17 TLR602-Tx [ 212 Pb/ 225 Ac] Target: αvβ6 Integrin Potential indications: Non-Small Cell Lung Cancer, NSCLC Target Validation Highly expressed across a range of cancers: 90%+ of ovarian cancer 1,4 90%+ of pancreatic cancer 2,4 50%+ of NSCLC 3,4 Status Planning FIH imaging study to demonstrate clinical proof of concept utilizing[ 89 Zr] Alpha-Payload: ( 212 Pb / 225 Ac) Minibody targeting agent TLR603-Tx [ 212 Pb/ 225 Ac] Target: DLL3 (Delta Like Ligand-3) Potential indications: Small Cell Lung Cancer, SCLC Target Validation Expressed in 85% of SCLC patients 4,6 High unmet need: 9% 5-year survival rate 6 Status Planning FIH imaging study to demonstrate clinical proof of concept utilizing[ 89 Zr] Minibody clinical example 7 (1st Gen. PSMA minibody uptake @MSKCC) SUV LBM MAX Time (h) 6 0 030406080100 8 10 12 14 16 120 4 2 Minibody bone lesions IgG bone lesions 1: Ahmed et al. Carcinogenesis. 2002. 2. Sipos et al. Histopathol. 2004. 3. Elayadi et al. Cancer Res. 2007. 4. American Cancer Society, Key Statistics 2025https://www.cancer.org/cancer/types.html. 5. Rojo et al. Lung Cancer. 2020. 6. American Cancer Society, Key Statistics 2025https://www.cancer.org/cancer/types.html. 7. Pandit-Taskar N, et al. J. Nuc. Med. 2016. Minibody candidates advancing into the clinic 17
Matching alpha and beta emitters to tumor biology •Emission profile •Half-life vs pharmacokinetics •Depth of penetration •Tumor size / distribution •Tumor microenvironment & heterogeneity •Supply chain considerations β-Radiation α-Radiation α vs β Therapeutic radiationRadioisotope paired to utility Match the radioisotope to targeting agent & use: •Diagnostic <> Therapeuticutility •Fast kinetics <> Slow kinetics Isotope selection tailored to biology, target and clinical activity 18
Global manufacturing, distribution & clinical support capabilities 19 1.TelixInnovations Brazil, Ltda., joint venture with R2PHARMA, a subsidiary of GSH Corp ParticipaçõesS.A. (Grupo GSH), Telixas 51% owner. 2.Partnership with Grand Pharmaceutical Group Limited (Grand Pharma) for the Greater China region. 3.Good Manufacturing Practice. TMS = Telix Manufacturing Solutions Multiple RLS sites in the U.S. with enhanced capabilities and therapy lines being added to selectedsites Strategic partner 1,2 TMS site Yokohama, Japan ARTMS QIS ® for isotope production ARTMS QIS ® technology, enabling highly efficient, cost-effective isotope production Sacramento, U.S. Clinical manufacture New Translational facility in Melbourne, Australia Clinical manufacturing, radiotracer dosing and SPECT/CT imaging Seneffe, Belgium GMP 3 capacity to deliver therapeutics
De-risking therapeutic development through early imaging studies ImagingTherapeutics Imaging complements Therapeutic development ✓Confirms clinical proof of concept ✓Provides safety dosimetry estimates to optimize dosing ✓Identifies the right patient population ✓Supports clinical endpoints Images from Telix’s STARSTRUCK study, data on file. Patient representative scans - individual results may vary. TOP: 89 Zr-girentuximab PET/CT atbaselineshowing uptake in a sacral metastatic lesion in a patient with ccRCC. BOTTOM: 89 Zr-girentuximab PET/CT after three cycles of therapy. 20
Mr. Richard Valeix CEO, Therapeutics Pipeline Overview
Pipeline: Late-stage and “next generation” assets 22 Pixlumi, Zircaix brand names subject to regulatory approval. PSMA: Prostate-specific membrane antigen. CAIX: Carbonic anhydrase IX. LAT1: L-Type amino acid transporter 1. CD66: Cluster of differentiation 66. PDGFRα: Platelet-derived growth factor receptor alpha. mAb: Monoclonal antibody. SM: Small molecule. FAP: Fibroblast activation protein.
Transformative portfolio expansion across early and late-stage assets 23 •Co-development and co-commercialization agreement to develop candidates focused on alpha therapies •4 initial therapeutic programs, with option for 4 additional programs •Up to $2.1B USD developmental and commercial milestone payments plus royalties (4 programs), with option for 4 additional programs Notes For Regeneron: Telix ASX disclosure April 13, 2026. For ITM: TelixASX disclosure September 21, 2026. The transaction with ITM is expected to close in FY2026 subject to Telix Shareholder approval, regulatory approvals, and other customary closing conditions. •Adds a complementary therapeutic franchise with multiple pathways for growth •ITM-11 Phase 3 expansion programs create meaningful commercial opportunities •Late-stage pipeline supports label expansion into G2/G3 GEP-NETs, plus NETs of lung or thymus origin •Globally scaled commercial-grade supplier - world’s largest supplier of 177 Lu
Dr. Alicia Morgans Associate Professor of Medicine at Harvard Medical School Genitourinary Medical Oncologist at Dana-Farber Cancer Institute Prostate Cancer Overview
•1 in 8 men diagnosed with prostate cancer during their lifetime, 1 in 44 patients die from it 1 •Projected U.S. figures for 2026 1 : -333,830 new prostate cancer diagnosis -36,320 deaths from prostate cancer •Metastatic disease remains associated with substantially poorer outcomes, with a 5-year survival rate of 38% vs. 90% for earlier disease 2 Prostate Cancer: Disease Overview 1.American Cancer Society (Cancer Facts & Figures 2025). The American Cancer Society relies on information from SEER (Surveillance, Epidemiology, and End Results) database, maintained by the National Cancer Institute. 2.American Cancer Society, between 2015 – 2021. Annual Incidence (US) 1 Most common cancer in men, second leading cause of cancer death in U.S. 1 25 Despite therapeutic advances, prostate cancer remains a substantial unmet need
Prostate Cancer patient journey Global Standards of Care (SoC) continue to evolve mAPMN/S (mHSPC) 3L+ mAPMR (mCRPC) 2L mAPMR (mCRPC) 1L mAPMR (mCRPC) •Taxane • 177 Lu-PSMA-617 post-taxane 2 • 223 Radium in bone predominant disease only •PARPs in BRCA2m and HRRm only 5 •ARPI •Taxane • 177 Lu-PSMA-617 pre-taxane 3 • 223 Radium in bone predominant disease only •PARPs in BRCA2m and HRRm only 5 •ARPI •Taxane for high volume disease •PARP in BRCA2m only 4
•
177
Lu-PSMA-617 recent
approval
4
Prostate Cancer Working Group 4 (PCWG4) Clinical States: mAPMN/S = metastatic androgen pathway modulator naïve / sensitive; mAPMR = metastatic androgen pathway modulator resistant,
HRRm = Homologous Recombination Repair Mutation. mHSPC = metastatic hormone resistant prostate cancer. mCRPC = metastatic castration resistant prostate cancer. ARPI = androgen receptor pathway inhibitor.
PARP = poly(ADP-ribose) polymerase.
Treatment algorithm for metastatic prostate cancer
1
Renal toxicity & QoL considerations increase, especially in earlier disease settings
26
- Adapted from Calais J. UCLA 2023 EANM 2023; NCCN Guidelines Version 5.2026 Category 1, 2. ClinicalTrials.gov ID: NCT03511664. 3. ClinicalTrials.gov ID: NCT04689828; NCCN Guidelines Version 5.2026 Category 2A. 4. NCCN Guidelines V7.2026: Some Panel members advocate waiting for more mature follow-up before using this regimen in the mCSPC (mAPMN/S) setting given the lack of OS benefit, moderate acute toxicity, and uncertain late toxicity. 5. Homologous recombination repair mutation: e.g. HRR, BRCA2.
Advancing beyond first generation PSMA RLT Managing xerostomia (dry mouth) and off-target uptake, remains an important unmet need Select USPI Adverse Reactions in patients treated with 177Lu-PSMA-617 PSMAddition 177Lu-PSMA- 617 + ARPI PSMAfore 177Lu-PSMA- 617 VISION 177Lu-PSMA- 617 + BSOC All Grades (%) Grades 3 or 4 (%) All Grades (%) Grades 3 or 4 (%) All Grades (%) Grades 3 or 4 (%) Xerostomia460610.9390 Decreased eGFR431.8410.9423.4 Xerostomia from salivary gland uptake impacts Quality of Life (QOL): –Grade 2: Oral intake alterations •Mouth lubricants, saliva substitutes, restricted diet (purees and/or soft moist foods) –Grade 3: Inability to adequately aliment orally •Tube feeding or Total Parenteral Nutrition (TPN)- nutrition provided by IV Risk of acute kidney injury, emerging concerns of long-term renal toxicity as agents move up treatment lines 1.Pluvicto Full Prescribing information, revised 07/2026. 2.National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0. 27
TLX591-Tx 177 Lu 177 Lu
TLX591-Tx is a novel therapy candidate for prostate cancer 1.Patient friendly 2-dose / 2-week regimen: Supports compliance to treatment and ease of integration with standard of care (SOC) 2.Safety and tolerability profile: Low radiation to salivary glands and kidneys, transient and manageable hematologic profile 3.Internalization and prolonged retention: Delivering a payload to the tumor, potentially maximizing cell killing effect 4.Supply, access, and radiation protection: Potential real-world advantages from lower administered activity (76 mCi per dose) Radio antibody-drug conjugate (rADC) approach addresses key unmet needs 1-4 Mechanism of Action 29 1.Sartor O, et al. Presented at: American Society of Clinical Oncology Annual Meeting 2024; TPS5115. 2.Sun M, et al. Curr Oncol Rep. 2021. 3.Lenzo et al. Cancers (Basel) 2026. 4.Tagawa ST, et al. Cancer. 2019.
Phase 3 study for TLX591-Tx Data review Eligible Patients Part 2: Randomized treatment expansion Part 1: Safety and dosimetry: completed •Ages ≥18 years •Confirmed recurrent glioblastoma Clinicaltrials.gov: NCT06520345
Eligibility: mAPMR 2 patients progressing on first ARPI Status: Enrolling patients in Part 2 globally 8 (Japan approved for Part 1) Global, multi center, open label study Primary endpoints (Part 1) •Safety and dosimetry Primary endpoint (Part 2) •rPFS 6 by BICR 7 TLX591-Tx (76mCi) x 2 cycles + abiraterone n = 10 TLX591-Tx + abiraterone/ enzalutamide/ docetaxel abiraterone enzalutamide docetaxel 2:1 TLX591-Tx (76mCi) x 2 cycles + enzalutamide n = 10 TLX591-Tx (76mCi) x 2 cycles + docetaxel n = 10 South Korea Singapore Part 1 completed, with FDA alignment to advance to Part 2 in U.S. 1 n = 30 n = ~490 ® 30
- Data to be submitted to the FDA following Type B meeting, to seek IND amendment to proceed to Part 2 in the U.S. 2. Metastatic androgen pathway modulation resistant prostate cancer. 3. Safety & tolerability reported as adverse events. 4. Independent Data Monitoring Committee review, October 2025. 5. Japanese regulator has granted approval for a Japan-specific Part 1 in nine patients, prior to commencing Part 2. 6. Radiographic progression-free survival. 7. Blinded independent central review. 8. Australia, New Zealand, Canada, Singapore, South Korea, Türkiye and UK.
Acceptable safety profile confirmed with no new safety signals Adverse Event Grade 1 Grade 2 Grade 3 Grade 4 Total (n) % of N=36 Non-hematologic events Fatigue107201953 Nausea54101028 Dry mouth9000925 Diarrhea5300822 Back pain4310822 Headache4100514 Hematologic events Thrombocytopenia665112878 Neutropenia24892364 Anemia510101644 WBC 3 decrease04651542 Lymphopenia05872056 ProstACT Global Part 1 (safety TEAE) 1 Key observations Treatment emergent adverse events (TEAE) •Most prevalent non-hematologic adverse events were fatigue (53%), nausea (28%) and dry mouth (25%) •Almost all TLX591-Tx related non-hematologic events were grade 1 or grade 2 2 •No treatment-related deaths Hematologic events: In line with profile expected for this class of therapy •Grade 3 thrombocytopenia 5/36 (14%) and neutropenia 8/36 (22%) events in line with profile expected for this class of therapy; single Grade 3 anemia •Grade 4 thrombocytopenia 11/36 (31%) and neutropenia 9/36(25%) 31 Patients may have experienced more than 1 event or more than 1 grade of the same event. 1.ProstACT Global Part 1 data on file. Telix Pharmaceuticals. 2.One grade 3 dizziness was considered treatment-related. 3.White blood cell. Non-hematologic events were low grade, hematologic events were transient and manageable
0.0 0.2 0.4 0.6 0.8 1.0 1.2 050100150200250300350400 AbirateroneEnzalutamideDocetaxel Hematological events transient and consistent across cohorts 32 n =11 TLX591-Tx (2 doses at 76 mCi each) Days Normalized Platelets (by cohort) Platelet recovery to Grade 1 or better 1 Recovery to Grade 1 or better, ~15 days post nadir Nadir in platelet counts: average 43 days from dose 1 177 Lu-rosopatamab TLX591-Tx, 177 Lu-rosopatamab 1.G1 platelets 75,000/μL to 150,000 /μL. 2. ProstACT Global Part 1 data on file. Telix Pharmaceuticals. Platelet counts recovered consistently in all three cohorts at ~15 days post nadir n =14 n =11
Demonstrates sustained activity, consistent across cohorts 1
TLX591-Tx demonstrated sustained tumor retention across all cohorts through 15 days 33 Key observations •Predictable PK profile: Low inter- patient variability supports reliable dosing, streamlined clinical development •No evidence of drug–drug interaction: Exposure and washout kinetics were consistent across cohorts •Sustained tumor retention: Lesion activity concentrations remained detectable through 15 days, demonstrating prolonged radiation exposure to the tumor Lesion activity Concentrations-Time profile Blood radioactivity Concentrations-Time Profile PK and lesion activity analyses are based on imaging datasets provided by the imaging CRO. Demographic and safety summaries are derived from the iQVIA clinical database; differences in patient numbers reflect data availability across datasets.
- ProstACT Global Part 1 data on file. Telix Pharmaceuticals. 2. Lesion and blood activity concentrations were measured following the first TLX591-Tx dose (2.8 GBq; ~76 mCi). 3. Number of patients in abiraterone cohort (n = 11), Docetaxel (n = 13), Enzalutamide (n = 10).
Organ radiation exposure remained below established safety limits EBRT: external beam radiation therapy; Gy: Gray; MBq: mega Becquerel; RLT: radioligand therapy; SD: standard deviation; TLX591-Tx, 177 Lu-rosopatamab. Notes: Organ mean absorbed dose reported in (n = 33) patients. Red Marrow dose determined from blood-based assay, 1.03 ± 0.31 Gy for 2 cycles of 2.81 MBq (76 mCi).
- Wahl RL, et al. J Nucl Med. 2021;62(Suppl 3):23S-35S. 2. Emami B, et al. Int J Radiat Oncol Biol Phys. 1991;21(1):109-22. 34 Organ mean absorbed dose (Gy) after two cycles of 177Lu-rosopatamab (76mCi) 1 Key observations •Liver (clearance organ), colon, rectum, spleen, kidney and red marrow mean absorbed dose (Gy) below threshold for known radiation injury 1,2 •Dose to organs at risk consistent with ProstACT SELECT data Organ mean absorbed dose (Gy) after 2 cycles of TLX591-Tx (2.81 MBq)
Patient case: TLX591-Tx (2 doses) + docetaxel (6 cycles) 1.Thoracic vertebrae, ribs. 2.ProstACT Global Part 1 data on file. Telix Pharmaceuticals. SPECT TLX591-Tx biodistribution:
Single dose Distribution of TLX591-Tx over 15 days 2 BASELINE PET 4 hours1 day4 days7 days15 days* TLX591-Tx seen in the vascular space and liver TLX591-Tx seen at metastatic sites (and liver) * 83-year-old patient with bony metastatic lesions 1 Post treatment SPECT imaging after one injection of TLX591-Tx 35 Patient representative scans – individual results may vary. Images are non-quantitative. Stable disease at day 341 (data cutoff)
Patient case: TLX591-Tx (2 doses) + abiraterone TLX591-Tx, 177 Lu-rosopatamab
- Subcarinal, right upper para-tracheal, abdominal, pelvic lymph nodes. SPECT TLX591-Tx biodistribution:
Single dose distribution of TLX591-Tx over 15 days BASELINE PET 4 hours1 day4 days7 days15 days* TLX591-Tx seen in the vascular space and liver TLX591-Tx seen at metastatic sites (and liver) * 64-year-old patient with metastatic disease in lymph nodes 1 36 Stable disease for339 days Post treatment SPECT imaging after one injection of TLX591-Tx Patient representative scans – individual results may vary. Images are non-quantitative.
Patient case: TLX591-Tx (2 doses) + enzalutamide TLX591-Tx, 177 Lu-rosopatamab
- Subcarinal, right upper para-tracheal, abdominal, pelvic lymph nodes. SPECT TLX591-Tx biodistribution:
Single dose distribution of TLX591-Tx over 15 days BASELINE PET 4 hours1 day4 days7 days15 days* TLX591-Tx seen in the vascular space and liver TLX591-Tx seen at metastatic sites (and liver) * 62 year-old patient with prior ARPI (darolutamide) and docetaxel 1 37 Stable disease and on study at 337 days (data cutoff) Patient representative scans – individual results may vary. Images are non-quantitative. Administration of first dose of TLX591-Tx
Dr. David N. Cade Group Chief Medical Officer, CMO TLX597-Tx
Disease progression shifts clinical priorities Distinct prostate cancer disease states bear implications for patient management 39 SOURCES:
- Kyriakopoulos et al. J Clin Oncol. 2018, Fizazi et al. Lancet Oncol. 2019
- Armstrong et al. Eur Urol. 2020; Ryan et al. Lancet Oncol. 2015 Androgen pathway modulator sensitive Androgen pathway modulator resistant Prognosis and patient profile Disease biology •Survival commonly extends beyond 4-5 years 1 , generally fitter patients • Approximately 2-3 years from initiation of 1L therapy 2 , greater clinical complexity •Variable tumor burden, more localized •Responsive to androgen suppression •Increasing tumor burden •Progressively resistant phenotypes Clinical implication •Intensify treatment to delay progression to mAPMR •Preserve long-term quality of life •Optimize sequencing across limited options •Maximize efficacy at each treatment line NOTE: Illustrative ranges; outcomes vary by disease volume, prior treatment, patient characteristics and therapy.
Addressing patient needs across the care continuum
TLX597-Tx and TLX591-Tx profiles are adapted to each disease state
40
TLX591-Tx: First-in-class rADC
2
TLX597-Tx: Next gen small molecule
1
1.Kahn at al. Dose Optimisation and PSMA Receptor intensification with 177Lu-PSMA-597 in metastatic castration-resistant prostate cancer, the Randomised Phase II OPTIMAL-PSMA trial, presented at IPCS / APCCC 2026; Omar et al, [ 177 Lu]Lu-DOTA-HYNIC-panPSMA radioligand therapy for patients with metastatic castration-resistant prostate cancer, presented at EANM 2025 2.Sartor et al. Presented at: American Society of Clinical Oncology Annual Meeting 2024; TPS5115; Sun et al. Curr Oncol Rep. 2021; Lenzo et al. Cancers (Basel). 2026; Tagawa ST, et al. Cancer. 2019. Excretion organ Kidney and salivary gland impact Efficacy signal •Liver excretion (radio-tolerant organ) with minimal dose to kidneys •Renal excretion BUT with 1/3 rd radiation dose to kidney vs PSMA-617 •Limited kidney dose and negligeable salivary gland uptake •Limited kidney dose, radiation to salivary gland 1/5 th vs PSMA-617 •rPFS of 8.8 months in ProstACT SELECT trial •High lesion dosimetry, positive signals from OPTIMAL-PSMA and PTherpan-Lu Dosing •2 doses of 76 mCi enables combination with mAPMR SOC (ARPI and chemo) •3-7 doses of 230mCi adaptively administered to limit overtreatment mAPMN/SmAPMR
TLX597-Tx early data suggests favorable dosimetry profile Selective tumor targeting with lower healthy tissue exposure TLX597-Tx SPECT scan, 5 hrs and 120 hrs Kidneys0.280.580.71 Lacrimals0.351.582.83 Submandibular0.250.740.64 Lesions (bone)9.743.574.1 Lesions (soft tissue)9.574.192.94 Patient representative scans – individual results may vary. TLX597-Tx (n = 12) 1 PSMA-617 2
(n = 297) PSMA-I&T 2 (n = 153) 1.Khan et al. J Nucl Med. 2026. Final dosimetry report for PSMA-597 (Ascinta Technologies). 2.Ells et al Dosimetry of [177Lu]Lu-PSMA–Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Meta analysis. JNM 2024; 65:1264–1271. < < < > > 5 hrs120 hrs Gy/GBq 41
Leveraging dose intensification and higher activity to enhance tumor response PSMA up-regulation can be seen 3 days after the initial dose through higher TTV Dose 1 (Day 1)Dose 2 (Day 3) SUV mean 5.7 SUV max 25 TTV 2379 mL SUV mean 7.9 SUV max 74 TTV 3977 mL 1.Crumbaker at al. Dose Optimisation and PSMA Receptor intensification with 177Lu-PSMA-597 in metastatic castration-resistant prostate cancer, the Randomized Phase II OPTIMAL-PSMA trial, presented at ASCO GU 2026. Day 1 8.5GBq (230mCi) Day 3 8.5GBq Day 15 8.5GBq Week 10 8.5GBq Week 20 8.5GBq Week 30 8.5GBq First 3 doses administered in 15 days Dose intensification consists of 2 components Higher administered activity of 8.5GBq/dose vs 7.5GBq 12 Dose intensification and higher activity are enabled by a favorable safety profile and biodistribution The rationale is to exploit upregulated PSMA expression and incomplete tumor DNA repair Patient representative scans - individual results may vary. 42
TLX597-Tx, Phase 2 OPTIMAL-PSMA study Exploring safety and efficacy of dose intensification vs standard treatment Investigator Initiated Trial (PI: Prof Louise Emmett, St Vincent’s Hospital, Sydney) Day 1 8.5GBq (230mCi) TLX597-Tx* Dose Intensified TLX597-Tx Standard of Care n = 80 2:1 Eligibility •Confirmed mAPMR •Progressed on prior ARPI •Baseline 68 Ga- PSMA-11 ENZA-p criteria (SUV max >15 at single site and >10 at larger sites) Primary Endpoints •PSA90 RR Secondary Endpoints •PSA50 RR •PSA-PFS •rPFS •OS •ORR •QoL •Safety •Dosimetry n = 40 Day 3 8.5GBq Day 15 8.5GBq Week 10 8.5GBq Week 20 8.5GBq Week 30 8.5GBq Day 1 7.5GBq (200mCi) Week 6 7.5GBq Week 12 7.5GBq Week 18 7.5GBq Week 24 7.5GBq Week 30 7.5GBq Initial 3 doses in 15 days Last 3 doses every 10 weeks 6 doses every 6 weeks 30 weeks of treatment in both arms Part B 68 Ga-PSMA-11 PSA at week 8 in both arms Majority of patients received prior taxane ANZCTR Registration Number: ACTRN12625000971437. 1.Pathmanandavel S, etal. J Nucl Med. 2022;63:1343-1351. 2.John N, Pathmanandavel S, etal. J Nucl Med. 2022;64:410-415. 3.Sheehan B, etal. Clin Cancer Res. 2022;28:3104-3115. 43 n= 120 PSA response as well understood surrogate biomarker for small molecules (not for mAbs)
Patient case: TLX597-Tx treatment post-chemo (2 lines) and ARPI 71-year-old patient with diffuse bone metastases •Normal kidney function •Substantial shrinkage of lesions •97% PSA response at week 10 Dose 1 (Day 1) Dose 2 (Day 3) Dose 3 (Day 15) Dose 4 (Week 10) NOTES: Hb, hemoglobin; PLT, Platelets; eGFR, estimated glomerular filtration rate (renal function). Day 1Day 3Day 15Week 6Week 10 PSA1,3801,48082813140 Hb112111117116106 PLT201198217190208 eGFR9090909089 44 Patient representative scans - individual results may vary.
Patient case: TLX597-Tx in advanced setting Extensive skeletal / bone marrow involvement at baseline •Improvement in hemoglobin •Normal kidney function •99% PSA response Dose 1 (Day 1) Dose 2 (Day 3) Dose 3 (Day 15) NOTES: Hb, hemoglobin; PLT, Platelets; eGFR, estimated glomerular filtration rate (renal function). Advanced setting refer to disease progression post ARPI, received chemotherapy/medically unfit to receive chemotherapy. Day 1Day 3Day 15Week 10Week 20 PSA487522358271.9 Hb817711367106 PLT130123109130244 eGFR7775818583 Dose 4 (Week 10) Dose 5 (Week 20) 45 Patient representative scans - individual results may vary.
Eligibility •Minimally treated mAPMN/S •High risk metachronous / synchronous •ADT < 30 days •Baseline PSMA- PET using VISION Criteria Primary endpoint •PSA <0.2ng/mL at 6mo. Secondary endpoints •Safety •PSMA PET response •PSA 50% & 90% RR •ORR •QoL •Dosimetry Day 1 ARPI 4 Dose 1 Day 8 8.5GBq Dose 2 Day 10 8.5GBq Dose 3 Week 6 8.5GBq 3 doses in 6 weeks Dose 4 Week 14 8.5GBq Dose 5 Week 22 8.5GBq Dose 6 Week 30 8.5GBq Screening Continuous ADT + ARPI 2 doses every 8-weeks Week 12 PSMA PET/CT Scan & PSA test 1
Week 24 PSMA PET/CT Scan & PSA test 2
- After Dose 3, treatment pause is allowed in participants with >90% reduction in volume, no residual large lesions and no new lesions and PSA < 1ng/mL, or in participants with residual PSMA avid disease confined to the prostate only who then receive prostate radiotherapy). 2. After Dose 5, participants who have not had a [177Lu]Lu-PSMA-597 treatment-pause, have a PSA < 1ng/mL, and a >90% reduction in volume, no residual large lesions and no new lesions on the 24-week PSMA PET/CT, will be eligible for a treatment pause. 3. Following 7 doses, an additional 3 doses (7+3) of [177Lu]Lu-PSMA-597 can be given in responding participants at the discretion of the treating investigator. 4. abiraterone, apalutamide, darolutamide, enzalutamide. Dose 7 Week 38 8.5GBq 2 doses every 8-weeks Week 44 PSMA PET/CT Scan & PSA test 3 Week 1 ADT Adaptive PSMA targeted radioligand therapy TLX597-Tx, Phase 2 OPTIMAL-e study in mAPMN/S (mHSPC) n= 20 46
Beyond Lu-PSMA in Prostate Cancer 225 Ac
TLX592-Tx: Evaluating two targeting modalities with alpha therapy Maximizing tumor delivery while limiting off-target uptake First-generation small molecules Clinical experience with first- generation ²²⁵Ac-PSMA agents identified severe/persistent xerostomia as a key dose-limiting challenge 1 Antibody-based approach TLX592 combines the biodistribution advantages of antibody constructs, with minimal salivary gland uptake and predominantly liver clearance, with an engineered accelerated clearance profile that has the potential to further enhance safety and tolerability 2 Small molecule approach An optimized small molecule approach aims to combine rapid plasma clearance and low kidney and salivary gland uptake with rapid tumor accumulation and prolonged tumor retention 1.Heynickx et al. Nuclear Medicine and Biology. 2021. 2.Refers to CUPID imaging study, using 64Cu-PSMA-RADmAb, presented at ASCO GU, Feb 2025. NCT04726033.
Telix is exploring antibody- and small molecule-based approaches in parallel for alpha-PSMA therapy 48
TLX090-Tx: Novel candidate for pain from bone metastasis
49
Positive Phase 1 data
Phase 1 program
1.Based on data generated by QSAM Biosciences. Data on file. Clinicaltrials.gov. ID: NCT 06008483, Study conducted under IND 156086.
2.Huang et al.Ann Transl Med.2020.
3.Guo et al.Skelet Radiol.2025.
4.Woolf et al.Annals of Oncology.2015.
Visual Analogue Scale (VAS) measures pain intensity on a scale of 100
0= no pain, 100 = worst pain
Phase 1 data
1
demonstrate encouraging efficacy signal
Phase 1 data
1
showed pain reduction scores on the VAS scale using two different
doses of TLX090-Tx
•Debilitating pain from osteoblastic bone
metastases is one of the most common and
burdensome complications of advanced prostate
and breast cancer
•Up to 90% of patients with metastatic prostate
cancer
3,4
are affected, contributing to reduced
quality of life and mental health
•Despite the availability of opioids and external
beam radiation therapy (EBRT), many patients
remain under-treated, underscoring a critical
unmet need for a systemic, targeted, and non-
opioid solution that can deliver durable relief
Encouraging pain reduction observed in Phase 1 study,
1
supporting potential for clinically meaningful benefit •Consistent pain reduction scores (VAS) observed for all patients •Anecdotal reports suggest improved mobility
Multi-product therapy portfolio in prostate cancer Androgen pathway modulator-sensitive Androgen pathway modulator resistant PSA tumor burden mAPMN/S3L+ mAPMR2L mAPMR 1L mAPMR Global TLX591-Tx Phase 2a in PSMA+ mAPMN/S patients TLX597-Tx OPTIMAL-e TLX592-Tx TLX090-Tx Palliative Phase 3 in PSMA+ mAPMR patients previously treated with 1 ARPI Aligned to disease state, patient needs and clinical opportunity 50 mAPMN/S = metastatic androgen pathway modulation naïve/sensitive; mAPMR = metastatic androgen pathway modulation resistant.
Dr. Varun Sundaram Urology Austin BiPASS Biopsy of the Prostate Avoidance Stratification Study ®
Current diagnostic pathway for prostate cancer relies on invasive biopsies •Template biopsies require 15-20 samples obtained through an invasive procedure under anesthesia •Sampling limitations may miss disease or fail to characterize tumor burden. Biopsies are blind to the tumor location •Risks of infection, bleeding, urinary retention, post- procedural complications •Recovery times may vary from days to weeks •Multiple biopsies are often required to diagnose, monitor progression or confirm treatment response Template biopsy 52
A significant unmet need remains in the diagnostic pathway Base (top) Apex (bottom) Men with elevated PSA values will often be recommended for MRI 1 , followed by biopsy •MRI is not specific and often inconclusive, leading to biopsy Areas of biopsy 6
- Magnetic resonance imaging. 2. Vickers et al. J Clin Oncol. 2010. 3. Ahmed et al. Lancet. 2017. 4. https://www.researchgate.net/figure/Complications-of-transrectal-ultrasound-guided-prostate-biopsy_tbl1_10978264
- Filho et al., 2025. 6. Picture credit: Georgia Radiation Therapy. 7. Schmeusser B, Levin B, Lama D, Sidana A. Hundred years of transperineal prostate biopsy. Ther Adv Urol. 2022;14:17562872221100590. Published 2022 May 21. doi:10.1177/17562872221100590. Biopsy false-negative rates can be as high as 50% 7 53 800,000 biopsies performed in the U.S. each year, up to 75% are negative 2 •Biopsy is blind to the location of cancer in the prostate •Only ~half of the needles provide useful samples (false negatives) 3 Up to 25% of patients refuse a recommended biopsy 5 •Reasons for refusal include fear or pain of complications •Skepticism about the necessity of the procedure Biopsies carry real risks 4 •Hematuria, rectal bleeding, hematospermia •Inconsistent practice around anticoagulants adds complexity
Key insights from PRIMARY and PRIMARY 2 Investigator Initiated Studies (IITs) PRIMARY (n = 291) 1 Ga-PSMA-PET +mpMRAmpMRI Sensitivity97%83% Specificity40%53% Negative predictive value91%72% PRIMARY SCORE 2 (analysis) Sensitivity94%89% Specificity68%74% P-Score 3 (analysis) Sensitivity94%89% Specificity66%74% PRIMARY2 4 (n = 660)Ga-PSMA-PET +mpMRA Biopsy reduction49% csProstate cancer detected12% vs 16% PRIMARY study established proof of concept that Ga- PSMA-11 PET + mpMRI improves the detection of prostate cancer. PRIMARY 2 study demonstrated that Ga-PSMA- 11 PET + mpMRI can safely reduce biopsies while maintaining a clinically significant detection of prostate cancer. 1.Emmett L, Buteau J, Papa N, et al. Eur Urol. 2021, 2. Emmett L, Papa N, Buteau J, et al. J Nucl Med. 2022, 3.Emmett L, Papa N, Hope TA, et al. J. Urol. 2024, 4. Buteau JP, Moon D, Fahey MT, et al. Lancet Oncol. 2026. 54
, Phase 3 study for detection of prostate cancer Biopsy of the Prostate Avoidance Stratification Study (BiPASS) mpMRI = multiparametric Magnetic Resonance Imaging.
- Histopathological confirmation will be used to detect prostate cancer. 55 Eligibility: Clinical suspicion of prostate cancer and indicated for template biopsy Status: Completed patient enrollment Global, multi center, open label, single arm study Clinicaltrials.gov: NCT07052214 68 Ga-PSMA-11
- mpMRI PI-RADS 1-4 Template biopsy (targeted biopsy) Primary Objective: Detection of clinically significant prostate cancer using mpMRI + 68 Ga-PSMA-11 PET 1
Co-primary endpoints: Sensitivity and specificity n = 350 6- month follow-up (confirm negative findings) ®
56 Image-guided biopsy Staging and surgical planning Precision biopsy 'One and Done' No biopsy 'None and Done' Ga-PSMA-PET at diagnosis aims to: •Improve predictive accuracy •Reduce 12-40 anatomical biopsies to 1-2 biopsies •For some, eliminate the need for biopsy altogether •Decrease risk and anxiety Enabling: •Clearer treatment stratification •Personalized diagnostic journey •Expedited therapy Symptoms or elevated PSA PSMA-PET + mpMRI 1
A personalized diagnostic pathway with Ga-PSMA-PET Smarter triage BEFORE biopsy. Integrating imaging with biopsy 1.Multiparametric MRI. 2.Prostate Imaging Reporting and Data System, a scoring system used by radiologists to assess the likelihood of prostate cancer based on multiparametric mpMRI findings. PI-RADS 2 1-4 PET Positive Potential high risk (PI-RADS 2 5) PIRADS 1-2 PET Negative Risk stratification
68 Ga has a lower propensity for indeterminate bone lesions (IBLs) 1,2
- Kuchar M, et al. Molecules. 2015;20(9):16186-16220.
- Rauscher I, et al. J NuclMed. 2020;61(1):51-57. Free 68 Ga, in contrast to 18 F, does not have an affinity to bone 57 With 18 F, a number of benign bone lesions accumulate PSMA and result in false positives on PSMA-PET/CT. SNMMI Guidelines for Prostate Cancer Imaging There are numerous advantages of having a more streamlined image pattern that guides you more to where the lesions are and avoids the distractions to where the lesions don't belong. Dr. Munir Ghesani
Case study: diagnostic accuracy of 68 Ga-PSMA-11
- Fendler WP, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging, 2023.
- Lowrance W, et al. Updates to advanced prostate cancer. F-18 PSMA PET Scan PSA 3.4 •Patient on active surveillance •No active treatment IBL detected 68 Ga-PSMA-11 PET Scan 6 months later Resolution without interval treatment confirms lesion benignity Interpreting bone lesions with 18F-based PSMA radiotracers can be more challenging compared to 68Ga due to detection of benign bone lesions 1,2 -SNMMI Guidelines 58 Patient case study from IIT: Intra-Individual Comparison of 68 Ga- and 18 F-Labeled PSMA PET for Skeletal Lesion Characterization in Prostate Cancer: A Pilot Feasibility, Study Interim Analysis led by Dr Ghesani. CTPETPET/CT Fused No rib lesion Patient representative scans – individual results may vary. Images are non-quantitative.
The future of prostate cancer detection
- Celli M, Gunelli R, Ferroni F, Costantini M, Barone D, Fantini L, Fragalà E, Marini I, Di orio V, Foca F, Monti M, Matteucci F and Caroli P (2026) Toward a PSMA PET–mpMRI pathway for biopsy decision-making in men with suspected prostate cancer: interim results from the prospective BIOPSTAGE trial. Front. Oncol. 15:1720861. doi: 10.3389/fonc.2025.1720861. Current state 3 MRI acquisitions Future state 1 PSMA PET scan •72 year old male was negative for suspicious findings (PI-RADS <3) •PSMA PET detected a focal uptake in the right anterior apex of the prostate 1 Patient representative scans – individual results may vary. Images are non-quantitative. 59
CEO of Precision Medicine Mr. Kevin Richardson
Initial biopsy protocol has remained unchanged since the addition of MRI Current state: PSMA-PET transformed staging and BCR detection PSMA-PET scans (in thousands) Initial staging 151 BCR 460 143 RLT selection 58 Monitoring for mAPMR progression Monitoring response to RLT 71 52 Response to treatment nmAPMR Disease progression Current indications Future indications Total addressable market Current TAM: ~670,000 scans/year TAM = Total addressable market, BCR = Biochemical recurrence, nmAPMR = non-metastatic androgen pathway modulation resistant, RPT = Radiopharmaceutical therapies. ClinicalTrials.gov: NCT07052214. Annual PSMA-PET scan volume in the U.S. based on internal estimates. 1M biopsies 61
Potential to double the size of the existing PSMA market Future state: revolutionizes biopsy decision-making BiPASS = Biopsy of the Prostate Avoidance Stratification Study, TAM = Total addressable market, RPT = Radiopharmaceutical therapies, Annual PSMA-PET scan volume in the U.S. based on internal estimates. 1.Estimate one million biopsies performed in the U.S. each year. Source: Schmeusser et al. Therapeutic Advances in Urology, 2022. 2.ClinicalTrials.gov: NCT07052214. Current indications Future indications Total addressable market BCR Monitoring for mAPMR progression (pre-biopsy) Move imaging utilization to the pre-biopsy stage Initial staging reduced 1M+ 1 821,000 scans/ year Monitoring response to RLT Disease progression Biopsies reduced 62 RLT selection Response to treatment to mAPMR
Key Takeaway: Patients show strong preference for a less invasive, imaging-first approach Patient Voice Many men request unnecessary radical prostatectomies simply to avoid getting another biopsy, which I thought was ludicrous. But after having two, with another biopsy on the horizon, I now understand. The biopsy was a necessary but stressful step. I strongly support the development of more accurate, less invasive diagnostic tools to reduce patient anxiety and physical complications. Non-invasive testing options would be a game changer for early detection and reducing anxiety. 95% Would have preferred MRI + PSMA PET prior to biopsy 71% Chose Imaging-First over Biopsy- First as their preferred approach 93% Want their doctor to discuss PSMA PET + MRI in future biopsy decisions 88% Would bring up PSMA PET + MRI if their doctor didn’t 1.Telix patient survey conducted in collaboration with PCEC, Prostate cancer education council. Patients show strong preference for a less invasive, imaging-first approach Survey (n = 1,002 patients who had prostate biopsy in the last 6 years) 1
63 Patient preference overwhelmingly favors Ga-PSMA PET scan over biopsy
~16,800 ~22,460 ~12,600 ~670,000 scans (~327k patients) ~821,000 scans (~821k patients) ~266,900 scans (~172k patients) Illuccix / Gozellix (Initial Staging, BCR, RLT selection) BiPASS ® (diagnosis of prostate cancer) Monitoring RLT therapy, Monitoring for progression in nmAPMR / mAPMR $20B opportunity in Prostate Cancer Therapeutics Precision Medicine TLX597-Tx: mAPMN/S TLX591-Tx: mAPMR 1L + 2L TLX592-Tx: mAPMR 2L+ U.S. TAM (Patients) Target Indication 64 USD $ $2.7B $3.3B $1.1B $4.2B $5.6B $3.2B $20B Source: Datamonitor, Clarivate, internal estimates. Total Addressable Market (TAM) for Precision Medicine uses $4,000/scan for modelling purposes. Therapeutics candidates are using $250,000/treatment based on commercial benchmarks/Datamonitor. These price points do not reflect the actual price charged or the price that Telix will charge in the future. Note: Intended for investor audience only. The FDA has approved Illuccix for use in initial staging, BCR, and RLT selection. The FDA has approved Gozellix for use in initial staging and BCR. Not intended to advertise or promote any other product or indication. BiPASS has not been accepted by the FDA to diagnose, treat, cure, or prevent any disease. Brand names subject to regulatory approval.
Dr. Sumanta (Monty) Pal, MD City of Hope Renal Cancer Overview
Disease overview: Kidney cancer 14 th most commonly diagnosed cancer worldwide 1 Age-standardized incidence & mortality highest in North America & Europe 1 Twice as common in men vs women 1 90% of kidney cancer is RCC, of which ~85% is ccRCC 2,3 Age-standardized rate per 100,000 (2022) 4 ccRCC, clear cell renal cell carcinoma; RCC, renal cell carcinoma.
- Bray F, et al. CA Cancer J Clin. 2024;74(3):229-263. 2. Qi X, et al. Front Oncol. 2021;11:727778. 3. Alchahin AM, et al. Nat Commun. 2022;13(1):5747. 4. Globocan2022 (version1.1) -08.02.2024. https://gco.iarc.who.int. 66
Significant unmet medical need in ccRCC
- Bray F, et al. CA Cancer J Clin. 2024;74(3):229-263. 2. Bukavina L, et al. Eur Urol. 2022;82(5):529-542. 3. Alchahn AM, et al. Nat Commun. 2022;13(1):5747. 4. National Cancer Institute. Cancer stat facts: kidney and renal pelvis cancer. Updated 2025. 5. Vento JA, et al. Cancers (Basel). 2022;14(20):5005. 6. Rysz J, et al. Int J Mol Sci. 2025;26(12):5577. 7. Schoenfeld A, et al. Cancer Cell. 2020;37(4):443-455. 8. Obeng-Kusi M, et al. Urol Oncol. 2024;42(2):32.e1-32.e8. 9. Rudresha AH, et al. Indian J Cancer. 2017;54(4):626-630. 10. Sunder S, et al. Signal Transduct Target Ther. 2023;8:262. 11. Mielcarek L, et al. Cancer Chemotherapy Pharmacology 2021;87(6):723-742. 67 ccRCC remains a high-burden disease with poor long-term outcomes despite recent advances Disease Burden Treatment Challenges Need for Better Tolerated Therapies ccRCC is a serious disease with substantial morbidity and mortality 1,2,3,4 20–40% of patients with localized ccRCC ultimately progress⁵ 4,700 patients/year in the U.S. need third-line therapy options⁸ •Incidence rates are rising (increased risk factors, incidental detection)² •~30% of patients present with metastatic disease at diagnosis (5-year survival rate ~20%)³ •~180,000 deaths annually worldwide from kidney cancer¹ •Current ICI- and VEGFR-based therapies achieve durable benefit in only a subset of patients⁶ •Primary and acquired resistance remain common⁷ •Treatment sequencing beyond 2nd line remains poorly defined⁸ •After 2nd line, no improvement in OS (5-year OS ~18%)⁸ •Disease progression typically occurs with ICI, TKI, belzutifan or everolimus⁹ •Adverse effects frequently lead to dose reductions, interruptions, or discontinuation¹⁰ •Need for targeted therapies that can provide durable disease control with manageable toxicity¹¹
•Transmembrane glycoprotein involved in oxygen-sensing pathways and regulator for pH 1,2 •Induced by hypoxia or by mutation of the Von Hippel-Lindau tumor suppressor gene 1-4 •Expressed in >95% of ccRCC 5-7 •Negligible expression in normal kidney tissue 7 Novel target in ccRCC - CAIX Adapted from Becker HG. 2 CAIX, carbonic anhydrase IX; ccRCC, clear cell renal cell carcinoma.
- Aldera AP, et al. J Clin Pathol. 2021;74(6):350-354. 2. Becker HM. Br J Cancer. 2020;122(2):157-167. 3 3. Wykoff CC, et al. Cancer Res 2000;60(24):7075–7083. 4. Maxwell PH, et al. Nature 1999;399(6733):271–275. 5. Courcier J, et al. Int J Mol Sci 2020;21(19):7146. 6. Bui MHT, et al. Clin Cancer Res 2003;9(2):802– 811. 7. Stillebroer AB, et al. Eur Urol 2010;58(1):75–83. 68
•VHL mutation is pathognomonic for ccRCC, leading to HIF stabilization, accumulation, and tumor growth 1
•CAIX is a target of HIF transcriptional activity under hypoxic conditions 2 •CAIX is a transmembrane protein and a tumor-specific protein important for maintaining pH balance 2 •CAIX is overexpressed in mVHL ccRCC, but shows only low-level expression in normal kidney 3,4 CAIX targeting in ccRCC Image adapted under a Creative Commons license from Al-Zuaini HH, et al. Front Oncol. 2023. doi:10.3389/fonc.2023.1207253. ARNT, aryl hydrocarbon receptor nuclear translocator; CAIX, carbonic anhydrase IX; ccRCC, clear cell renal cell carcinoma; HIF, hypoxia-inducible factors; IO, immuno-oncology; mVHL, mutated von Hippel- Lindau; RCC, renal cell carcinoma; VEGF, vascular endothelial growth factor.
- Chintala S, et al. BMC Cancer. 2012;12:293.2. van Kuijk SJ, et al. Front Oncol. 2016;6:69. 3. Patard JJ, et al. Int J Cancer. 2008;123(2):395-400. 4. Yousef A, et al. Cancer Diagn Progn. 2022;2(6):661-667.
- Muselaers CH, et al. Eur Urol. 2016;69(5):767-770. Normal cells ccRCC CAIX is is a highly promising target for ccRCC 5 CAIX is a highly promising target for ccRCC 5 69
Monoclonal antibody-based theranostics CAIX, carbonic anhydrase IX; PET, positron emission tomography.
- Oosterwijk-Wakka et al. Int J Mol Sci. 2013;14(6):11402-23; 2. Kulterer et al. J Nucl Med. 2021;62(3):360-5. 3. Merkx et al. Eur J Nucl Med Mol Imaging. 2021;48(10)3277-85 4. Chamie et al, 2-15. Girentuximab •IgG1 kappa light chain chimeric monoclonal antibody •Girentuximab - highly specific binding to CAIX and internalization •Safety data from Phase 1-3 clinical studies with girentuximab in RCC, including nearly 500 patients and healthy volunteers 1-4 •Hepatic clearance Payload: 89 Zr (imaging) •Positron emitter •Half-life3.3 days •Suitablefor antibody-based PET imaging Payload: 177 Lu (therapy) •Medium-energy β-emitter •Half-life 6.7days •Suitable for antibody-based therapy 70 TLX250-Tx for treatment of ccRCC and TLX250-Px for imaging
Disease
recurrence
or
development
of metastatic
disease
Favorable Risk:
IO + VEGFR TKI
2
or
IO + IO
3
Intermediate / Poor:
IO + TKI or
IO + IO or
TKI monotherapy
4
IO-Exposed:
TKI
5
or
mTOR + TKI
6
or
HIF-2α inhibitor
7
IO-Naive:
IO + IO
3
or
IO + TKI
2
Switch TKI
5
or
mTOR
6
- TKI or
mTOR
8
or
HIF-2α inhibitor
7
Oligometastatic
1
:
Active Surveillance or
SBRT or
Metastasectomy Diagnosis and management of localized disease •In 3L+, limited options, poor outcomes •Opportunity to bring novel mode of action (MoA) through fast development pathway as monotherapy LUTEON / LUTEON ATLAS Patient journey for a metastatic kidney cancer patient Unmet needs remain in improving efficacy in 1L and 2L treatments and outcomes in 3L+ therapies 71 1.Options only available for patients with select favorable disease features. 2.Axitinib/Pembrolizumab; Cabozantinib/Nivolumab; Lenvatinib/Pembrolizumab. 3.Ipilumumab/Nivolumab. 4.Cabozantinib only. 5.Cabozantinib; Axitinib; Tivozanib. 6.Lenvatinib/Everolimus.
7.Belzutifan. 8.Everolimus. Opportunity to improve efficacy of approved combination therapies in 1-2L setting SOURCE: NCCN Guidelines, Kidney Cancer. Diagnosis and Surgery1L therapy2L therapy3L+ therapy
ccRCC administered activity schedule rationale Observations from prior studies (Phase 1, n=23; Phase 2, n=14) 1,2 ●Patients receiving the maximum number of cycles (3) were predominantly in the lower administered activity* cohorts (80% at ≤3145 MBq; none >4088 MBq) ●More treatment cycles correlated with better outcomes (mOS: 49.3m for 3 cycles, 22.2m for 2 cycles, 18.7m for 1 cycle, respectively) ●Higher administered activity increased hematological toxicity; no Gr 3-4 leukocyte or platelet toxicities received in the lowest activity cohort (1887 MBq) ●Lower administered activity (1887 MBq) was well tolerated and allowed multiple cycles in a previous study (n=11) 3 Pharmacology rationale ●TLX250-Tx tumor residence time suggests little/no relevant therapeutic activity remains in tumor after ~3 weeks ●Fractionating the administered activity and reducing the interval from 3 months to 1-2 months can enhance efficacy ●Each fraction stays low enough to avoid dose-limiting toxicity due to cumulative toxicity 1887 MBq every 2 months x 3 cycles Based on activity levels administered in previous studies 1258 MBq every month x 6 cycles Fractionation of 2516 MBq to match tumor exposure window Lower fractionating enables more cycles with manageable toxicity 1 2 3
- Stillebroer AB, et al. European Urology. 2013;64:478-485. 2. Muselaers CHJ, et al. European Urology. 2016;69:767-770. 3. Starstruck - Telix and Merck terminated co-developed Ph1b study *BSA= ~ 1.7m 2 . 72
TLX250-Tx: LUTEON (Ph3) and LUTEON-ATLAS (Ph2a) trial design HREC = Human Research Ethics Committee, ccRCC = clear cell renal cell carcinoma, DR1 = Dosing regimen 1, DR2 = Dosing regimen 2, PET = positron emission tomography, R= randomization, RP3D = recommended Phase 3 dose, SoC = Standard of care. HREC approval received 1 U.S. FDA ‘May Proceed’ received / EU under review Population: •Advanced or metastatic ccRCC •Disease progression on/after 2 to 3 prior systemic lines of therapy •CAIX-positive by 89 Zr-TLX250 PET Part 1: Dose Optimization (Phase 2a) Treatment period (months) 1:1 1887 MBq1887 MBq1887 MBq 1258 MBq 1258 MBq 1258 MBq 1258 MBq 1258 MBq 1258 MBq 123456 RP3D N=TBD N=TBD Part 2 (Phase 3) Investigators choice (SOC) Dose administration 1-month intervals 2-month intervals 1:1 177 Lu-TLX250 (RP3D) US/EU: LUTEON-ATLAS (Ph2a) AUS: LUTEON (Ph3)
- ClinicalTrials.gov ID NCT07197580. 2. Australia: recruiting, U.S.: site activation, Europe: application under review.
73 1,887 MBq 1,258 MBq Safety Lead-in* N=3 N=3 RP2a *3 pts in Safety Lead-in included in total 20 pts in Part 1 (Dose Optimization); No Safety Lead-in in AUS DR2 = 20 DR1 = 20 Global study locations 2 ClinicalTrials.gov ID NCT07197580
Dr David Cade Group Chief Medical Officer, CMO Zircaix (TLX250-Px) 1 1 Zircaix brand name subject to regulatory approval.
Unmet need in diagnosis of ccRCC The most common – and one of the most aggressive – forms of renal cancer 75 1.ccRCC, clear cell Renal Cell Carcinoma; CT, computed tomography; MRI, magnetic resonance imaging; NPV, negative predictive value; RCC, Renal Cell Carcinoma. 2.1. Qi X, et al. Front Oncol. 2021;11:727778. 2. Alchahin AM, et al. Nat Commun. 2022;13(1):5747. 3. Abu Haeyeh Y, et al. Bioengineering (Basel). 2022;9(9). 4. Metin M, et al. Medicina (Kaunas). 2022;58(2). 5. Finelli A, et al. Eur Urol. 2020;78(3):460-467. 6. Patel HD, et al. J Urol. 2016;195(5):1340-1347. 7. Oei T, et al. Imaging in Medicine. 2011;3(2):207-218. 8. Baio R, et al. Diseases. 2023;11(1):27. Limitations of anatomic imaging (CT, MRI) •Cannot reliably distinguish benign vs malignant Risk of overtreatment and related complications •Up to 30% resected small renal masses found to be benign 7 •30% complication rate of partial nephrectomy in these patients 8 Limitations of renal biopsy •Non-diagnostic, 10-15% •Invasive, related risks •Sampling error, 70% NPV 6 Need for early & accurate diagnosis / treatment •Up to 85% of RCCs are ccRCC 1,2
•ccRCC causes ~90% of deaths of all RCC 3,4 •For patients with small renal masses on active surveillance, ccRCC subtype reported to progress most rapidly 5 Lymph node Gerota’s facia Adrenal gland Kidney Lymph node Tumor <7 cm in greatest dimension and limited to kidney; 5-year survival, 95% Tumor >7 cm in greatest dimension and limited to kidney; 5-year survival, 88% Tumor in major veins or adrenal gland, tumor within Gerota’s fascia, or 1 regional lymph node involved; 5 year survival, 59% Tumor beyond Gerota’s fascia, or >1 regional lymph node involved; 5 year survival, 20% Stage IV Stage III Stage II Stage I 75
TLX250-Px: Highly accurate in detecting ccRCC 1 Phase 3 ZIRCON trial validates CAIX as a novel target CAIX, carbonic anhydrase IX; ccRCC, clear cell renal cell carcinoma; mAb, monoclonal antibody; PET, positron emission tomography; rADC, radio antibody-drug conjugate; T 1/2 , half-life. 1.Shuch B, et al. Lancet Oncol. 2024;25(10):1277-1287. 2.ZIRCON ClinicalTrials.gov ID:NCT03849118. •IgG1 CAIX-targeting mAb •Payload: 89 Zr, positron emitter with T 1/2
3.3 days •Hepatically cleared •Demonstrated accuracy and favorable safety profile in Phase 3 ZIRCON study and real-world cases 2 ZIRCON study results summary Sensitivity & specificity of small lesions ≤4 cm (n=145) •Sensitivity: 85% •Specificity: 90% ≤2 cm (n=20) •Sensitivity: 97% •Specificity: 97% Reader agreement The Fleiss’ κ statistic for inter- reader variability: 91% Cohen's κ statistic for intrareader variability: 100% for each reader Safety & tolerabilityFavorable profile indicated Primary endpoints: (n=284) Sensitivity: 86% | Specificity: 87% 89 Zr-girentuximab 76
Clinical background: Initial small renal mass detected. CT and MRI demonstrated bilateral masses cT1a (2-4cm), no evidence of extended disease. Initial plan: partial nephrectomy and radioablation TLX250-Px: Patient case study 1 Clinical utility in real-world setting Negative 89 Zr-girentuximab scan Following negative scan results, decision made to change initial surgical and treatment plan to active surveillance. Invasive procedure and surgical organ removal avoided. 77 Use of TLX250-Px scan changed clinical management, avoiding unnecessary nephrectomy Patient representative scans – individual results may vary. Images are non-quantitative.
Clinical background: 78 year old male with biopsy-confirmed ccRCC and metastases Clinical challenge: Patients with ccRCC frequently develop extension of tumor into renal vein and inferior vena cava. Distinguishing tumor thrombus from bland thrombus is critical – however conventional imaging modalities often unable to reliably differentiate 89 Zr-girentuximab demonstrated uptake in: •Primary renal tumor •Bone metastasis •Pulmonary metastases •IVC thrombus consistent with tumor involvement TLX250-Px: Patient case 2 Detection of metastatic ccRCC 78 TLX250-Px scan identified metastatic ccRCC and distinguish tumor thrombus from bland thrombus Patient representative scans – individual results may vary. Images are non-quantitative.
Mr. Kevin Richardson CEO, Precision Medicine
Building on existing relationships with referring physicians TLX250-Px, Illuccix and Gozellix share common referral stakeholders Presentation Imaging Treatment/Management Urologist Radiologist /Nuclear Medicine Physician Primary Care Physician Medical Oncologist Radiation Oncologist Interventional radiologist Patient 80 Urologist
~4,700 ~10,700 ~116,320 Scans (~116k patients) ~56,650 Scans (~23k patients) Diagnosing indeterminant renal masses Detection of localized and metastatic recurrence of ccRCC $4.5B opportunity in Renal Cell Carcinoma Therapeutics Precision Medicine TLX250-Tx: 3 rd Line CAIX-positive ccRCC TLX252-Tx: 2 nd Line+ CAIX-positive ccRCC U.S. TAM (Patients)Target Indication 81 USD $ $600M $300M $1.1B $2.5B $4.5B Source: Datamonitor, Clarivate, internal estimates. Total Addressable Market (TAM) for Precision Medicine uses $5,000/scan for modelling purposes. Therapeutics candidates are using $230,000/treatment based on commercial benchmarks/Datamonitor. These price points do not reflect the price Telix intends to charge in the future. Note: Intended for investor audience only. Not intended to advertise or promote any product. TLX-250-Px, TLX-250-Tx, and TLX252-Tx have not been accepted by the FDA to diagnose, treat, cure, or prevent any disease. Not intended to advertise or promote any use or indication.
Dr. Arthur Braat University Medical Center Utrecht Brain Cancer overview
~25k new brain and CNS tumor cases/yr with ~18k deaths/yr (U.S.) 1 GBM is the most common and most aggressive type of brain cancer, accounting for ~50% of all malignant CNS tumors or ~15k+ patients/year 2 Disease overview: Glioblastoma (GBM) Burden of GBM is increasing, howeversurvival rates have not improvedin 20+ years 1 1.American Cancer Society (Cancer Facts & Figures 2025). 2.Grochans S, et al. Cancers (Basel). 2022;14(10):2412. 3.Nahm et al.J Clin Oncol41,e14057(2023). Annual Incidence (US) 1 Average Survival (US) 1 4 0 2 197519851995200520152022 Year of Diagnosis Rate per 100,000 Relative Survival (%) 60 0 20 40 20020042008201220162022 Year of Diagnosis 83 Patients with GBM have a median overall survival of 12-15 months 1 from diagnosis and 3-9 months from recurrence 3
Glioblastoma patient journey Diagnosis First Line treatment Surgical resection Radiotherapy Concomitant & adjuvant chemotherapy ~7 mo. Recurrence Radiotherapy Concomitant & adjuvant chemotherapy Surgical resection ~3 mo. Refractory First line GBM treatment includes maximal safe surgical resection followed by radiochemotherapy •Most patients progress after ~7 months 1 •Recurrence occurs in 90% of patients within 2 years 1 Upon recurrence, patients are treated with systemic therapy, re-resection, re-irradiation or pointed to a clinical trial 2 •Recommendation by NCCN is participation in a clinical trial 2 Current imaging modalities (e.g. gold standard MRI) have some limitations 4 •New imaging modalities have some advantages (FET PET) Treatment options forGBM remain a significant unmet need
- Fisher, J.P.; Adamson, D.C. Current FDA-Approved Therapies for High-Grade Malignant Gliomas. Biomedicines 2021, 9, 324.
- Vaz-Salgado et al. Cancers (Basel). 2023 Aug 26;15(17):4279.
- NCCN guidelines for Central Nervous Cancers recommend participation in a clinical trial for recurrent or progressive glioblastoma patients.
- Bernstock et al. Standard clinical approaches and emerging modalities for glioblastoma imaging, Neuro-Oncology Advances, Volume 4, Issue 1, January-December 2022, vdac080. 84 There is currently no established standard of care for recurrent GBM 4
•Large amino acid transporters, LAT1 and LAT2are highly expressed in gliomas 1,2 compared to normal tissue •LAT1 is expressed on both luminal and abluminal membranes, playing a key role in BBB permeation 2,3 •Pixclara targets LAT1 and LAT2 while TLX101-Tx and TLX102-Tx therapeutic candidates target LAT1 A novel mechanism of action overcoming the blood brain barrier Targeted radiation that providesimaging and therapeutic potential 1.Singh N and Ecker GF. Int J Mol Sci. 2018;19(5):1278. 2.Haining Z, et al. BMC Clin Pathol. 2012;12:4. 3.Ahmed HS. Mol Neurobiol. 2025;62(3):3813-3832. Pixclara TLX101-Tx ( 131 I) TLX102-Tx ( 211 At) Pixclara TLX101-Tx ( 131 I) TLX102-Tx ( 211 At) Blood (luminal) Brain (abluminal) 4F2hcLAT1 C N S-S 85 A potential first-in-class theranostic pairing in neuro-oncology
First-in-class, therapeutic candidates in GBM and LMD Competitive de-risked portfolio GBM = glioblastoma, LMD = leptomeningeal disease.
- Samnick S, et al. J Nucl Med. 2009;50(12):2025-2032. Israel I et al. Nucl Med Biol 2011; 38:451-460. 2. Pichler J, et al. Neurooncol Adv. 2024;6(1):vdaw130. 3. Plus Therapeutics website: https://clinicaltrials.gov/study/NCT05533242 using implanted reservoir. 4. El Ghalbouni 2026. 5. IPAX Linz topline data Leibetseder A, et al. Presented at: EANM; 4-8 Oct 2025. Barcelona, Spain. 6. TLX101- Tx: Pitchler 2024 (IPAX-1), Tolboom N, et al. Eur J Nucl Med Mol Imaging. 2024;51(Suppl 1):1-1026. 7. Watabe T et al Oncotarget 2020; 11(15):1388-1398; Bormann N et al Nuklearmedizin 2013; 52: 212-
•Readily passes blood-brain-barrier, a major challenge in GBM treatment 1,2 •IV administration vs intracranial administration 3 •Outpatient setting (U.S.) improving quality of life •Encouraging safety and tolerability data and compassionate use program 4 (TLX101-Tx) •Encouraging preliminary efficacy data 5 (TLX101-Tx) •Clinically validated candidates 5,6,7 Orphan Drug Designation, ODD in glioma (U.S. & EU) Competitive advantages TLX101-Tx TLX102-Tx Orphan Drug Designation, ODD in glioma (U.S.) 86
Prior studies have demonstrated favorable safety profile and encouraging efficacy in malignant gliomas
-
Investigator-initiated trial referring to clinical study report (CSR), 2. Across various trials (IPAX-1, IPAX-Linz, IPAX-2, IPAX BrIGHT) and compassionate use program. 3. Telix media release May 19, 2026. Our strategy is to establish clinical proof in later-line disease before expanding into earlier treatment Demonstrated safety and tolerability profile in combination trials with EBRT and TMZ •IPAX-1 (Phase 1), IPAX Linz1 (Phase 2), IPAX-2 (Phase 1), compassionate use program •Treated ~60 patients to date, including pediatric patients 2 •Well tolerated, no DLTs observed in IPAX-2 3 Demonstrated early efficacy results •Median OS of 23mo. (IPAX-1) and 32.2mo. (IPAX-Linz1) from initial diagnosis •Median OS of 13mo. (from initiation of treatment, IPAX-1) and 11.9mo. (from progression prior to start of treatment, IPAX-Linz1) Ongoing trials •Phase 3 trial, IPAX BrIGHT, in combination with lomustine, first recurrence – dosing patients •Phase 1 trial, IPAX-2, in newly diagnosed patients – completed enrollment, awaiting readout 87
-
Europe includes Austria, Belgium, Denmark, France, Germany, Netherlands, Spain where we have regulatory approvals or filings.
-
IND not yet filed. , A global Phase 3 study for TLX101-Tx 88 Data review Conventional MRI and 18 F FET PET used for imaging response Eligible Patients Part 2: Randomized treatment expansion Part 1: Dose optimization •Ages ≥18 years •Confirmed recurrent glioblastoma TLX101-Tx + Lomustine Lomustine Clinicaltrials.gov: NCT07100730 Eligibility: recurrent GBM (WHO 2021), 18 years+ Status: Study open to enrollment in Austria, Australia, Belgium and Netherlands.
Regulatory approval in Denmark, France, Germany, Spain and Singapore. IND filing in U.S. planned next. Global, multi center, prospective, open label study Primary endpoints (Part 1) •Max tolerated dose, MTD and recommended dose for Part 2 Primary endpoint (Part 2) •Overall survival (OS) If combination dose not tolerated, lower either TLX101-Tx dose and/or Lomustine. Mono therapy is an option n = up to 50 Europe Singapore U.S. 1 2 TLX101-Tx (4 GBq) + Lomustine (90 mg/m 2 ) x 3 cycles n = 3 TLX101-Tx (4 GBq) + Lomustine (90 mg/m 2 ) x 3 cycles n = 12 1:1 TM
14 patients with recurrent disease
•10 Glioblastoma (GBM) patients
•2 oligodendroglioma patients (WHO G2)
•1 oligodendroglioma patient (WHO G3)
•1 astrocytoma patient (WHO G2)
Heavily pretreated patients
•all patients received TMZ, 50% received Lomustine, some patients had re-irradiation, re-debulking
Disease stage:
•5 at first recurrences
•9 at second+ recurrences
Median treatment with TLX101-Tx post diagnoses: 22 months (9mo. - 203 mo.)
TLX101-Tx, Compassionate use experience
- Tolboom N. et al. EANM 2025. 2. El Ghalbouni et al. EANO 2026 / EANM 2026., El Ghalbouni et al. EJNMMI 2025, Tolboom et al, CVIR 2024, El Ghalbouni et al. Manuscript pending submission. UMC Utrecht Real-world data from 14 patients 89
Safe and tolerable treatment -Grade 3 adverse events, cerebral edema (1), common for this condition, judged not likely due to TLX101-Tx -No Grade 4 adverse events TLX101-Tx, has demonstrated a favorable safety profile, with stable disease observed Note: Named patient program, UMC Utrecht. MRI RANOPatients Stable disease (SD)3 of 12 Progressive disease (PD) not confirmed7 of 12 Progressive disease (PD) confirmed2 of 12 PET RANOPatients Stable disease (SD)7 of 7 90 Overall, over 23 patients have been treated globally with TLX101-Tx in compassionate use in Austria, Australia, Germany and New Zealand with no Grade 4 adverse events reported
Baseline [
18
F]FET
Case Study 1
GBM, third recurrence (Stupp, re-debulking and Lomustine)
Baseline MRI
MRI after 2 cycles
MR RANO unconfirmed
Progressive Disease
No [
18
F]FET performed
El Ghalbouni et al. Manuscript pending submission.
Patient representative scans – individual results may vary.
OS 11.3 months
91
Patient with recurrent glioblastoma treated with TLX101-Tx Case study 2: Near complete response Patient •56 year old male, with progressive, treatment refractory glioblastoma •Inoperable due to its location •Treatment with TLX101-Tx initiated with 2 cycles of 5 GBqwith 3 cycles of Lomustineas bridging therapy and 2 cycles of TLX101-Tx 5 GBq Key results •Treatment was well tolerated, with no effects on kidney, liver, or bone marrow functions •Tumor response demonstrated ongoing regression •To date, 31mo since biopsy, 23mo sincestarting treatment with TLX101-Tx, his treatment response is ongoing Ghalbouni et al. EJNMMI. 2026. https://doi.org/10.1007/s00259-025-07742-w. Before After Patient representative scans – individual results may vary. Update: After 33 Months 92
Patient representative scans – individual results may vary. Case study 3: Oligodendroglioma Baseline [ 18 F] FET [ 18 F] FET 10 monthslater After3x 5 GBqTLX101 Patient •38-year-old male •Diagnosed 4 years ago •After resection, EBRT+TMZ, PVC and Lomustine •Treatment holiday, due to new seizures Key results •Significant reduction of tumor after 10 months •TLX101-Tx utility is not just limited to glioblastoma 93
IPAX-2, Phase 1 study for TLX101-Tx (newly diagnosed GBM) Met Primary endpoint: Max Tolerated Dose (MTD) of 5GBq x 2cycles + SoC achieved Conventional MRI and [ 18 F]FET PET used for imaging Austria Netherlands n = 12 SoC = Maximal safe resection followed by concomitant EBRT + TMZ and adjuvant TMZ EBRT = external beam radiation therapy, TMZ = temozolomide.
- Post surgical resection and prior to systemic therapy or radiation therapy for GBM. Clinicaltrials.gov: NCT05450744 Global, multi center, open label, single arm study Primary endpoints •Safety and tolerability •Max tolerated dose and recommended dose Dose escalation TLX101-Tx (4 GBq) x2 cycles
- SoC TLX101-Tx (3 GBq) x 2 cycles
- SoC TLX101-Tx (5 GBq) x2 cycles
- SoC Eligibility: newly diagnosed glioblastoma patients 1 Status: Study completed Results: no dose limiting toxicities observed at maximum dose of (5 GBq) x 2 cycles within DLT window (63 days) Next steps: data supports advancement into Phase 2 study 94
TLX102-Tx 211 At
I-APACHE –FIH Study of TLX102-Tx in recurrent GBM Intra-arterial TLX102-Tx ( 211 At) Phase 1 dose escalation in [ 18 F]FET positive first recurrence GBM An Investigator Lead Trial (led by Dr. Braat) - Phase 1 Dose Escalation trial Funding support provided by KWF (Dutch Cancer Society) 211 At can be easily imaged compared to other α-emitters (SPECT phantom of 211 At) 96
Rapidly progressive and uniformly fatal condition: Unmet medical need in Leptomeningeal Disease (LMD) A rapidly progressive disease with limited treatment options Severe neurological morbidity: Limited and poorly effective treatment options: Biological and anatomical barriers to effective therapy: Median survival estimated at 3.8- 5.4 months for LMD from breast cancer, 3-8.7 months for LMD from lung cancer, and ~5.2 months for LMD from melanoma Leptomeningeal disease is an aggressive complication of cancer with a median survival typically measured in weeks to a few months, even with available interventions Diffuse involvement of the leptomeninges leads to multifocal neurological deficits including cognitive decline, cranial nerve dysfunction, seizures, and loss of functional independence Current approaches (intrathecal chemotherapy, focal radiotherapy, or systemic therapy) provide modest and transient benefit, are often poorly tolerated, and rarely achieve durable disease control The blood–CSF barrier, diffuse tumor spread, and microscopic disease burden limit drug delivery and therapeutic efficacy, highlighting the need for targeted, CNS-penetrant treatment strategies 97
Leptomeningeal disease –LAT-1 expression confirmed with [18F]-FET 4th recurrence PXA in 16 year old girl with leptomeningeal spread ? Patient representative scans – individual results may vary. 98
Pixclara Mr. Kevin Richardson CEO, Precision Medicine
100 MAA = Marketing authorization application. EANM = European Association of Nuclear Medicine. EANO = European Association of Neuro-Oncology. RANO = Response Assessment in Neuro-Oncology. SNMMI = Society of Nuclear Medicine and Molecular Imaging.
- Launch and brand names subject to final regulatory approval. 2. ASX release July 20, 2026. 3. Telix ASX disclosure September 14, 2026. 4. Telix ASX disclosure October 6, 2020. •Pixlumi ®1 MAA accepted in Europe •Included in National Comprehensive Cancer Network (NCCN ® ) guidelines •Inclusion in International guidelines: EANM/EANO/RANO/SNMMI •Expanding into new indication: brain metastases 2 •Addresses high unmet need – helps to differentiate tumor progression vs. treatment effects 3 •Granted orphan drug designation 4 First-in-class imaging agent approved for glioma 1 First FDA approved imaging agent for gliomas (U.S.)
Pixclara positioned for successful launch Insights based Shoreline Research, Awareness trial andutilizationreport,January 2026. Key Market Insights ~70% of physicians surveyed indicated they are ready to prescribe Pixclara upon FDA approval ~80% of referrers rely on NCCN guidelines when ordering imaging for glioma >90% availability of PET scanners in-house Majority of referrers rank high differential uptake in glioma and high image quality as the most important features of a PET radio tracer Strong existing awareness of Pixclara among prescribers 101
21,200 Scans (11k patients) Characterization of Progression in Glioma Patients$106M 16,800 Scans (16k patients) Radiation Planning in adult Glioma Patients$84M 100,000 Scans (49k patients) Characterization of Brain Metastasis$500M 8,100Second line recurrent IDH-wild type glioblastoma$1.2B 10,910First-line IDH-wild type glioblastoma$1.6B $3.5B opportunity in Neuro-Oncology U.S. TAM (Patients) Target Indication USD $ Therapeutics Precision Medicine Source: Datamonitor, Clarivate, internal estimates. Total Addressable Market (TAM) for Precision Medicine uses $5,000/scan for modelling purposes. Therapeutics candidates are using $150,000/treatment based on commercial benchmarks/Datamonitor. These price points do not reflect the actual price charged or the price that Telix will charge in the future. Note: Intended for investor audience only. The FDA has approved Pixclara for use in positron emission tomography (PET) to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older. Not intended to advertise or promote this indication, or any other use or indication. $3.5B 102
Dr. David N. Cade Group Chief Medical Officer, CMO TLX400-Tx
•FAP present on more than 90% of epithelial cancers, identified as a potential target for molecular imaging and therapy •Broad expression on tumor stroma across solid tumors (including pancreatic, colorectal, breast, bladder) suggests pan- tumor potential •In certain cancers (e.g., sarcoma, ovarian, pancreatic) FAP also expressed on cell surface, potentially enhancing efficacy •Not expressed in most normal adult tissues TLX400-Tx- Broad FAP expression supports pan-cancer potential Source: Kratochwil et al. J Nucl Med. 2019. 104 Payload: 177 Lu T 1/2 : 6.7 days 68Ga-TLX400 imaging agent After treatment with TLX400-Tx (4 cycles) Patient representative scan – individual results may vary. TLX400-Tx
Dataset: Clinical data available inpatients across multiple cancer types Safety: Treatment is well tolerated even in late- stage patients with poor prognosis Low Normal Organ Uptake: Dosimetry data 7
shows low normal organ uptake which enables
the administration of higher radiation doses than
most competitor products
Efficacy:
•Encouraging tumor responses (>50% disease
control rate across multiple tumor types)
•Encouraging overall survival (OS) and
progression free survival (PFS) that compare
favorably to existing standard of care
treatments in earlier stage patients
TLX400-Tx: High level of clinical confidence
Clinical benefit reported across multiple indications and in treatment refractory patients
CancerPatients (#)Median OS/PFSTumour Response
RR-Thyroid
Cancer
1
15
OSPFSCRPRSDN/A
NRNR0%27%20%53%
Medullary Thyroid
2
19
OSPFSCRPRSDPD
42 mo26 mo0%33%47%20%
RAI-R Follicular
Thyroidcarcinoma
(FTC)
3,5
73
OSPFSCRPRSDPD
32 mo29 mo
0%
(0/36)
50%
(18/36)
25%
(9/36)
25%
(9/36)
Breast
4,6
19
OSPFSCRPRSDPD
12 mo8.5 mo0%25%37%37%
Sarcoma
8
10
OSPFSCRPRSDPD
7 mo6 mo0%20%40%40%
NR = Not reached, CR = Complete response, PR = Partial response, SD = Stable disease, PD = Progressive disease
- Ballal et al., Thyroid, 2022. 2. S. Ballal, ICPO Theranostics Summit 2024 & Ballal et al., EJNMMI 2026. 3. Ballal et al, Thyroid 2025. 4. Yadav et al, 2023 EJNMMI. 5. Molecular response using [68Ga]Ga- DOTA.SA.FAPi was assessed in 36 of the 73 patients. 6. Molecular response using [68Ga]Ga-DOTA.SA.FAPi was assessed in 16 of the 19 patients. 7. Kurth el a., SNMMI 2024 Poster No. 242022. 8. Ballal et al., J. Nuc. Med. 2025. 105
TLX400-Tx, Case study in breast cancer 54-year-old breast cancer patient treated with TLX400-Tx after multiple lines of prior therapy 1 106
- Source: Yadav et al. Eur J Nucl Med Mol Imaging. 2024. Significant reduction in disease burden Clinical data Patient Patient representative images, individual results may vary. Baseline scan Follow up scan post 4 cycles of TLX400-Tx Follow up scan post 5 cycles of TLX400-Tx Imaging: FDG FAP FDG FAP FAP
TLX400-Tx, in 19 patients with thyroid cancer 1 107 1.BallalS., PriyankaG.B., YadavM.P.etal. Longterm outcomes in medullary thyroid cancer patients treated with [177Lu] Lu-DOTAGA.FAPi dimer therapy. EJNMMI Res (2026). 2.Adapted from Sanjana Ballal, ICPO Theranostics Summit 2024 using RECIST 1.1. 3.Radiological and molecular imaging response was assessed in 15 out of 19 patients, as four patients did not have follow-up imaging available for evaluation. Patient representative images, individual results may vary. Feb 2022 Oct 2022 May 2023 May 2024 Partial Response in patient treated with TLX400-Tx 2
Eligibility: FAP positive medullary thyroid cancer (MTC) Treatment: ¹⁷⁷Lu LuDOTAGA.Glu.(FAPi)₂ or ²²⁵Ac-DOTAGA.Glu.(FAPi)₂, receiving a median of 5 cycles Imaging: FDG FAP FAP FAP FAP OutcomeResult Medullary thyroid cancer (total)19 patients Assessable for radiological response 3 15 patients Partial response (PR)5 patients (33%) Stable disease (SD)7 patients (47%) Progressive disease (PD)3 patients (20%) Disease control rate (DCR)80% Median PFS26 months Median OS42 months
Mr. Richard Valeix CEO, Therapeutics TLX66-Tx TLX300-Tx
TLX66-Tx: Investigator Initiated Trial FDA and EMA Orphan Drug Designation granted forTLX66-Tx for bone marrow conditioning. 1.ClinicalTrials.org: NCT0485621. Payload: 90 Y T 1/2 : 2.66 days TLX66-Tx, 90 Y-DTPA-besilesomab Targeting molecule / target: Monoclonal Antibody/ CD66 Mechanism of Action • 90 Y-DTPA-besilesomab binds myeloid precursors expressing CD66 in the marrow •Mid-to-long range beta crossfire ablates the adjacent stem-cell niche •May directly contribute to anti-tumor activity Potential indication(s) Bone marrow conditioning for HSCT; priority indication: alloHSCT in high risk acute myeloid leukemia (AML) patients Value to patients Targeted conditioning with TLX66-Tx will enable myeloablation for HSCT without high intensity chemo (HIC) regimen
Strategic ambition Replace HIC as the standard conditioning regimen across HSCT – from high-risk AML to non-malignant and non-oncology indications Ongoing IIT clinical activities Phase 2 Investigator Initiated Trial in pediatric high-risk leukemia atGreat Ormond Street Hospital in London, UK 109
TLX66-Tx has been tested in >90 patients (including pediatric patients) across a range of hematological malignancies. Completed studies include: •Phase 1: Dose-escalation study in hematological malignancies (n=55 pts) •Phase 1: Study in pediatric relapsed/refractory leukemia (n=9 pts) •Phase 2: A randomized Ph2 study in multiple myeloma (n=24 pts) Safety •TLX66 was well tolerated in adult patients across multiple haematological malignancies, with no detectable non-hematological toxicities (eg mucositis/colitis) •In pediatric patients (aged 4 – 16 years), TLX66-Tx was well-tolerated with no serious toxicities Efficacy •All patients engrafted •Encouraging increases in relapse free and overall survivalwere observed relative to historical data. Overall survival >10 years was seen in most adult patients 1 Extensive clinical data in >90 patients across multiple malignancies Excellent safety profile and encouraging long-term efficacy signals
- Orchard EBMT Presentation 2026. Encouraging long-term survival in high-risk AML, MM, CML and B-ALL patients (OS >10 years in most patients) 1 110
Name: ZOLAR imaging study Description: Evaluate the safety, pharmacokinetics, biodistribution and dosimetry of 89 Zr-labelled- olaratumab Phase: 1 (dosimetry) Primary endpoints: •Adverse events (AEs), /Serious Adverse events (SAEs) •Evaluate uptake of 89Zr- labelled-olaratumabwithin tumors and normal organs Clinical Trial Olaratumab TLX300-Tx: Program overview ClinicalTrials.gov ID: NCT06537596 1.Telix ASX disclosure April 11, 2022. 2.TapW.D., JonesR.L., VanTineB.A., etal. Olaratumab plus doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase1b and randomized phase2 trial. Lancet. 2016. Targeting molecule / target: •Antibody (olaratumab)/ •Platelet-derived Growth Factor Receptor alpha (PDGFRα) Potential indication(s) Advanced metastatic Soft Tissue Sarcoma (STS), other PDGFRα expressing tumors Clinical experience •Olaratumab was in-licensed from Eli Lilly and Company with exclusive rights to develop as a radiopharmaceutical 1 •657 STS patients have been treated with olaratumab (across Ph 1b/2 and Ph 3 trials). Clinical safety profile was favorable 2 TLX300-Tx 89 Zr (imaging isotope) 111
Dr. Christian Behrenbruch Managing Director and Group CEO Closing Remarks
A proven leader in Radiopharma innovation and execution 1.Subject to close of transaction, the transaction with ITM is expected to close in FY2026 subject to Telix Shareholder approval, regulatory approvals, and other customary closing conditions. ~$1B Estimated 2026 sales 3 Approved products on market 22 countries Illuccix available 4 Pivotal trials near readout Diversified, de-risked pipeline •PSMA, CAIX, LAT1 and FAP targets •New targets in GEP-NETs, 1 lung and other areas •R&D platform leading next- generation targeting Vertically integrated leadership •Established a vertically integrated radiopharma industry leader •World-class radioisotope production secures supply at scale •Global footprint supporting commercial delivery worldwide Transformational growth engine •Transactions and partnerships accelerating entry into therapeutics •Proven ability to advance assets from development to regulatory approval •Radiopharmaceuticals positioned to transform standards of care Proven commercial execution, a deep and diversified pipeline and integrated supply — positioned to lead the next decade of radiopharmaceuticals 113
Invitation from the Chair Dear Shareholder On behalf of the Board of Directors, I am pleased to invite you to attend a General Meeting (Meeting) of Telix Pharmaceuticals Limited (Telix), relating to the proposed transaction of Telix and ITM Isotope Technologies Munich SE (ITM), a global leader in radioisotope production and radiopharmaceutical development. As announced on September 21, 2026, Telix has entered into a strategic agreement (the Transaction) to acquire 100% of the shares in ITM for total upfront consideration valued at US$1.65 billion on a cash-free/debt-free basis (as further described in the Explanatory Notes below) and additional contingent consideration of up to US$700 million upon achievement of future regulatory approvals and commercial sales milestones for ITM-11, ITM’s lead therapy candidate for the treatment of neuroendocrine tumors. The Transaction has been unanimously approved by Telix’s Board of Directors and, as of the date of this letter, has been agreed to by shareholders holding over 93% of ITM’s shares1. The Meeting is being held to seek Shareholder approval for certain matters related to the Transaction and will be convened at 10:00 a.m.
Appendix 2A - Application for quotation of securities 1 / 6 Announcement Summary Entity name TELIX PHARMACEUTICALS LIMITED Announcement Type New announcement Date of this announcement Wednesday October 28, 2026 The +securities to be quoted are: Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.
Shares issued under the Telix Non-Executive Director Rights Plan Rules - Australia. Refer to Equity Incentive Plan Rules at governance/documents-charters for Non-Executive Director Rights Plan Rules as referencedhttps://ir.telixpharma.com/ in 2025 Remuneration Report (Appendix 4E and 20-F, February 2026), section 5.1.athttps://www.sec.gov/Archives/edgar/ data/2007191/000162828026009887/a20260220appendix4eand20.htm Total number of +securities to be quoted ASX +security codeSecurity description Number of +securities to be quotedIssue date TLXORDINARY FULLY PAID1,09529/10/2026 Refer to next page for full details of the announcement Other
Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 2 / 6 Part 1 - Entity and announcement details 1.1 Name of entity TELIX PHARMACEUTICALS LIMITED We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules. 1.2 Registered number type ACN Registration number 616620369 1.3 ASX issuer code TLX 1.4 The announcement is 1.5 Date of this announcement 28/10/2026 New announcement
Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 3 / 6 Part 2 - Type of Issue 2.1 The +securities to be quoted are: Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue. 2.2 The +class of +securities to be quoted is: 2.3c Have these +securities been offered under a +disclosure document or +PDS? 2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B Shares issued under the Telix Non-Executive Director Rights Plan Rules - Australia. Refer to Equity Incentive Plan Rules at governance/documents-charters for Non-Executive Director Rights Plan Rules as referencedhttps://ir.telixpharma.com/ in 2025 Remuneration Report (Appendix 4E and 20-F, February 2026), section 5.1.athttps://www.sec.gov/Archives/edgar/ data/2007191/000162828026009887/a20260220appendix4eand20.htm 2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of: Not applicable - the entity has arrangements in place with the holder that ensure the securities cannot be on-sold within 12 months in a manner that would breach section 707(3) or 1012C(6) No Additional +securities in a class that is already quoted on ASX ("existing class") Other
Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 4 / 6 Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B Additional +securities to be quoted in an existing class ASX +security code and description TLX : ORDINARY FULLY PAID Issue date 29/10/2026 Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class? Issue details Number of +securities to be quoted 1,095 Are the +securities being issued for a cash consideration? In what currency is the cash consideration being paid? AUD - Australian Dollar What is the issue price per +security? AUD 16.43520000 Any other information the entity wishes to provide about the +securities to be quoted The purpose(s) for which the entity is issuing the securities Other Please provide additional details Shares issued under the Telix Non-Executive Director Rights Plan Rules - Australia. Refer to Equity Incentive Plan Rules at governance/documents-charters for Australian employee participants and Non-Executivehttps://ir.telixpharma.com/ Director Rights Plan Rules as referenced in 2025 Remuneration Report (Appendix 4E and 20-F, February 2026), section 5 .1.athttps://www.sec.gov/Archives/edgar/data/2007191/000162828026009887/a20260220appendix4eand20.htm Yes Yes
Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 5 / 6 Part 4 - Issued capital following quotation Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise: The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing. 4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application) ASX +security code and description Total number of +securities on issue TLX : ORDINARY FULLY PAID340,331,480 4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX) ASX +security code and description Total number of +securities on issue TLXAY : DEFERRED SHARE RIGHTS66,140 TLXAX : DEFERRED SHARE RIGHTS EX-US87,649 TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL15,000 TLXAZ : SHARE RIGHTS US430,742 TLXAR : PERFORMANCE RIGHTS9,965,235 TLXAP : SHARE RIGHTS1,080,000 TLXAO : SHARE APPRECIATION RIGHTS14,386,513 TLXAT : CONVERTIBLE NOTES6,250 TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL100,000 TLXAU : DEFERRED SHARE RIGHTS EX-US 20246,575 TLXAW : PERFORMANCE SHARE APPRECIATION RIGHTS US 20258,298,175 TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS440,000
Appendix 2A - Application for quotation of securities Appendix 2A - Application for quotation of securities 6 / 6 Part 5 - Other Listing Rule requirements 5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1? 5.1a Select the number of the applicable exception in Listing Rule 7.2 13 Yes
Appendix 3Y Change of Director’s Interest Notice
- See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity Telix Pharmaceuticals Limited ABN 85 616 620 369
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director Dr Christian Behrenbruch Date of last notice 1 June 2026
Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
Direct or indirect interest
Direct
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change 26 October 2026 No. of securities held prior to change Direct interest: • 654,006 fully paid ordinary shares (including 400,000 American Depository Shares (each representing 1 ordinary share) in Telix Pharmaceuticals Limited). • 93,114 PSARs (notional exercise price $4.95) (TLXO012 – TLXAO) issued following shareholder approval at the AGM held 18 May 2022. • 100,223 PSARs (notional exercise price $6.90) (TLXO015 – TLXAO) issued following shareholder approval at the AGM held 24 May 2023. • 144,037 PSARs (notional exercise price $11.94) (TLXO024 – TLXAO) issued
Appendix 3Y Change of Director’s Interest Notice
- See chapter 19 for defined terms.
Appendix 3Y Page 2 01/01/2011
following shareholder approval at the AGM held 22 May 2024. • 166,483 PSARs (notional exercise price $28.67) (TLXO030 – TLXAO) issued following shareholder approval at the AGM held 21 May 2025. • 2,595 SRs (Nil exercise price) (TLXO031 – TLXAU) issued following shareholder approval at the AGM held 21 May 2025. • 339,845 PSARs (notional exercise price $13.43) issued following shareholder approval at the AGM held 21 May 2026 • 27,121 SRs issued following shareholder approval at the AGM held 21 May 2026 38,750
Indirect interest: • 20,742,935 fully paid ordinary shares (Elk River Holdings Pty Ltd as Trustee for The Behrenbruch Family Trust).
Class Ordinary Shares Number acquired
38,750 Ordinary Shares
Number disposed
NIL
Value/Consideration
Note: If consideration is non-cash, provide details and estimated
valuation
$12.8935 per Ordinary Share
Appendix 3Y Change of Director’s Interest Notice
- See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 3 No. of securities held after change
Direct interest • 654,006 fully paid ordinary shares (including 400,000 American Depository Shares (each representing 1 ordinary share) in Telix Pharmaceuticals Limited). • 93,114 PSARs (notional exercise price $4.95) (TLXO012 – TLXAO) issued following shareholder approval at the AGM held 18 May 2022. • 100,223 PSARs (notional exercise price $6.90) (TLXO015 – TLXAO) issued following shareholder approval at the AGM held 24 May 2023. • 144,037 PSARs (notional exercise price $11.94) (TLXO024 – TLXAO) issued following shareholder approval at the AGM held 22 May 2024. • 166,483 PSARs (notional exercise price $28.67) (TLXO030 – TLXAO) issued following shareholder approval at the AGM held 21 May 2025. • 2,595 SRs (Nil exercise price) (TLXO031 – TLXAU) issued following shareholder approval at the AGM held 21 May 2025. • 339,845 PSARs (notional exercise price $13.43) issued following shareholder approval at the AGM held 21 May 2026 • 27,121 SRs issued following shareholder approval at the AGM held 21 May 2026 Indirect interest • 20,781,685 fully paid ordinary shares (Elk River Holdings Pty Ltd as Trustee for The Behrenbruch Family Trust). Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back On-market purchase on ASX
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
Detail of contract N/A Nature of interest
N/A
Appendix 3Y Change of Director’s Interest Notice
- See chapter 19 for defined terms.
Appendix 3Y Page 4 01/01/2011
Name of registered holder (if issued securities)
N/A
Date of change
N/A
No. and class of securities to which
interest related prior to change
Note: Details are only required for a
contract in relation to which the
interest has changed
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
Note: If consideration is non-cash,
provide details and an estimated
valuation
N/A Interest after change N/A
Part 3 – + Closed period
Were the interests in the securities or contracts detailed above
traded during a +closed period where prior written clearance
was required?
No
If so, was prior written clearance provided to allow the trade to
proceed during this period?
N/A
If prior written clearance was provided, on what date was this
provided?
N/A
Appendix 3Y Change of Director’s Interest Notice
- See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Rule 3.19A.2 Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11
Name of entity Telix Pharmaceuticals Limited ABN 85 616 620 369
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director David Gill Date of last notice 25 September 2026
Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
Direct or indirect interest Direct Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change 23 October 2026 (US time) No. of securities held prior to change 30,048 Share Appreciation Rights (SARs) 22, 000 ADS Class TLX American Depositary Share (ADS) each representing one ordinary share Number acquired 3,250 Number disposed NIL Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation US$9.194 per ADS
Appendix 3Y Change of Director’s Interest Notice
- See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 2
No. of securities held after change 30,048 SARs 25,250 ADS Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back Nasdaq on market trade (NASDAQ:TLX).
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
Detail of contract N/A Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A Date of change N/A No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
N/A Interest acquired N/A Interest disposed N/A Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
N/A Interest after change N/A
3 – + Closed period Part
Were the interests in the securities or contracts detailed above traded during a + closed period where prior written clearance was required? No If so, was prior written clearance provided to allow the trade to proceed during this period? N/A If prior written clearance was provided, on what date was this provided? N/A
Appendix 3Y Change of Director’s Interest Notice
- See chapter 19 for defined terms. 01/01/2011
Appendix 3Y Page 1
Rule 3.19A.2 Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11
Name of entity Telix Pharmaceuticals Limited ABN 85 616 620 369
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director William Jellison Date of last notice 1 June 2026 William R Jellison & Joanne S Jellison Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
Direct or indirect interest Direct Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change 22 October 2026 (US time) No. of securities held prior to change 21,597 Share Appreciation Rights (SARs)
Class TLX American Depositary Share (ADS), each
representing one ordinary share
Number acquired 25,000 ADS held jointly by William R Jellison & Joanne
S Jellison
Appendix 3Y Change of Director’s Interest Notice
- See chapter 19 for defined terms. 01/01/2011
Appendix 3Y Page 2
Number disposed NIL Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation US$9.4931 per share
No. of securities held after change 21,597 SARs 25,000 ADS held jointly by William R Jellison & Joanne S Jellison. Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back Nasdaq on market trade (NASDAQ:TLX).
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
Detail of contract N/A Nature of interest
N/A
Name of registered holder
(if issued securities)
N/A Date of change N/A No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
N/A Interest acquired N/A Interest disposed N/A Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
N/A Interest after change N/A
3 – + Closed period Part
Appendix 3Y Change of Director’s Interest Notice
- See chapter 19 for defined terms. 01/01/2011
Appendix 3Y Page 3
Were the interests in the securities or contracts detailed above traded during a + closed period where prior written clearance was required? No If so, was prior written clearance provided to allow the trade to proceed during this period? N/A If prior written clearance was provided, on what date was this provided? N/A
Telix Reports Third Quarter 2026 Financial Performance Melbourne (Australia) and Indianapolis, IN (U.S.) – October 21, 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a financial update on its commercial and operational performance for the quarter ended September 30, 2026 (Q3 2026). Q3 2026 Highlights1 • Group revenue of US$245 million increased 19% over the prior corresponding quarter (Q3 2025) driven by continued strong demand for the commercial portfolio, in line with expectations. September sales drove a higher quarterly exit rate indicating continued strength in underlying demand for Telix's PSMA products. • Precision Medicine revenue of US$201 million, increased 30% over the prior corresponding quarter, driven by both Gozellix® and Illuccix®2. Telix's commercial PSMA-PET imaging3 portfolio continued to strengthen its market position, driven by strong demand for our clinically differentiated products. • U.S. Food and Drug Administration (FDA) approved Pixclara®4 for glioma imaging, marking a significant milestone and establishing the first approved imaging agent for this indication in the U.S.5.
Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia ASX ANNOUNCEMENT Page 1 Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging • FDA Fast Track designation granted for Telix’s BiPASS® program, which is evaluating 68Ga-PSMA-PET imaging alongside MRI in the pre-biopsy prostate cancer setting. • The designation recognizes the program’s potential to address an important unmet need by enabling an imaging-first approach to initial prostate cancer diagnosis. • Fast Track facilitates more frequent engagement with the FDA and may enable expedited review of the planned NDA. Melbourne (Australia) and Indianapolis, IN (U.S.) – September 30, 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s BiPASS® program. BiPASS (Biopsy of the Prostate Avoidance Stratification Study1) is evaluating gallium-68 (68Ga) PSMA-PET imaging2 in combination with MRI3 for the detection of prostate cancer prior to biopsy.
2 Disclaimer and forward-looking statements Notices: This presentation should be read together with Telix Pharmaceuticals Limited’s (Telix) risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. This presentation is for informational purposes only and does not constitute an offer to sell, or the solicitation of any offer to buy any securities of Telix or ITM Isotope Technologies Munich SE (ITM) in any jurisdiction, including the United States, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The American Depositary Shares to be issued by Telix as consideration in the transaction have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (Securities Act), and are being issued in reliance on exemptions from registration, including Rule 802 under the Securities Act (and Regulation S and/or Regulation D, as applicable).
Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia ASX ANNOUNCEMENT Page 1 Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse • Transformational merger reinforces Telix’s long-term growth strategy as a vertically integrated radiopharmaceutical company with enhanced capabilities across development, isotope production and global manufacturing, underpinned by commercial excellence and the industry’s most extensive therapeutic pipeline. • ITM is the world’s leading supplier of therapeutic radioisotopes, with broad capabilities spanning lutetium-177 (177Lu), actinium-225 (225Ac) and terbium-161 (161Tb) production. • ITM is the only producer of globally scaled commercial-grade 177Lu and serves as a key supplier for both commercially available and future therapeutic radiopharmaceuticals. • ITM’s commercial-scale and profitable isotope production business significantly contributes to cash generation while deepening Telix’s supply chain for isotopes required for its therapeutics pipeline.
Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia ASX ANNOUNCEMENT Page 1 FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara • Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer). • Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related change in adults and pediatric patients. • FET-PET imaging is recommended in international clinical practice guidelines, including NCCN Guidelines®. • Pixclara expands Telix’s industry-leading Precision Medicine business and reinforces the Company’s leadership in diagnostics and targeted radiopharmaceutical therapies (together, “theranostics”). Melbourne (Australia) and Indianapolis, IN (U.S.) – September 14, 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).
Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia ASX ANNOUNCEMENT Page 1 Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway • The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients. • Telix has positively engaged with the FDA on a New Drug Application (NDA) pathway in the U.S. that would support new product reimbursement and broaden access to 68Ga-PSMA- PET imaging across a significantly larger patient population. • BiPASS is designed to evaluate the diagnostic performance of 68Ga-PSMA-11 PET combined with MRI for the detection of prostate cancer prior to biopsy. Melbourne (Australia) and Indianapolis, IN (U.S.) – September 2, 2026.
Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia ASX ANNOUNCEMENT Page 1 Telix Appoints David Gill as Chair • David Gill appointed Chair of the Telix Board, effective immediately. • Mr. Gill joined Telix as a Non-Executive Director in May 2026, with the intention that he would become Chair. • Dr. Mark Nelson will continue to serve on the Board as a Non-Executive Director, having served as interim Chair. Melbourne (Australia) and Indianapolis, IN (U.S.) – September 1, 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix” or the “Company”) today announces that David Gill has been appointed Chair of the Board, effective immediately. Mr. Gill joined Telix as a Non-Executive Director in May 2026 as part of the Company’s Board expansion and succession planning1, with the intention that he would be appointed Chair in due course. He succeeds Dr. Mark Nelson, who has served as interim Chair and will remain on the Board as a Non-Executive Director. Mr.
Gozellix®. As the Company advances toward near-term regulatory milestones and progresses a promising pipeline of
therapeutic candidates, these strategic investments in our late-stage candidates are positioning Telix to deliver its next
phase of growth and make a meaningful difference to patients' lives, underpinned by a resilient and diversified business
model with multiple revenue streams.
Our operations have been financed primarily through cash generated by our commercial operations and the issuance of
Ordinary Shares and Convertible Bonds.
Reported profit after tax attributable to Telix Shareholders was $38.3 million for the period ended June 30, 2026,
compared to a loss of $2.3 million for the period ended June 30, 2025. The net profit reflects the impact of income on
entering our strategic collaboration with Regeneron, and continued success in our commercial businesses, allowing us to
increase investment in our Therapeutic pipeline.
Our total comprehensive income was $9.5 million for the period ended June 30, 2026, compared to $3.3 million for the
period ended June 30, 2025.
Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne, Victoria, 3051 Australia Appendix 4D Half-year ended June 30, 2026 Results announcement to the market Current Reporting Period: June 30, 2026 Previous Reporting Period: June 30, 2025 This page and the following pages comprise the half-year information given to the ASX under Listing Rule 4.2A. The results are prepared in accordance with International Financial Reporting Standards (IFRS), and also comply with Australian Accounting Standards. Amounts are presented in US dollars (US$). Revenue and net profit/(loss) 6 months to June 30, 2026 Change Change Change 6 months to June 30, 2025 US$'000 US$'000 % US$'000 Revenue from contracts with customers 477,350 Up 86,991 22 390,359 Profit/(loss) after income tax for the year attributable to members 38,330 Up 40,622 1,772 (2,292) Total comprehensive income for the period attributable to members 9,458 Up 6,203 191 3,255 No dividend was proposed or paid. Should any dividends be paid in the future, no assurances can be given as to the level of franking credits attaching to such dividends.
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress Melbourne (Australia) and Indianapolis, IN (U.S.) – July 21, 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026). Q2 2026 Highlights1 • Group revenue of US$247 million, up 7% quarter-over-quarter (QoQ) and up 21% year-over- year (YoY). • Precision Medicine continues to deliver strong growth, revenue of US$202 million, up 9% QoQ and up 30% YoY. • Telix expects FY 2026 revenue and other income to be in excess of US$1 billion, with revenue tracking in line with the upper end of FY 2026 guidance of US$950 million to US$970 million plus US$40 million non-refundable other income received from Regeneron. • United States (U.S.) Food and Drug Administration (FDA) alignment on ProstACT Global Phase 3 study of TLX591-Tx in mCRPC2 to advance to Part 2 in the U.S.3 • BiPASSTM, patient enrollment nearing completion for study of Illuccix® and Gozellix® for initial prostate cancer diagnosis in the pre-biopsy setting4.
Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia ASX ANNOUNCEMENT Page 1 FDA Alignment to Advance ProstACT Global Phase 3 Trial • FDA and Telix align on advancement into Part 2 of the ProstACT Global Phase 3 study in the United States. • FDA agrees with the clinical protocol and proposed statistical framework across three standard-of-care combination cohorts. • Part 2 (randomized cohort) continues to recruit in jurisdictions where the study has regulatory approval. MELBOURNE, Australia and INDIANAPOLIS, July 2, 2026 -- Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX, “Telix”) today announced the successful outcome of a Type B meeting with the United States (U.S.) Food and Drug Administration (FDA) to review the Part 1 safety and dosimetry data and Part 2 protocol design of the ProstACT Global Phase 3 trial of its therapeutic candidate TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan) in metastatic castration resistant prostate cancer. The FDA has confirmed that the safety data from Part 1 of the study is sufficient to enable progression of Part 2 of ProstACT Global into the U.S.
Precision Medicine near-term growth strategy PSMA portfolio provides platform for growth, potential upside from new product launches Successful Type A meetings completed to align with FDA on key resubmission items ZIRCON-X study showed TLX250-Px imaging has meaningful impact on clinical decisions4 Commercially available in 22 countries1 Pursuing further geographic expansion in China (NDA accepted)2 and Japan (Phase 3 study dosing patients)3 MAA filed for TLX101-Px in Europe and NDA accepted by U.S. FDA, assigned PDUFA goal date September 11, 20265 In a survey of 100 physicians (U.S.), ~70% indicated they are ready to prescribe Pixclara upon FDA approval6 Successful launch (U.S.) BiPASS™, Phase 3 study launched and recruiting rapidly – will support significant market expansion for Illuccix and Gozellix Austria, Czech Republic, Italy, Slovakia, Switzerland, UK, France, Germany, Spain, Portugal, Belgium, Luxembourg, Netherlands, Denmark, Sweden, Finland, Norway, Australia, New Zealand, Brazil, U.S. and Canada. Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) accepted the filing of a NDA, Telix ASX disclosure January 20, 2026.
Melbourne (Australia) and Indianapolis, IN (U.S.) – April 14, 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) (“Telix”) today launches an offering of US$550 million convertible notes due 2031 to be issued by its wholly-owned subsidiary, Telix Pharmaceuticals (Investments) Inc. (the “Issuer”), and guaranteed by Telix and Telix Pharmaceuticals (US) Inc. (the “Offering”). The convertible notes, also referred to as “convertible bonds” (“Convertible Bonds”), are convertible into fully paid ordinary shares in Telix (“Ordinary Shares”).
Managing Director and Group CEO, Dr. Christian Behrenbruch, said: “The refinance of the existing Convertible Bonds represents our proactive approach to capital management. The new Convertible Bonds will continue to provide the business with cost effective financing.”
The new Convertible Bonds represent attractive, low-cost financing to Telix and are non-dilutive until any potential future conversions occur. The initial conversion price will be at a premium to Telix’s current share price.
Melbourne (Australia) and Indianapolis, IN (U.S.) – April 14, 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) (“Telix”) is pleased to announce that it has successfully priced and upsized its 1.50 per cent convertible notes due 2031 to be issued by its wholly-owned subsidiary, Telix Pharmaceuticals (Investments) Inc. (the “Issuer”), and guaranteed by Telix and Telix Pharmaceuticals (US) Inc. from US$550 milion to US$600 milion due to strong demand (the “Offering”). The convertible notes, also referred to as “convertible bonds” (“Convertible Bonds”), are convertible into fully paid ordinary shares in Telix (“Ordinary Shares”). The Offering received strong support from eligible investors globally.
The initial conversion price of the Convertible Bonds is US$13.85 (~A$19.55) per Ordinary Share, which represents a conversion premium of 37.5 per cent over the reference share price (A$14.22 per Ordinary Share), subject to anti-dilution adjustments set out in the final terms and conditions of the Convertible Bonds.
The Convertible Bonds will bear interest at a rate of 1.50 per cent per annum.
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of April, 2026
Commission File Number: 001-42128
North Melbourne, Victoria 3051, Australia
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-
F.
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On April 10, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited filed an announcement with the
Australian Securities Exchange titled “FDA Accepts NDA for TLX101-Px (Pixclara®) ” a copy of which is attached
to this Form 6-K as Exhibit 99.1.
The information contained in this Form 6-K, except for (i) the commentary in Exhibit 99.1 appearing in the third,
fourth and fifth paragraphs on page 1 and (ii) information accessible by hyperlinks included therein, is incorporated
by reference into our Registration Statement on Form F-3ASR (File No. 333-293611) and Registration Statement on
Form S-8 (File No. 333-283917).
Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia ASX ANNOUNCEMENT Page 1 Telix Strengthens Board with Additional Director Appointments Melbourne (Australia) and Indianapolis, IN (U.S.) – April 9, 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces two additional Non-Executive Director (NED) appointments, effective May 11, 20261, as part of Board expansion and succession planning: • Maria Rivas, MD is an experienced public company board director and S&P 100 senior pharmaceutical executive with more than 25 years’ experience in late-stage clinical development, commercialization and governance leadership. Dr. Rivas currently serves on the board of directors of The Cooper Companies, Inc. (NASDAQ: COO), a medical technology company, and also served as an independent director for Medidata (NASDAQ: MDSO) from 2018-2019 until its successful merger with Dassault Systèmes. Dr.
7 Primarily sales of Illuccix and Gozellix in our Precision Medicine business.
8 Telix Manufacturing Solutions (TMS) third-party revenue predominantly driven by RLS Radiopharmacies (RLS),
excludes Illuccix and Gozellix sales and TMS inter-segment revenue. Q1 2025 includes RLS revenue contribution since
acquisition close on January 28, 2025.
Page 1
North Melbourne
Victoria, 3051
Australia
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline
Advancement
Melbourne (Australia) and Indianapolis, IN (U.S.) – April 7, 2026. Telix Pharmaceuticals Limited
(ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational
performance for the quarter ended March 31, 2026 (Q1 2026).
Q1 2026 Highlights
•Q1 2026 unaudited Group revenue of US$230 million, up 11% quarter-over-quarter.
•FY 2026 revenue guidance of US$950 million to US$970 million is reaffirmed.
•Precision Medicine Q1 2026 unaudited revenue of US$186 million, up 16% quarter-over-
quarter. Strong revenue growth in both Illuccix® and Gozellix® segments.
Melbourne (Australia) and Indianapolis, IN (U.S.) – April 2, 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 20261. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as a NED.
Mr. Gill is a life sciences executive with over 35 years’ experience in senior general management and financial leadership roles across commercial and clinical-stage biopharmaceutical (including radiopharmaceuticals) and medical device companies. He currently serves on the boards of Evolus, Inc. (NASDAQ: EOLS), Allucent LLC, Bridge to Life Ltd, RapidPulse Inc. and huMannity Medtec (formerly Alfred Mann Foundation), and was until recently a board member of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), Strongbridge Biopharma plc (NASDAQ: SBBP), Alpha Source Inc, Healthtronics, Inc, and Perimetrics, LLC.
Mr.
Melbourne (Australia) and Indianapolis, IN (U.S.) – March 16, 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®1, Floretyrosine F 18 or 18F-FET), an investigational PET2 imaging agent for the characterization of recurrent or progressive glioma (brain cancer) from treatment related changes in both adult and pediatric patients.
Telix has resubmitted the NDA with the additional data requested by the FDA. The Company believes, based on the Type A meeting and ongoing consultation with the FDA, that the additional data and statistical analysis, along with the primary data set provided in the original submission, appropriately addresses the Complete Response Letter3.
Given the potential to address significant unmet medical need, TLX101-Px has been granted Orphan Drug4 and Fast Track5 designations by the FDA.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Dec 31, 2025 | Reporting currency | Its US reports are in USD instead of AUD from this period. Earlier figures are shown in USD, converted at each period end's exchange rate. |
| Dec 31, 2023 | Reporting currency | Its AU reports are in USD instead of AUD from this period. Earlier figures are shown in USD, converted at each period end's exchange rate. |
ETFs Holding Telix Pharmaceuticals Limited
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| CORO | 0.02% | 23,044 | $ 3.419M | Nov 16, 2026 |
| DFSI | 0.02% | 22,364 | $ 208.649K | Nov 12, 2026 |
| DFIS | 0.02% | 98,614 | $ 920.038K | Nov 12, 2026 |
| APIE | 0.01% | 8,699 | $ 96.472K | Aug 31, 2026 |
| DFIC | 0.01% | 106,625 | $ 994.778K | Nov 12, 2026 |
| DFAI | 0.01% | 111,918 | $ 1.044M | Nov 12, 2026 |
| DFAX | 0.00% | 43,415 | $ 405.049K | Nov 12, 2026 |
| IALT | 0.00% | 2,228 | $ 330.548K | Nov 16, 2026 |
| AVSD | 0.00% | 60 | $ 533.39 | Nov 16, 2026 |
| AVDS | 0.00% | 27 | $ 240.02 | Nov 16, 2026 |